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ABSTRACT 
 
The Role of CtIP in BRCA1-Mediated Tumor Suppression 
Colleen R. Reczek 
 
 
      Familial cases of breast and ovarian cancer are often attributed to germline mutations 
of the BRCA1 tumor suppressor gene.  Although the mechanisms of BRCA1 tumor 
suppression are poorly understood, its protein product has been implicated in multiple 
aspects of the DNA damage response.  As such, BRCA1 may suppress tumor 
development through its role in the maintenance of genomic integrity.  The C-terminus of 
BRCA1 contains two tandem BRCT motifs that form a single phosphoprotein binding 
motif that mediates the interaction of BRCA1 with at least three distinct phospho-ligands; 
Abraxas, BACH1, and CtIP.  We recently reported that the tumor suppression activity of 
BRCA1 is dependent on the phospho-recognition function of its BRCT motifs.  Of the 
three known phospho-ligands, the CtIP repair protein is intriguing because its interaction 
with BRCA1 is ablated by tumor-associated missense mutations in the BRCT domain.  
Accordingly, CtIP may be a critical mediator of the genome maintenance and tumor 
suppression functions of BRCA1.  Here we evaluate the role of CtIP in these BRCA1-
dependent processes using murine cells expressing Ctip polypeptides (Ctip-S326A) that 
fail to interact with Brca1.  Surprisingly, we demonstrate that the BRCA1-CtIP 
interaction is dispensable for mammalian cell viability, critical aspects of BRCA1 
function in genome stability, and BRCA1-mediated tumor suppression.   
      Given that CtIP plays a diverse role in maintaining genome integrity, we also 
assessed whether CtIP has functions relevant to tumor suppression independent of its 
interaction with BRCA1.  To test this hypothesis, we generated mice carrying a 
conditional-null Ctip (CtipCo) allele and used Cre recombination to inactivate the gene 
specifically in mammary epithelial cells.  Unexpectedly, we found that mammary-
specific inactivation of Ctip does not induce breast carcinogenesis.  Additionally, when 
we examined the effects of mammary-specific Ctip loss in a tumor-prone setting, we 
found that p53-deficient mammary tumorigenesis was dramatically inhibited by Ctip 
inactivation.  This result indicates not only that Ctip inactivation fails to potentiate p53-
induced mammary tumor formation, but that Ctip loss actually provides a protective 
effect against tumorigenesis in this setting.   
      Furthermore, since we recently demonstrated that the genome maintenance and tumor 
suppression functions of BRCA1 do not depend on its individual interaction with the 
BRCT phospho-ligands Abraxas, BACH1, or CtIP, we examined whether the interaction 
of BRCA1 with two or more of these phospho-ligands mediates these functions.  
Strikingly, the genome maintenance functions of BRCA1 are grossly perturbed only 
when the interaction of BRCA1 with its three known BRCT phospho-ligands are 
simultaneously ablated.  Thus, the major BRCA1 supercomplexes assembled from these 
interactions (complexes A, B, and C) have the potential to act in a compensatory manner 
with respect to one another.  In light of these results, it will be important to ascertain 
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A. BRCA1 in hereditary breast cancer 
       Breast cancer is among the most common malignancies in the United States, 
affecting more than one in eight women.  Moreover, women with a family history of 
breast cancer are at an increased (2-fold) risk of developing the disease.  These women 
often carry inherited mutations in the breast cancer susceptibility genes BRCA1 or 
BRCA2.  Women with a mutated allele of either BRCA1 or BRCA2 face a lifetime risk of 
60-85% for breast cancer, as well as an overall increased risk for ovarian cancer (Wooster 
and Weber, 2003).  The tumors that arise in women with germline BRCA1 or BRCA2 
mutations show loss or mutation of the corresponding wildtype allele, thus rendering both 
copies of the gene nonfunctional.  Therefore, BRCA1 and BRCA2 behave as classic tumor 
suppressor genes in accord with Knudson’s “two-hit” model (Knudson, 1971).   
       In its role as a tumor suppressor, BRCA1 behaves as a caretaker that maintains the 
integrity of the genome.  Its protein product has been implicated in a rather diverse set of 
cellular processes that include ubiquitination, cell cycle checkpoint control, DNA repair, 
centrosome duplication, and transcriptional regulation (reviewed in Deng, C.-X., 2006; 
Nagaraju and Scully, 2007; Greenberg, R. A., 2008; Huen et al., 2010; Moynahan and 
Jasin, 2010; Roy et al., 2011).  Although the exact mechanism of tumor suppression by 
BRCA1 remains elusive, it is conceivable that loss of BRCA1 destabilizes the genome, 
triggering mutations in other tumor suppressors and oncogenes, ultimately leading to 





B.  The BRCA1 protein 
      The BRCA1 gene encodes a large nuclear protein of 1863 amino acids in humans and 
1812 amino acids in mice (Miki et al., 1994; Bennett et al., 1995).  It contains two 
recognizable amino acid motifs, an N-terminal RING domain and two tandem copies of 
the BRCT domain at its C-terminus (Miki et al., 1994) (Figure 1).  The RING domain 
contains a metal-binding core that coordinates two atoms of zinc (Freemont, P.S., 1993).  
This domain can be found in a large and diverse family of eukaryotic proteins that 
possess E3 ubiquitin ligase activity (Joazeiro and Weissman, 2000).  The BRCA1 
carboxy-terminal (BRCT) domain was first identified as an ~80-100 amino acid motif 
that exists in two tandem copies at the C-terminus of BRCA1; subsequently, this domain 
was identified in an array of proteins which function in the cellular response to DNA 
damage (Koonin et al., 1996; Bork et al., 1997; Callebaut, I. and Mornon, J.-P., 1997).  
The paired BRCT repeats of BRCA1 form a characteristic globular structure that can act 
as a phosphopeptide binding domain (Manke et al., 2003; Yu et al., 2003).  While most 
cancer-predisposing BRCA1 mutations cause gross truncations that eliminate one or both 
of the BRCT repeats, single amino acid substitutions in the RING or BRCT domains 
have also been found in some familial patients (Miyake et al., 2000).  Therefore, these 
domains are critical for the tumor suppression activity of BRCA1.   
      The steady-state protein levels of BRCA1 fluctuate with the cell cycle.  In particular, 
these levels remain low in resting G0 cells and early cycling G1 cells; however, as cells 
traverse the G1/S boundary, the expression of BRCA1 increases dramatically and remains 
high throughout the S and G2/M phases (Chen et al., 1996).  Localization of BRCA1 to 
















Figure 1.  Domain structures of BRCA1 and BARD1.  Both proteins harbor an amino-
terminal RING domain (yellow) and two carboxy-terminal BRCT repeats (green).  In 


















S-phase foci (Scully et al., 1997a).  This is in contrast to the diffuse distribution of 
BRCA1 polypeptides observed throughout the nucleoplasm of resting cells and G1 
cycling cells (Scully et al., 1997a).  When cells experience a genotoxic insult, the S-phase 
BRCA1 foci disperse and BRCA1 polypeptides relocate and accumulate at sites of DNA 
damage along with other DNA damage response proteins (Scully et al., 1997b).  This 
dynamic change in the localization of BRCA1 in response to DNA damage further 
supports an important role for BRCA1 in the maintenance of genomic integrity.   
 
C. The functions of BRCA1 
      The integrity of the genome is maintained in part by BRCA1’s broad spectrum of 
cellular functions.  Some of these include cell cycle checkpoint control, DNA repair, and 
centrosome duplication (reviewed in Deng, C.-X., 2006; Nagaraju and Scully, 2007; 
Greenberg, R. A., 2008; Huen et al., 2010; Moynahan and Jasin, 2010; Roy et al., 2011).  
In response to genotoxic stress, cell cycle checkpoints preserve genome integrity by 
halting cell cycle progression and allowing for proper repair of the damaged DNA.  If 
damage is too extensive, cells may undergo growth arrest and apoptosis.  In contrast, if 
the checkpoint is not functional, then cell cycle progression may proceed in the face of 
DNA damage, promoting genomic instability and ultimately tumorigenesis (Xu, X. et al., 
1999; reviewed in Deng, C.-X., 2006).   
      BRCA1 has been implicated in a number of cell cycle checkpoints induced by 
ionizing radiation (IR), including two distinct G2/M checkpoints: the IR-induced transient 
G2/M checkpoint and the IR-induced G2 accumulation checkpoint (Xu, B. et al., 2002).  
6 
These checkpoints prevent cells from entering mitosis with damaged DNA.  The transient 
G2/M and G2 accumulation checkpoints are both defective in HCC1937 cells, a human 
breast cancer line that expresses a C-terminally-truncated BRCA1 polypeptide lacking 
one of the tandem BRCT motifs.  Moreover, both checkpoints can be restored by 
reconstitution of HCC1937 cells with wild-type BRCA1 (Xu, B. et al., 2001; Yarden et 
al., 2002; Yu et al., 2003).  A defective G2/M checkpoint has also been observed in 
Brca1∆11/∆11 mouse embryonic fibroblasts (MEFs), which carry a targeted deletion of 
exon 11 (Xu, X. et al., 1999).  Therefore, BRCA1, and more specifically, the BRCT 
domains of BRCA1 are important for proper activation of these cell cycle checkpoints.  
Interestingly, the checkpoint functions of BRCA1 are determined in part by proteins that 
bind in a phosphorylation-dependent manner to its BRCT motifs (Yu et al., 2003; Yu and 
Chen, 2004; reviewed in Huen et al., 2010).  For example, the interaction between 
BRCA1 and a phosphorylated isoform of the BACH1 protein is required for activation of 
the G2 accumulation checkpoint (Yu et al., 2003), while the interaction of BRCA1 with 
phosphorylated CtIP  mediates the transient G2/M checkpoint (Yu and Chen, 2004).  The 
importance of these interactions with respect to the genome stability and tumor 
suppression functions of BRCA1 will be discussed in more detail later.   
      BRCA1 also contributes to genome stability through its role in homology-directed 
repair (HDR) of DNA double-strand breaks (DSBs).  Chromosomal DSBs can arise from 
both endogenous and exogenous threats, including ionizing radiation (IR).  Since these 
DSBs can induce aberrant chromosomal rearrangements and ultimately cell death, proper 
DSB repair is vital to the integrity of the genome (Moynahan et al., 2001; reviewed in 
Moynahan and Jasin, 2010).  A function for BRCA1 in HDR emerged from early studies 
7 
in which BRCA1 was shown to disperse from S-phase foci following DNA damage and 
re-emerge as IR-induced foci (IRIFs) along with the Rad51 protein, a central component 
of the HDR pathway (Scully et al., 1997b).  Additional evidence suggestive of a role for 
BRCA1 emerged from studies of genomic stability in various BRCA1-deficient settings.  
For example, the HCC1937 human breast cancer cell line, expressing a C-terminally 
truncated form of BRCA1, is aneuploidy and harbors a high number of chromosomal 
aberrations (Tomlinson et al., 1998).  In addition, MEFs derived from Brca1∆11/∆11 mice 
exhibit extensive spontaneous chromosomal instability, resulting in aneuploidy, 
chromosome breaks, and translocations (Xu, X. et al., 1999).  Similarly, the Brca1-
deficient mouse embryonic stem (ES) cell line 236.44 accumulates high levels of 
chromosomal rearrangements, even in the absence of overt genotoxic stress (Moynahan 
et al., 2001).  Brca1-deficient cells are also hypersensitive to genotoxic agents, such as IR 
and DNA-crosslinking drugs, that cause DSB formation, further suggesting a key role for 
BRCA1 in DSB repair (Shen et al., 1998; Abbott et al., 1999; Moynahan et al., 1999).   
      Compelling evidence implicating BRCA1 in the HDR pathway of DSB repair arose 
when Moynahan et al. (1999) used an in vivo assay to measure the efficiency of HDR in 
Brca1∆223-763/∆223-763 ES cells (Brca1-null ES cell line 236.44).  Notably, they observed 
that these cells are unable to efficiently repair an enzymatically-induced chromosomal 
break by HDR (Moynahan et al., 1999).  Moreover, the HDR defect of Brca1∆223-763/∆223-
763 ES cells was partially ameliorated following complementation with wild-type Brca1 
(Moynahan et al., 2001).  These findings specifically implicate BRCA1 in the HDR 
pathway of DSB repair.   
8 
      The regulation of centrosome duplication is another potential caretaker function of 
BRCA1.  Mammalian cells normally contain one or two centrosomes depending on the 
cell cycle phase.  In mitosis, the duplicated centrosomes reside at opposite poles to form 
the vertices of the bipolar spindle, which is critical for proper chromosome segregation.  
Thus, aberrant replication of centrosomes can result in chromosomal aneuploidy and 
ultimately lead to tumorigenesis (Deng, C.-X., 2002).  The aneuploidy often observed in 
BRCA1-deficient cells, as mentioned above, suggests a role for BRCA1 in maintaining 
the fidelity of chromosome segregation.  This is supported by the observation that 
centrosome amplification occurs in approximately 25% of interphase and M phase 
Brca1∆11/∆11 MEFs, leading to formation of multipolar spindles and missegregation of 
chromosomes (Xu, X. et al., 1999).  Additionally, abnormal centrosomes and 
chromosome numbers were reported in high-grade human breast tumors (Lingle et al., 
1998; Pihan et al., 1998).  These results suggest that dysregulation of centrosome 
duplication in the absence of BRCA1 may directly contribute to genetic instability in 
cancer.   
 
D.  The BRCA1/BARD1 heterodimer 
      BRCA1 exerts its pleiotropic functions by interacting with a diverse set of proteins.  
The BRCA1-associated RING domain protein BARD1 is an obligate binding partner of 
BRCA1 and a central mediator of BRCA1 function (Wu et al., 1996; reviewed in Baer 
and Ludwig, 2002; Irminger-Finger and Jefford, 2006; Huen et al., 2010).  Like BRCA1, 
BARD1 contains an N-terminal RING domain and two C-terminal BRCT repeats (Wu et 
al., 1996).  Additionally, BARD1 has three central ankyrin (ANK) repeats, a common 
9 
amino acid motif that may serve to mediate protein-protein interactions (Figure 1) (Wu et 
al., 1996; Mosavi et al., 2004).  Most, if not all, of the cellular pool of endogenous 
BRCA1 polypeptides associates with BARD1 to form the BRCA1/BARD1 heterodimeric 
complex in vivo (Yu and Baer, 2000).  This association is mediated by sequences 
encompassing their respective RING domains (Wu et al., 1996).  In particular, the two 
alpha-helices that flank the RING domains of both proteins combine to form a four-helix 
bundle, stabilizing the BRCA1/BARD1 heterodimer (Brzovic et al., 2001).   
      As a heterodimer, BRCA1/BARD1 acts as a potent ubiquitin E3 ligase (Hashizume et 
al., 2001) that catalyzes the formation of K6-linked polyubiquitin chains, a novel linkage 
not associated with proteasomal degradation (Wu-Baer et al., 2003; Nishikawa et al., 
2004).  Tumorigenic missense mutations in the RING domain of BRCA1 inactivate the 
E3 ligase activity of the heterodimer (Ruffner et al., 2001).  Therefore, insight into the 
molecular underpinnings of BRCA1-mediated tumor suppression may be attained by 
studying the ubiquitination targets of BRCA1/BARD1 (Baer and Ludwig, 2002).  It is 
important to note that CtIP is a bona fide ubiquitination substrate of BRCA1/BARD1 (Yu 
et al., 2006) and, as will be discussed below, may play a role in BRCA1-mediated tumor 
suppression.   
 
E.  BRCA1/BARD1 in tumor suppression 
      Mouse models have been employed to examine the role of BRCA1 in tumor 
suppression.  In contrast to human BRCA1 mutation carriers, mice bearing either null or 
hypomorphic Brca1 alleles in a heterozygous setting are not susceptible to tumor 
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formation (reviewed in Deng and Scott, 2000; Evers and Jonkers, 2006).  Homozygous 
Brca1-null mice, on the other hand, are embryonic lethal (E6.5-E7.5) and suffer from a 
severe defect in cellular proliferation (Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 
1997; reviewed in Evers and Jonkers, 2006).  On the surface, this appears contradictory 
to the unrestrained cell proliferation associated with BRCA1-mutated cancers.  However, 
close examination revealed increased expression of the cyclin-dependent kinase inhibitor 
p21 in Brca1-null embryos, suggesting that the impaired cellular proliferation could be 
the result of p53-dependent G1 cell cycle arrest (Hakem et al., 1996).  This notion is 
supported by the fact that concomitant loss of Brca1 and p53 prolongs survival of mutant 
embryos to ~E8.5-E9.5 (Hakem et al., 1997; Ludwig et al., 1997).  In this regard, it is 
intriguing that most breast tumors of human BRCA1 mutation carriers also harbor 
somatic mutations of the p53 gene (Crook et al., 1997).  
      To circumvent the embryonic lethality associated with Brca1 nullizygosity, mouse 
models using a conditional Brca1-null allele and the Cre-loxP recombination system have 
been developed to study BRCA1-associated breast cancer (Xu et al., 1999a; Liu, X. et al., 
2007; McCarthy et al., 2007; Shakya et al., 2008).  Indeed, several groups have shown 
that mammary-specific loss of Brca1 in mice leads to the development of mammary 
tumors, albeit with long latency, that closely resemble the basal-like mammary 
carcinomas that arise in human BRCA1 mutation carriers (McCarthy et al., 2007; Liu, X. 
et al., 2007; Shakya et al., 2008).  These tumors typically display a basal-like 
histopathology, including positive staining for the cytoskeletal markers CK5 and CK14, 
and display the “triple-negative” phenotype which reflects lack of expression of the 
estrogen receptor (ER), progesterone receptor (PR) and HER2/neu surface marker 
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(McCarthy et al., 2007; Liu, X. et al., 2007; Shakya et al., 2008).  Additionally, cells from 
Brca1-mutant mammary tumors display extensive chromosomal instability characterized 
by aneuploidy and elevated levels of gross chromosomal rearrangements (Xu et al., 
1999a; Shakya et al., 2008).  Presumably, the genomic instability that results from Brca1 
loss triggers genetic alterations in other genes that eventually lead to tumor formation.  
To ascertain whether p53 mutations represent one of the genetic changes that promote 
BRCA1-associated tumorigenesis, Brca1 conditional mice were bred to have only one 
functional copy of p53 (Donehower et al., 1992; Xu et al., 1999a).  If p53 deficiency does 
promote BRCA1 tumorigenesis, then tumor formation in these mice may be accelerated 
since only the single wildtype p53 allele needs to be mutated (Xu et al., 1999a; Deng and 
Scott, 2000).  Indeed, Xu et al. (1999a) reported that loss of p53 accelerates the formation 
of mammary tumors in these mice and thus, Brca1 and p53 cooperate in mammary 
tumorigenesis.   
      The study of BRCA1-mediated tumor suppression is greatly facilitated by animal 
models that accurately recapitulate the responsible genetic lesion(s) and consequent 
tumor phenotype of human BRCA1-associated carcinogenesis.  For example, a mouse 
model was employed to determine whether the tumor suppression activity of Brca1 is 
mediated by the Brca1/Bard1 heterodimeric complex or through a Bard1-independent 
aspect of Brca1 function.  Since Bard1-null mice suffer an early embryonic death similar 
to Brca1-null animals (McCarthy et al., 2003), tumor suppression was examined in a 
mammary-specific fashion using a conditional Bard1-null allele (Shakya et al., 2008).  
Significantly, mammary-specific inactivation of Bard1 induced breast tumors in mice 
that were indistinguishable from those that arise in conditional Brca1-null females in all 
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measurable respects, including the kinetics of tumor formation, histopathology, and gene 
expression profiles (Shakya et al., 2008).  These results implied that BARD1 itself serves 
as a tumor suppressor in mammary epithelial cells.  Indeed, cancer-predisposing lesions 
of BARD1, although rare, were subsequently implicated in hereditary breast cancer (De 
Brakeleer et al., 2010; Sabatier et al., 2010; Ratajska et al., 2012).  Furthermore, double 
conditional Brca1/Bard1-mutant mice develop mammary tumors with kinetics that are 
indistinguishable from those of the single Brca1- and Bard1-mutant animals (Shakya et 
al., 2008).  The epistatic behavior of the Brca1 and Bard1 genes implies that their protein 
products mediate tumor suppression through a common functional pathway involving the 
Brca1/Bard1 heterodimer (Shakya et al., 2008). 
 
F. The BRCT domains of BRCA1 
      Apart from the RING domain, the only other identifiable structural domain of 
BRCA1 is the C-terminal BRCT motif, which mediates phospho-dependent protein-
protein interactions.  The BRCT domain is an evolutionarily conserved amino acid motif 
found in more than forty non-orthologous eukaryotic proteins, either as an isolated 
domain or as multiple tandem repeats comprised of two or more BRCT units (Bork et al., 
1997; Huyton et al., 2000).  The two tandem BRCT repeats of BRCA1 fold in a head-to-
tail fashion through a large hydrophobic interface with a deep surface cleft (Williams et 
al., 2001) (Figure 2).  Most tumor-associated mutations in BRCA1 result in the partial 
truncation or complete loss of one or both BRCT motifs (Williams et al., 2003; Wooster 




       
  
Figure 2.  Structure of the tandem BRCT repeats of BRCA1.  The N- and C-terminal 
BRCT repeats of BRCA1 are joined by a linker (αL, blue) and pack in a head-to-tail 
manner involving a large hydrophobic interface.  Each single repeat consists of a parallel 
four-stranded β-sheet (green), which is flanked on one side by a pair of α-helices (α1 and 
α3, gold) and on the other side by a single α-helix (α2, gold).  In the second BRCT 
repeat, the corresponding structural elements are indicated by primes (e.g., α1’, β1’, etc.).  







from a germline BRCA1 mutation carrier, expresses a truncated BRCA1 protein product 
lacking the C-terminal BRCT domain (Tomlinson et al., 1998).  Additionally, mice that 
express a truncated Brca1 polypeptide lacking both BRCT domains are highly tumor 
prone (Ludwig et al., 2001).  Therefore, the BRCT repeats play an important role in 
mediating the tumor suppressor function of BRCA1.   
      Further insight into the function of the BRCT domains emerged with the realization 
that two tandem BRCT motifs can fold into a globular domain that serves as a phospho-
protein interaction surface (Manke et al., 2003; Yu et al., 2003).  The tandem BRCT 
repeats of BRCA1 preferentially recognize a pSer-x-x-Phe motif in partner proteins 
(Manke et al., 2003; Rodriguez et al., 2003).  The phosphoserine (pSer) residue of the 
phospho-ligand binds to a basic pocket in the N-terminal BRCT repeat while the 
phenylalanine (Phe) residue fits into a hydrophobic pocket at the N- and C-terminal 
BRCT interface (Clapperton et al., 2004; Shiozaki et al., 2004; Williams et al., 2004) 
(Figure 3).  Tumor susceptibility in some breast cancer families can be ascribed to 
missense mutations in conserved residues of the BRCT repeats (e.g. S1655F and 
M1775R) (Williams et al., 2001).  These single amino acid substitutions prevent the 
interaction of BRCA1 with its BRCT phospho-ligands by perturbing the integrity of 
either the phosphoserine or phenylalanine binding pockets (Clapperton et al., 2004; 
Shiozaki et al., 2004; Williams et al., 2004).  For example, the serine to phenylalanine 
mutation at position 1655 (S1655F) disrupts hydrogen bond formation between S1655 of 
BRCA1 and the pSer residue of the phospho-ligand.  Furthermore, the methionine to 
arginine mutation at position 1775 (M1775R) results in a severe steric clash between the 
arginine side chain and the Phe (+3) residue of the phospho-ligand (Clapperton et al.,   
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Figure 3.  Phosphopeptide recognition by the BRCT repeats of BRCA1.  The BRCT 
repeats of BRCA1 act as a phosphopeptide binding module that preferentially recognizes 
a pSer-x-x-Phe motif in partner proteins (dark blue).  The phosphoserine (pSer) residue 
binds to a basic pocket in the N-terminal BRCT repeat while the phenylalanine (Phe +3) 
residue fits into a hydrophobic pocket at the interface between the two repeats.  Cancer-
associated missense mutations in conserved residues of the BRCT repeats (e.g. S1655F 




2004;  Shiozaki et al., 2004; Williams et al., 2004).  Mutations which ablate 
phosphoprotein recognition by the BRCT repeats of BRCA1 elicit breast tumors, as seen 
recently in mice bearing the Brca1-S1598F mutation, corresponding to human residue 
S1655 (Shakya et al., 2011).  Thus, the phosphopeptide binding property of the BRCT 
repeats is essential for BRCA1-mediated tumor suppression.  
 
G.  The BRCT-interacting phosphoproteins 
      The BRCT domains of BRCA1 are known to interact in vivo with a number of 
cellular proteins containing the pSer-x-x-Phe motif, including Abraxas/CCDC98, 
BACH1/BRIP1/FancJ, CtIP, and Acetyl-CoA carboxylase alpha or ACCA (Wong et al., 
1998; Yu et al., 1998; Cantor et al., 2001; Magnard et al., 2002; Yu et al., 2003; Yu et al., 
2004; Ray et al., 2006; Kim et al., 2007; Liu, Z. et al., 2007; Wang et al., 2007).  Since 
the phospho-recognition surface of a tandem BRCT motif can only accommodate one 
phospho-ligand at a time, at any given moment, a single BRCA1 polypeptide will bind 
Abraxas, BACH1, CtIP, or ACCA in a mutually exclusive manner (Yu and Chen, 2004; 
Greenberg et al., 2006; Kim et al., 2007; Liu, Z. et al., 2007; Wang et al., 2007).  Thus, 
BRCA1, in association with BARD1, forms a distinct complex with each of these BRCT-
interacting phosphoproteins.  Notably, three of the BRCT phospho-dependent 
interactions mediate unique aspects of BRCA1 function in the cellular response to DNA 
damage (Greenberg et al., 2006).  These BRCA1 supercomplexes are often referred to as 
complex A, complex B or complex C, depending on BRCA1’s association with the 
phosphoprotein Abraxas, BACH1, or CtIP, respectively (Wang et al., 2007).   
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      Complex A:  In the absence of DNA damage, Abraxas associates independently with 
both BRCA1 and RAP80, a protein that harbors a ubiquitin-interacting motif (UIM).  
While the interaction between Abraxas and the BRCT domains of BRCA1 require 
phosphorylation of the S406 residue of Abraxas, the Abraxas/RAP80 interaction is 
phosphorylation-independent.  In response to DNA damage, the three proteins form a 
complex whereby Abraxas bridges the association between BRCA1 and RAP80.  This 
complex also contains several additional repair proteins: NBA1/Merit40, BRCC45 and 
BRCC36 proteins.  The resulting supercomplex targets BRCA1 to sites of DNA damage 
in part through the recognition of ubiquitinated histones by the UIM of RAP80.  
Consequently, IR-induced foci (IRIFs) of BRCA1 fail to form in cells treated with 
Abraxas siRNA.  In contrast, Abraxas recruitment to IRIFs is unaffected by BRCA1 
depletion.  Therefore, Abraxas acts upstream of BRCA1 in the DNA damage response.  
Interestingly, although complex A is required for the damage-induced transient G2/M 
checkpoint, the checkpoint defect observed in Abraxas-deficient cells is less severe than 
that of BRCA1-deficient cells, despite the placement of Abraxas upstream of BRCA1.  
This suggests that complex A mediates only part of BRCA1 function in response to DNA 
damage (Kim et al., 2007; Kim et al., 2007a; Liu, Z. et al., 2007; Sobhian et al., 2007; 
Wang et al., 2007; Yan et al., 2007). 
      Complex B:  The BRCT repeats of BRCA1 interact with a second phospho-ligand, 
the BRCA1-associated carboxyl-terminal helicase (BACH1) (Cantor et al., 2001), which 
is equivalent to the FancJ component of the Fanconi pathway (Levitus et al., 2005; 
Levran et al., 2005; Litman et al., 2005).  BACH1 is phosphorylated in a cell-cycle 
dependent manner at residue S990 at the S to M phase transition, allowing for the 
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phospho-dependent interaction between BACH1 and the BRCT sequences of BRCA1.  
Thus, formation of the BRCA1-BACH1 complex is regulated with respect to cell cycle 
progression (Yu et al., 2003).  Following DNA damage, the checkpoint protein TopBP1 
associates with BRCA1-BACH1 to form complex B.  This supercomplex appears to be 
essential for activation of the IR-induced G2 accumulation checkpoint since expression of 
siRNA-resistant BACH1-S990A mutant is not sufficient to rescue the checkpoint defect 
observed in BACH1 siRNA-treated cells, indicating that the phosphorylation-dependent 
interaction between BACH1 and BRCA1 is necessary for G2 accumulation checkpoint 
control (Yu et al., 2003).  More recently, this supercomplex has been shown to activate a 
second checkpoint, the IR-induced S-phase checkpoint as elevated levels of DNA 
synthesis are observed in IR-treated U2OS cells transfected with either BRCA1, BACH1 
or TopBP1 siRNA (Greenberg et al., 2006).  Proper activation of these checkpoints may 
be an important mechanism to prevent genomic instability and suppress tumor formation.   
      Complex C:  BRCA1 function in DNA-damage induced checkpoint control is further 
mediated by its interaction with the BRCT-interacting phosphoprotein CtIP (Wong et al., 
1998; Yu et al., 1998; Yu and Chen, 2004).  CtIP associates with the BRCT sequences of 
BRCA1 in a cell cycle-dependent manner (Yu and Baer, 2000).  This interaction requires 
phosphorylation of CtIP at residue S327, which occurs transiently in the late S and G2 
phases of the cell cycle (Yu and Chen, 2004).  Therefore, the BRCA1-CtIP complex 
primarily exists in the late S and G2 phase, in contrast to the S to M phase-specific 
BRCA1-BACH1 complex.  Notably, the BRCT domains of BRCA1 bind to the BACH1 
phosphopeptide with a 5-fold higher affinity than to the CtIP phosphopeptide, perhaps 
explaining the transient nature of the BRCA1-CtIP complex (Yu and Chen, 2004; Varma 
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et al., 2005).  The difference in cell cycle-dependent regulation of these BRCA1 
complexes is consistent with the distinct functions of these complexes in DNA damage-
induced checkpoint control (Yu and Chen, 2004).  In response to DNA damage, the 
BRCA1-CtIP complex associates with the proteins of the MRN complex 
(Mre11/Rad50/Nbs1) to form a third supercomplex, complex C (Greenberg et al., 2006).  
This complex is required for the IR-induced transient G2/M checkpoint.  Indeed, siRNA-
mediated CtIP depletion specifically ablates the transient G2/M checkpoint, but not the 
BACH1-dependent G2 accumulation checkpoint (Yu and Chen, 2004).  Furthermore, the 
checkpoint defect of CtIP-depleted cells could be rescued by exogenous expression of 
wild-type CtIP, but not a mutant CtIP (S327A) that fails to bind BRCA1 (Yu and Chen, 
2004).  It is important to note however, that both complex A and complex C contribute to 
the BRCA1-dependent transient G2/M checkpoint (Wang et al., 2007).  Perhaps these 
different BRCA1-containing complexes promote distinct steps to ensure efficient cell 
cycle arrest and checkpoint control (Wang et al., 2007).  A better understanding of the 
role of each of these BRCA1 complexes in genome stability and tumorigenesis is 
necessary.   
 
H.  The CtIP protein 
      CtIP/RBBP8 (CtBP interacting protein/Retinoblastoma binding protein 8) is a 
ubiquitously expressed 897 amino acid nuclear protein (Fusco et al., 1998; Schaeper et 
al., 1998; Wong et al., 1998; Yu et al., 1998).  In addition to binding BRCA1, CtIP has 
also been reported to interact with the transcriptional co-repressor CtBP (C-terminal 
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binding protein) (Schaeper et al., 1998) and the tumor suppressor Rb (retinoblastoma 
protein) (Fusco et al., 1998).  CtIP contains several short sequence motifs required for 
interaction with these protein partners (Figure 4).  As mentioned above, the BRCT 
sequences of BRCA1 recognize the pSer-x-x-Phe motif centered on S327 of CtIP (Yu 
and Chen, 2004).  A conserved PLDLS motif is present in the central region of CtIP to 
mediate the association of CtIP with CtBP (Schaeper et al., 1998).  Furthermore, Rb and 
its family members, p130 and p107 are reported to interact with human CtIP through an 
LxCxE motif that lies in the N-terminal region of the protein (Fusco et al., 1998; Stokes 
et al., 2007).  These interactions appear to mediate the function of CtIP in transcriptional 
regulation, the DNA damage response, and cell cycle checkpoint control (Meloni et al., 
1999; Li et al., 2000; Yu and Chen, 2004; Chen, P.-L. et al., 2005; Liu and Lee, 2006).  
Apart from these short sequence motifs, the only recognizable structural domain of CtIP 
is an N-terminal coiled-coil sequence that mediates CtIP homodimerization (Figure 4) 
(Dubin et al., 2004).  Although the biological role of this domain has not yet been 
determined, it may stabilize the in vivo interaction of CtIP with the Rb family of proteins 
(Stokes et al., 2007). 
       Interestingly, CtIP protein expression varies with the cell cycle in parallel with 
BRCA1 (Yu and Baer, 2000).  The steady-state levels of CtIP are low in resting and 
cycling G1 cells; however, as cells traverse the G1/S boundary, CtIP protein expression is 
dramatically induced, with peak expression in late S and G2 (Yu and Baer, 2000; Yu and 
Chen, 2004).  The cell cycle-regulated phosphorylation of CtIP on residue S327 by 
cyclin-dependent kinase 2 (CDK2) coincides with peak expression of CtIP (Yu and Chen, 
2004; Yata and Esashi, 2009).  Thus, the BRCA1-CtIP complex forms when cellular  
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Figure 4.  The human CtIP polypeptide.  A schematic map of human CtIP (897 amino 
acids) illustrating the N-terminal coiled-coil domain (pink) that mediates CtIP 
homodimerization and C-terminal sequences that share homology with the yeast Sae2 
protein (Sae2 motif).  The S327 phosphorylation site that facilitates BRCA1 binding is 
also shown, as are the short sequence motifs implicated in binding the Rb tumor 
suppressor (LxCxE) and the CtBP transcriptional co-repressor (PLDLS).  In addition, two 



















levels of both CtIP and BRCA1 proteins are maximal.  Co-immunoprecipitation 
experiments reveal that in unsynchronized cells 10-20% of the BRCA1 polypeptide pool 
and 5-20% of the CtIP polypeptide pool interact to form a BRCA1-CtIP complex (Yu and 
Baer, 2000).   
       In response to DNA damage, CtIP is phosphorylated by the ATM kinase at S664 and 
S745 (Figure 4) (Li et al., 2000) and relocalizes from a diffuse nuclear distribution to 
discrete punctate foci that co-localize with γH2AX, a marker of DSBs, and BRCA1 (Yu 
et al., 2006).  DNA damage-induced CtIP focus formation is reported to require the 
BRCA1-CtIP interaction, as CtIP fails to form IRIFs in HCC1937 cells, which express a 
truncated BRCA1 polypeptide lacking the C-terminal BRCT repeat (Yu et al., 2006).  
Moreover, the BRCA1-CtIP interaction is required for BRCA1/BARD1-mediated 
ubiquitination of CtIP following DNA damage, a modification that promotes the 
recruitment of CtIP to damaged sites (Yu et al., 2006).  Perhaps DNA damage-induced 
CtIP hyperphosphorylation triggers the BRCA1/BARD1-dependent ubiquitination of 
CtIP and thus, the formation of CtIP foci (reviewed in Barber and Boulton, 2006).  The 
resulting accumulation of ubiquitinated CtIP on chromatin following DNA damage may 
mediate the transient G2/M checkpoint since catalytically inert BRCA1 polypeptides fail 
to activate this checkpoint (Yu et al., 2006).  Although the precise mechanism by which 
CtIP ubiquitination promotes the transient G2/M checkpoint remains unclear, these results 
highlight the importance of the coordinated action of the RING and BRCT domains in 
regulating BRCA1-dependent functions. 
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I.   The functions of CtIP 
      To define the role of Ctip in vivo, a Ctip-null allele was generated using ES cell 
technology (Chen, P.-L. et al., 2005).  Correctly identified recombinant ES cell clones 
were used to generate chimeric mice and subsequently heterozygous Ctip+/– mice.  
Intercrossing the Ctip+/– animals failed to produce Ctip–/– nullizygous mice, indicating 
that Ctip is essential for early embryonic development (Chen, P.-L. et al., 2005).  The 
Ctip-null embryos died at embryonic day 4 (E4.0), as the blastocysts failed to enter S 
phase (Chen, P.-L. et al., 2005).  Although Ctip- and Brca1-null mutations both affect 
cell proliferation, Ctip-null embryos die earlier in utero than Brca1-null embryos (E6.5-
E7.5), suggesting essential Brca1-independent functions of Ctip in early embryogenesis 
(Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Chen, P.-L. et al., 2005).  
Furthermore, the phenotypic defects associated with the Ctip-null mutation, in contrast to 
the Brca1-null mutation (Hakem et al., 1997; Ludwig et al., 1997), could not be mitigated 
in a p53-null background (unpublished data).  Therefore, p53 is not required for the early 
lethality of Ctip-null embryos.  
      Recent studies with mice bearing the Ctip-null allele also suggest a direct role for 
Ctip in tumorigenesis (Chen, P.-L. et al., 2005).  Although healthy, heterozygous Ctip+/– 
mice succumb to multiple tumors, predominantly lymphomas, at an increased rate 
relative to the wildtype Ctip+/+ mice (Chen, P.-L. et al., 2005).  Since the wildtype Ctip 
allele was retained in these Ctip+/– tumors, Chen, P.-L. et al. (2005) propose that Ctip 
lesions promote tumor formation by haploid insufficiency. 
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      To date, mutations that alter both CtIP alleles in accord with the Knudson “two-hit” 
tumor suppressor model have not been observed in human tumors, including familial 
breast cancer (Wong et al., 1998; Gorringe et al., 2008).  Nevertheless, a mutational 
screen of CtIP cDNA from 89 human tumor cell lines revealed missense variants in the 
human CtIP gene in cell lines derived from breast, ovarian, pancreas and colon 
carcinomas (Wong et al., 1998).  Furthermore, a monoallelic one basepair deletion within 
the A9 repeat of the CtIP gene, which would result in a C-terminally truncated protein, 
has been observed in over 20% of mismatch repair-deficient colorectal carcinomas 
(Vilkki et al., 2002).  Perhaps inactivation of one CtIP allele is sufficient for human 
oncogenesis given that tumorigenesis in mice has been attributed to CtIP 
haploinsufficiency (Chen, P.-L. et al., 2005; Chinnadurai, G., 2006).   
      Since CtIP is itself a candidate tumor suppressor, it may modulate the tumor 
suppressor function of BRCA1, its interacting partner, in part by promoting genome 
stability.  In fact, CtIP has been implicated in at least two critical aspects of the DNA 
damage response; cell cycle checkpoint control (Yu and Chen, 2004) and DNA double-
strand break (DSB) repair (Sartori et al., 2007).  As mentioned above, CtIP is involved in 
the BRCA1-dependent transient G2/M checkpoint after DNA damage (Yu and Chen, 
2004).  Activation of this checkpoint requires the BRCA1-CtIP interaction as well as the 
E3 ligase activity of the BRCA1/BARD1 heterodimer (Yu and Chen, 2004; Yu et al., 
2006).  Thus, checkpoint control by CtIP may be a critical mediator of the genome 
maintenance and tumor suppression functions of BRCA1.   
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      Furthermore, recent studies have implicated CtIP in DNA resection, an early step in 
the cellular response to DNA double-strand breaks (DSBs) (Sartori et al., 2007).  
Chromosomal DSBs are highly toxic mutagenic lesions that must be repaired to maintain 
the integrity of the genome (Rouet et al., 1994; Helleday et al., 2007).  Due to the 
tumorigenic potential of unrepaired or misrepaired DSBs, eukaryotes have evolved 
complex and highly conserved mechanisms to detect and repair such lesions (Khanna and 
Jackson, 2001; Jackson, S. P., 2002).  The repair of DSBs in mammalian cells is achieved 
primarily through two major pathways, non-homologous end joining (NHEJ) and 
homology-directed repair (HDR) (Figure 5) (reviewed in Raynard et al., 2008; Huertas, 
P. 2010; Paull, T. T. 2010; Mimitou and Symington, 2011; Symington and Gautier, 
2011).  NHEJ is an error-prone process that requires little or no nucleolytic processing of 
the two DNA ends for ligation and repair of the DSB.  In contrast, HDR requires 
extensive 5’ to 3’ resection of the DSB ends to produce 3’ single-stranded DNA (ssDNA) 
overhangs.  The resected ssDNA tail is initially coated with the RPA heterotrimer to form 
a ssDNA/RPA filament that activates checkpoint signaling through the ATR kinase (Zou 
and Elledge, 2003).  Subsequently, RPA is displaced from the nucleofilament by the 
recombination protein Rad51 in a process facilitated by the BRCA2 polypeptide (Yang et 
al., 2005).  The resulting ssDNA/Rad51 filament can then recognize, invade, and 
recombine with a homologous template, preferably a sister chromatid, to accurately 
restore genetic information disrupted by the DSB.  
      Although NHEJ occurs throughout all phases of the cell cycle, it assumes the greatest 
importance in the G0 and G1 phases, whereas HDR is largely restricted to the S and G2 
phases when sister chromatids are available as templates for homologous repair  
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Figure 5.  DNA double strand break repair pathways in eukaryotes.  Left, non-
homologous end joining (NHEJ) pathway.  Right, homology-directed repair (HDR) 
pathway.  DNA double strand break repair proceeds through a number of distinct steps: 
(a) DNA damage detection, (b) minimal DNA end processing, (c) DNA end ligation, (d) 
5’ to 3’ DNA resection, (e) strand invasion and DNA synthesis, (f) DNA end ligation, 
and (g) resolution.  DNA sequences of the damaged chromosome are depicted in black, 
while those of the template chromosome used for HDR are shown in red.  (Adapted from 
Lisby and Rothstein, 2004) 
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(reviewed in Haber, J. E., 2000; Karran, P., 2000; Khanna and Jackson, 2001; Jackson, S. 
P., 2002; Lisby and Rothstein, 2004; Raynard et al., 2008; Huertas, P. 2010; Paull, T. T. 
2010; Mimitou and Symington, 2011; Symington and Gautier, 2011).  Cell cycle control 
of DSB repair pathway choice is an important aspect of genome maintenance, as gross 
chromosomal rearrangements may result if HDR occurs in the G1 phase (Lisby and 
Rothstein, 2004).  This coordination of the DNA repair pathway and the cell cycle is 
regulated by cyclin-dependent kinases (CDKs).  In part, CDKs govern the choice 
between repair pathways by regulating 5’ to 3’ resection of DSBs (Figure 5d), an event 
that is necessary for HDR but actually inhibits NHEJ (Aylon et al., 2004; Ira et al., 2004).  
Given the critical role of DNA resection as both a regulator and effector of HDR, the 
factors that mediate resection are of keen interest.  
      For a long time, the MRN (Mre11/Rad50/Nbs1) complex was the only known 
component of the DNA resection machinery in higher eukaryotes (Jazayeri et al., 2006; 
Williams et al., 2007; Buis et al., 2008).  The MRN complex is comprised of three 
polypeptides: Mre11, Rad50, and Nbs1 (Xrs2 in S. cerevisiae) (D’Amours and Jackson, 
2002).  In response to DSBs, MRN acts as a sensor that rapidly localizes to sites of DNA 
damage to initiate damage-induced signaling through activation of the ATM kinase 
(Mirzoeva and Petrini, 2001; Uziel et al., 2003; Lee and Paull, 2004; Lisby et al., 2004).  
ATM activation requires the DNA nuclease activity of Mre11 (Uziel et al., 2003) and 
results in the phosphorylation of a number of downstream substrates, including H2AX, 
Mre11, Nbs1, CtIP, RPA, BRCA1, and the protein kinase Chk2 (reviewed in Lavin and 
Khanna, 1999; Khanna et al., 2001; Shiloh, Y., 2001; D’Amours and Jackson, 2002).  
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Phosphorylation of these and other substrates by ATM initiates cell-cycle arrest and 
facilitates DNA repair.   
      Interestingly, the MRN complex acts as both an upstream activator and downstream 
target of the ATM kinase.  Recent evidence indicates that DNA-damage induced 
phosphorylation of Mre11 and Nbs1 may stimulate the nuclease activity of Mre11, and 
thereby modulate the DNA resection function of the MRN complex (Costanzo et al., 
2001; D’Amours and Jackson, 2002; Jazayeri et al., 2006; Buis et al., 2008).  DNA 
resection and the consequent formation of ssDNA/RPA filaments in response to 
genotoxic stress can be observed cytologically by the formation of nuclear foci that stain 
with RPA-specific antibodies.  In Mre11-deficient ataxia-telangiectasia-like disorder 
(ATLD) cells containing either an empty vector or a Mre11-nuclease mutant, RPA focus 
formation is markedly impaired following ionizing radiation, implicating the mammalian 
MRN complex and its nuclease activity in the initial processing of DSBs (Jazayeri et al., 
2006).  Furthermore, a reduction in RPA focus formation has also been observed in 
Mre11∆/∆ (MRN-deficient) and Mre11H129N/∆ (nuclease-deficient) MEFs (Buis et al., 
2008).  Using a DR-GFP assay to more definitively examine DSB repair, Buis et al. 
(2008) measured HDR of an I-SceI endonuclease-induced DSB in Mre11∆/+, Mre11∆/∆, 
and Mre11H129N/∆ MEFs.  A pronounced defect in HDR was observed in both the 
Mre11∆/∆ and Mre11H129N/∆ cell lines relative to control cells (Mre11∆/+), as measured by 
the percentage of GFP-positive cells.  Overall, these data implicate the nuclease activities 
of the mammalian MRN complex in the DNA resection step of the HDR pathway.   
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      In vitro, the Mre11 protein shows single-stranded endonuclease and 3’ to 5’ 
exonuclease activities (Paull and Gellert, 1998).  The polarity of the exonuclease activity 
however is opposite from that required to generate, in a direct manner, the 3’ single-
stranded DNA overhangs that arise from DNA resection in vivo.  It is possible that Mre11 
functions in concert with a DNA helicase that unwinds the DNA duplex and allows the 
Mre11 endonuclease to resect 5’ ends (Krogh et al., 2005).  However, recent studies in S. 
cerevisiae demonstrate that DSB resection is a more complex process that occurs in at 
least two separate stages (Gravel et al., 2008; Mimitou and Symington 2008; Zhu et al., 
2008; Nicolette et al., 2010; Niu et al., 2010).  In this model, the 5’ endonuclease activity 
of the MRX complex (the yeast counterpart of the MRN complex), together with the 
Sae2 protein, carries out the initial stage of resection to yield short ssDNA tails of 
roughly 100-400 nucleotides.  In a subsequent extension stage, ssDNA tails greater than a 
kilobase in length are generated through the coordinated action of the 5’ to 3’ 
exonucleolytic activities of the Exo1 protein or the Sgs1/Dna2 helicase/exonuclease 
complex (Gravel et al., 2008; Mimitou and Symington, 2008; Zhu et al., 2008; Nicolette 
et al., 2010; Niu et al., 2010).  A similar two stage DSB resection process has also been 
identified in mammalian cells, in which the initial stage is mediated by the MRN 
complex in collaboration with CtIP, which shares amino acid homology with the yeast 
Sae2 protein.  The minimally resected DSB intermediates generated by MRN/CtIP then 
recruit helicases and nucleases, including BLM (Sgs1 in budding yeast), Exo1, and Dna2, 
to catalyze extensive and processive resection (Gravel et al., 2008; Raynard et al., 2008). 
       The amino acid homology between mammalian CtIP and yeast Sae2 is restricted to 
an approximately 100 residue region located at the C-termini of both proteins.  This 
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homology, herein termed the “Sae2 motif”, contains potential CDK and ATM/ATR 
phosphorylation sites that may serve to regulate DSB resection and HDR (Figures 4 and 
6) (Sartori et al., 2007; Huertas et al., 2008).  Notably, the Sae2 motif of CtIP contains a 
CDK consensus site analogous to S267 of Sae2, a phosphorylatable residue that mediates 
cell cycle control of DSB resection in S. cerevisiae (Huertas et al., 2008; Huertas and 
Jackson, 2009).  Phosphorylation of the analogous residue of human CtIP (T847) is 
needed for effective ssDNA generation, RPA recruitment, and RPA phosphorylation in 
response to DNA damage (Huertas and Jackson, 2009).  Exactly how phosphorylation of 
CtIP at residue T847 modulates DNA resection remains unresolved, since T847 
phosphorylation is not required for the CtIP-MRN interaction (Sartori et al., 2007).  
Nonetheless, the mechanism by which DSB resection is controlled and the role of CtIP in 
the initial processing of a DSB appears to be conserved over a vast phylogenetic 
spectrum. 
      The biochemical mechanisms by which CtIP facilitates MRN-mediated DNA 
resection are not understood.  Interestingly, the yeast Sae2 protein harbors an intrinsic 
endonuclease activity that acts cooperatively with MRX to cleave hairpin DNA structures 
in vitro (Lengsfeld et al., 2007).  Although a corresponding enzymatic activity for CtIP 
has not yet been reported, recent studies indicate that CtIP promotes DNA resection by 
physically associating with and stimulating the endonuclease activity of the MRN 
complex (Sartori et al., 2007).  Moreover, CtIP downregulation dramatically impairs 
ssDNA generation and RPA focus formation (Sartori et al., 2007), as well as ATR-
dependent Chk1 phosphorylation (Yu and Chen, 2004).  Furthermore, siRNA-mediated 






Figure 6.  Alignment of the C-terminus of human CtIP with those of CtIP/Sae2 
homologues from different species.  Potential CDK (S/T-P) and ATM/ATR (S/T-Q) 
phosphorylation sites are indicated.  Conserved residues are shaded black.  Asterisks (*) 
show the position of the conserved CtIP T847 and Sae2 S267 residues.  GenBank 
accessions: Human CtIP (AAC14371), Chicken CtIP (XP_419158), Xenopus laevis CtIP 
(AAH73395), Phaeosphaeria nodorum (EAT90897), Chaetomium globosum 
(XP_001224668), Neurospora crassa (XP_957865), Cryptococcus neoformans 
(EAL19137), Yarrowia lipolytica (XP_502193), Ashbya gossypii (NP_984048) and 
Saccharomyces cerevisiae Sae2 (NP_011340).  (Adapted from Sartori et al., 2007) 
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comparable to those achieved by depleting Mre11 or the key homologous recombination 
protein Rad51 (Sartori et al., 2007).  Since depletion of CtIP and Mre11 in tandem does 
not decrease HDR efficiency any further, the two proteins likely promote DSB repair by 
homologous recombination through a common mechanism (Sartori et al., 2007).  
Therefore, in mammalian cells, CtIP collaborates with the MRN complex to resect DSB 
ends and thereby initiate both checkpoint signaling and homologous recombination.   
       It is unclear as to whether BRCA1 is required for the DNA resection functions of 
CtIP.  This notion is attractive as it could potentially explain how BRCA1 controls 
various checkpoints and HDR pathways.  A requirement for BRCA1 in CtIP-mediated 
resection would also be consistent with genetic data that places BRCA1 upstream of 
BRCA2 in the HDR pathway (Stark et al., 2004).  Furthermore, the BRCA1, BARD1, 
CtIP, and MRN polypeptides are known to form a discrete protein complex (BRCA1 
complex C) in mammalian cells that could potentially mediate the resection functions 
ascribed to CtIP and MRN (Greenberg et al., 2006; Chen et al., 2008).  If so, complex C 
may control the transient G2/M checkpoint indirectly through its role in DNA end 
resection (reviewed in Huen et al., 2010).  It has been reported by one group that RPA 
focus formation in response to IR is impaired in HCC1937 cells, a BRCA1-mutant 
human breast tumor line, but not in HCC1937 cells reconstituted with wild-type BRCA1 
(Chen et al., 2008).  Although this result suggests that BRCA1 is required for DNA 
resection, another group reported that siRNA-mediated depletion of BRCA1 in HeLa 
cells has no effect on IR-induced RPA focus formation (Zhao et al., 2007).  The 
requirement for BRCA1 in CtIP-dependent DNA resection remains a critical issue, as it 
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may help explain the molecular mechanisms by which BRCA1 maintains genomic 
stability and suppresses tumor formation. 
 
J.   Goals and Rationale 
      Although a clear understanding of the mechanism of BRCA1-mediated tumor 
suppression has been obscured by the broad spectrum of cellular activities attributed to 
BRCA1 and the plethora of BRCA1-interacting partners, meaningful insights have 
recently emerged using an accurate mouse model of basal-like breast cancer.  For 
instance, despite the importance of both the RING and BRCT domains in tumor 
suppression, only the phosphopeptide binding property of the BRCT repeats, and not the 
E3 ligase activity of the RING domain, is required for BRCA1-mediated tumor 
suppression (Shakya et al., 2011).  Thus, mammary tumor formation in mice homozygous 
for the S1598F mutation (corresponding to the human mutation S1655F) is accelerated 
relative to wildtype mice and comparable with that of conditional Brca1-null mice 
(Shakya et al., 2011).  On the other hand, tumor formation is suppressed in homozygous 
Brca1-I26A mutant mice expressing an enzymatically defective Brca1 (Shakya et al., 
2011).  This result emphasizes the importance of BRCT phosphopeptide recognition for 
tumor suppression.  It is noteworthy that at least three different DNA damage response 
proteins (Abraxas, BACH1, and CtIP) interact with the BRCT repeats of BRCA1 to form 
distinct protein complexes (reviewed in Huen et al., 2010; Moynahan and Jasin, 2010).  
Since BRCA1’s association with one or more of these BRCT phosphopeptides (and/or 
others yet to be discovered) appears to mediate its tumor suppression function (Shakya et 
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al., 2011), analysis of these interactions is critical and may provide novel targets for 
cancer therapy. 
       In this study, we sought to determine the role of CtIP in BRCA1-mediated tumor 
suppression.  Among the three known BRCT-interacting phospho-ligands, CtIP seemed a 
likely candidate to mediate BRCA1 function in genome stability and tumor suppression.  
First, CtIP is the only known BRCT-interacting phosphopeptide that is also an enzymatic 
substrate of BRCA1/BARD1’s E3 ligase activity (Yu et al., 2006).  When this research 
began, a role for the E3 ligase activity of BRCA1 in tumor suppression was predicted 
based on the presence of tumor-associated mutations in the RING domain that inactivate 
BRCA1 enzymatic activity (Hashizume et al., 2001).  Second, cancer-associated 
missense mutations in the BRCT domains of BRCA1 disrupt the BRCA1-CtIP 
interaction, highlighting the potential importance of a stable BRCA1-CtIP complex for 
tumor suppression (Yu et al., 1998).  Third, CtIP plays a prominent role in maintaining 
genome stability by activating the transient G2/M checkpoint (Yu and Chen, 2004) and 
promoting the DNA resection and homology-directed repair of DSBs (Sartori et al., 
2007).  Therefore, we hypothesized that CtIP may be a key downstream mediator of the 
genome maintenance and tumor suppression functions of BRCA1.  
       To elucidate the role of CtIP in these BRCA1-dependent processes, we examined 
genome stability in cells and tumor suppression in mice that express a Ctip polypeptide 
with a missense mutation (Ctip-S326A) that ablates its interaction with Brca1.  
Furthermore, we assessed if CtIP serves as a tumor suppressor in mammary epithelial 
cells, and, if so, whether this activity is epistatic with Brca1-mediated tumor suppression.  
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To this end, we tested whether mammary-specific lesions of Ctip lead to basal-like breast 
tumors similar to those observed in conditional Brca1-null mice (Shakya et al., 2008).  
Finally, for reasons that will be discussed, we also examined how the phospho-dependent 
interaction of BRCA1 with two or more of its BRCT-binding partners affects genome 

































A.  Targeted mutagenesis 
A1.  CtipS326A 
      The homology arms of the CtipS326A targeting construct (Figure 7B) were derived 
from a 6.0 kilobasepair EcoRI fragment of genomic DNA from strain 129-derived E14 
TG2a ES cells (Warren et al., 1994).  This fragment encompasses exons 10, 11, and 12 of 
the Ctip locus.  The natural serine codon (TCT) for residue 326 in exon 11 was 
substituted with an alanine codon (GCA) by site-directed mutagenesis (Stratagene).  An 
AgeI restriction site was also introduced into exon 11 in this manner by converting the 
sequence TCCGGT to ACCGGT.  In the final construct, the homology fragment was 
interrupted at the HpaI restriction site of intron 10 by insertion of a loxP-flanked PGK 
promoter-driven neomycin selection marker cassette.  A gene cassette encoding herpes 
simplex virus type 1 thymidine kinase (HSV-TK) was also included in the construct as a 
negative selection marker.  For gene targeting, NotI-linearized targeting vector DNA was 
introduced into 129/Sv embryonic stem (ES) cells by electroporation (30 ug of DNA at 
0.8 kV/3 µF), and after neomycin selection, drug-resistant ES cell subclones were 
analyzed for gene targeting by Southern blotting PvuII-digested genomic DNA with a 5’ 
flanking Ctip probe (“Ctip #6”) spanning exon 9 (Figure 7A).  Correctly targeted 
heterozygous CtipS326A-neo/+ 129/Sv ES cells were identified (Figure 7C and 9). 
      An identical CtipS326A targeting construct was generated by replacing the loxP-flanked 
neomycin resistance cassette with a loxP-flanked PGK promoter-driven hygromycin 
selection marker.  The CtipS326A-hyg targeting construct was linearized with the NotI 
restriction enzyme and electroporated into Ctip+/– ES cells (30 ug of DNA at 0.8 kV/3 
µF).  The functionally null Ctip– allele of these cells was generated previously by 
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replacing 1.2 kilobases of Ctip genomic DNA, including part of exon 11 and all of exon 
12, with a MC1 promoter-driven neomycin expression cassette (unpublished data; 
Ludwig, Baer, and Efstratiadis, Columbia University).  DNA was prepared from the 
hygromycin-resistant ES cell subclones and digested with the PvuII restriction enzyme.  
Southern analysis using the exon 9-spanning 5’ flanking Ctip probe (“Ctip #6”) revealed 
correctly targeted CtipS326A-hyg/– ES clones (Figure 8).  Adeno-cre virus infection of these 
ES cells resulted in CtipS326A/– ES subclones with the loxP-flanked hygromycin resistance 
gene cassette removed (Figure 7D).  Briefly, an Adeno-cre virus stock solution was 
prepared by adding 3 ul of Adeno-cre virus (2.84 x 1010 pfu/mL) to 300 ul of pre-warmed 
Dulbecco’s Modified Eagle Medium (DMEM) (Cellgro) supplemented with 2.5% heat-
inactivated fetal bovine serum (FBS; HyClone ES Cell Screened, Thermo Scientific).  
CtipS326A-hyg/– ES cells in a subconfluent well of a 12-well plate were washed twice with 
1X PBS and incubated at 37°C in 300 ul of virus stock solution for 1 hour.  Every 15 
minutes, the 12-well plate was gently shaken by hand to distribute the virus.  Following 
virus infection, the cells were washed twice with 1X PBS and provided fresh DMEM 
supplemented with 15% heat-inactivated FBS, 2 mM L-glutamine, 1% non-essential 
amino acids, 0.1 mM 2-mercaptoethanol, and LIF (1,000 units/mL) (Esgro; Millipore).  
The next day, the virus-infected cells were seeded at a 1:250 dilution onto a 10-cm layer 
of mitotically inactive primary embryonic fibroblasts (Feeders).  DNA was prepared from 
individually picked ES subclones and analyzed by Southern for removal of the loxP-





      A2.  CtipCo 
      The conditional-null CtipCo-neo targeting vector consisted of a 9.7 kb fragment 
containing exon 1 and exon 2 of Ctip (Figure 24B).  A single loxP site was introduced 
upstream of the transcriptional initiation site in the NheI restriction site of intron 1.  A 
second loxP site was cloned into the EcoRV restriction site of intron 2, along with an 
FRT-flanked PGK-neomycin resistance cassette.  The HSV-TK negative selection gene 
cassette was included in the construct for selection against random integration.  Gene 
targeting was performed by electroporating NotI-linearized targeting vector DNA (30 ug 
of DNA at 0.8 kV/3 µF) into 129/Sv ES cells and selecting for neomycin-resistant ES 
subclones.  Genomic DNA prepared from the surviving drug-resistant ES cell subclones 
was digested with SpeI and analyzed by Southern blotting with a 5’ flanking Ctip probe 
(“Ctip-2”) upstream of exon 1 (Figure 24A).  Several heterozygous CtipCo-neo/+ 129/Sv ES 
clones were obtained (Figure 25). 
 
B.  ES cell culture 
      ES cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Cellgro) 
supplemented with 15% heat-inactivated fetal bovine serum (FBS; HyClone ES Cell 
Screened, Thermo Scientific), 2 mM L-glutamine, 1% non-essential amino acids, 100 
ug/mL penicillin/streptomycin, 0.1 mM 2-mercaptoethanol, 1.25 ug/mL Plasmocin 
(InvivoGen) and LIF (1,000 units/mL) (Esgro; Millipore) at 37°C in 5% CO2/95% 
humidity.  For all recombination reporter assays, ES cells were maintained in the above 
ES medium without penicillin/streptomycin, Plasmocin, and LIF.  Unless otherwise 
noted, ES cells were grown on a layer of mitotically inactive primary embryonic 
40 
	  
fibroblasts in the presence of LIF to maintain their pluripotency.  For gene targeting, ES 
cells were selected with 250 ug/mL neomycin (G418/Geneticin; Gibco), 200 ug/mL 
hygromycin B (Roche), 1.5 ug/mL puromycin (Sigma), or 10 ug/mL 6-thioguanine 
(Sigma).  ES cells targeted with the HSV-TK containing targeting vectors mentioned in 
Section A were simultaneously selected with 2 µM ganciclovir (Roche) for 3 days 
starting on day 2 of selection.  All ES cells were frozen down in an equal volume of 2X 
freezing medium, 80% heat-inactivated FBS and 20% dimethylsulfoxide (DMSO). 
 
C.  Animals 
      The mice used in this study were housed in an AAALAC-accredited facility at 
Columbia University.  All experiments involving mice were performed according to the 
Columbia University Institutional Animal Care and Use Committee-approved protocols.  
CtipS326A-neo/+ 129Sv ES cells were injected into C57BL/6J blastocysts to derive germline 
chimeric male mice, which were mated to C57BL/6J females (B6).  CtipS326A-neo/+ mice 
were intercrossed to generate homozygous CtipS326A-neo/S326A-neo mutants or mated with 
Ctip+/– animals to obtain CtipS326A-neo/– mice.  Heterozygous CtipS326A-neo/+ animals were 
also crossed to mice that ubiquitously express Cre recombinase (RosaCre animals) to 
produce CtipS326A/+ mice with the loxP-flanked neomycin resistance cassette removed 
(Figure 7D).  Subsequent intercrossing of these animals yielded homozygous 
CtipS326A/S326A mice.  The CtipS326A/S326A mice were also crossed with homozygous 
AbxS404A/S404A and homozygous Bach1FH-S994A/FH-S994A mutant mice (kindly provided by Dr. 
Thomas Ludwig, Columbia University) to produce heterozygous double mutant mice, 
which upon intercrossing, generated homozygous double mutant animals (e.g., 
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AbxS404A/S404A/CtipS326A/S326A (AC) and Bach1FH-S994A/FH-S994A/CtipS326A/S326A (BC)).  
Similarly, the AbxS404A/S404A and Bach1FH-S994A/FH-S994A mice were crossed and ultimately 
bred to generate the AbxS404A/S404A/Bach1FH-S994A/FH-S994A (AB) double mutant animals.  The 
double mutant mice were then crossed to produce animals bearing four mutant alleles 
(e.g., AbxS404A/+/Bach1FH-S994A/FH-S994A/CtipS326A/+) and subsequently bred to generate triple 
homozygous (AbxS404A/S404A/Bach1FH-S994A/FH-S994A/CtipS326A/S326A (ABC)) mutant mice. 
      The CtipCo-neo/+ 129Sv ES cells were also injected into C57BL/6J blastocysts to derive 
germline chimeras that mated with B6 females.  CtipCo-neo/+ heterozygotes were mated 
with Flpe-expressing mice to produce offspring expressing the CtipCo allele with the 
FRT-flanked neomycin cassette removed (Figure 24D).  By intercrossing these animals, 
homozygous CtipCo/Co mice were obtained and used in a breeding regimen to derive 
experimental and control cohorts as described in Section B5a of Chapter IV.  The WapCre 
mice (Ludwig et al., 2001a) and the p53flex7 mice, hereafter referred to as the p53 
conditional-null (p53Co) mice, have been described (Chen, Z. et al., 2005; Shakya et al., 
2011).  Additionally, the p53LSL-R270H mouse strain (number 01XM3) (Olive et al., 2004) 
was obtained from the NCI-Frederick Mouse Repository.  Homozygous CtipCo/Co mice 
were also mated with RosaCre animals (kindly provided by Dr. Thomas Ludwig, 
Columbia University) to generate CtipCo-rec/+ RosaCre/+ heterozygotes, which were then 
intercrossed to assess the function of the Cre-recombined product of the conditional-null 
CtipCo allele.  Furthermore, analysis of concomitant loss of Ctip and Ku70 was made 
possible with the Ku70–/– mice provided by Dr. Shan Zha (Columbia University).  All 
mice generated in this study were maintained on a mixed 129/B6 genetic background. 
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C1.  Whole-body IR treatment 
      To assess the sensitivity of various mouse genotypes to ionizing radiation (IR), mice 
at 2 months of age were irradiated on a rotating platform with a sublethal dose of 8 Gys 
using the Mark I Cesium-137 mouse irradiator (J. L. Shepard and Associates).  All mice 
were carefully monitored for at least 6 weeks following irradiation for signs of distress or 
death, at which time necropsies were performed. 
 
D.  Generating MEFs 
      To generate primary mouse embryonic fibroblasts (MEFs), E13.5 day embryos were 
aseptically dissected from a pregnant mother mouse and placed in a 10-cm dish 
containing sterile 1X PBS.  The uterine membrane was cut to free the individual 
embryos.  The yolk sac of each embryo was collected and saved in a 1.5 mL Eppendorf 
tube for genotyping.  Using forceps, the embryo’s head, intestines and liver were 
removed.  The remainder of the embryo was transferred to a 60 mm plate and minced 
using two scalpels in a sterile tissue culture hood.  Each embryo was incubated at 37ºC in 
500 ul of Trypsin-EDTA 1X (0.25% Trypsin, 2.21 mM EDTA in Hank’s Balanced Salt 
Solution without sodium bicarbonate, calcium, and magnesium) (Cellgro) for 8 minutes.  
Following incubation, 9.5 mL of MEF media (see below, Section F) was added to each 
60 mm dish and the cells/media were passed first through an 18.5 gauge needle (3 times) 
and then through a 21.5 gauge needle (3 times) using a 10 mL syringe.  On the last needle 
passage, the cells/media (10 mL) were transferred to a 15 mL tube with 4 mL of MEF 
media.  The tube was inverted three times and then left undisturbed for 5 minutes to 
allow the undigested tissue to settle at the bottom of the tube.  Only the cells in a single-
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cell suspension (~12 mL) were then plated onto a 10-cm gelatinized dish.  The next day, 
the cells were washed twice with 1X PBS and provided fresh MEF media.  When 
confluent, the cells were split at a 1:5 dilution and seeded onto five 10-cm gelatinized 
plates for freezing and maintenance.  Using Lipofectamine 2000 (Invitrogen), primary 
MEFs at early passage were immortalized by transfection with the pMSSVLT plasmid 
(10 ug/10-cm plate), a vector which drives expression of the SV40 large-T antigen 
(Schuermann M., 1990).  Cells were passaged until only the immortalized MEFs 
remained in culture (approximately 12 passages/4 weeks).  Established immortalized 
MEF cell lines were then frozen down and re-genotyped. 
 
E.  Generating mammary tumor cells 
      Two weeks after mammary neoplasms were detected by palpation, the mouse was 
sacrificed and a piece of tumor tissue was collected in order to establish a primary 
mammary tumor cell line.  The mammary tumor tissue was placed in a 60 mm dish and 
transferred to a sterile tissue culture hood.  Using two scalpels, the mammary tumor 
tissue was diced and then incubated at 37ºC for 5 minutes in 500 ul of Trypsin-EDTA 1X 
(0.25% Trypsin, 2.21 mM EDTA in Hank’s Balanced Salt Solution without sodium 
bicarbonate, calcium, and magnesium) (Cellgro).  After trypsinization, 5 mL of MEF 
media was added directly to the 60 mm plate.  With a 10 mL syringe, the cells/media 
were passed through an 18.5 gauge needle three times followed by three passages with a 
21.5 gauge needle.  After the final passage, the cells/media were dispensed onto a 
gelatinized 10-cm plate.  5 mL of MEF media was again added to the 60 mm plate to 
collect the remaining cells and this too was transferred to the 10-cm plate.  The 10-cm 
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plate was then left undisturbed for 4 days in the 37ºC incubator to allow for the tumor 
tissue pieces to adhere before being provided fresh MEF media.  Mammary tumor cells 
were split once the cells reached 60% confluency.  By approximately the sixth passage (4 
weeks), the mammary tumor cell line was established, the cells were frozen down and 
collected for DNA. 
      Ctip/p53-null mammary tumor cell lines were established from mammary carcinomas 
that arose in experimental females (e.g., CtipCo/–,Co/Co/p53Co/+,Co/Co/WapCre/+) following 
mammary-specific co-inactivation of Ctip and p53 (Figure 30).  Mammary tumor cell 
lines were also established from the breast tumors that developed in CtipCo/Co/p53LSL-
R270H/+/WapCre/+ experimental females, which underwent mammary-specific inactivation 
of Ctip and expression of the p53R270H dominant-negative mutation (Figure 31).  
Additionally, p53-null and p53R270H mutant mammary tumor cell lines were derived from 
the mammary tumors of control CtipCo/+,+/+/p53Co/+,Co/Co/WapCre/+ and CtipCo/+,+/+/p53LSL-
R270H/+/WapCre/+ females, respectively (Figures 30 and 31). 
 
F.  MEFs and mammary tumor cell culture 
      Primary and immortalized MEFs and mouse mammary carcinoma cell lines were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Cellgro) supplemented with 
10% heat-inactivated fetal bovine serum (FBS; Tissue Culture Biologicals), 100 ug/mL 
penicillin/streptomycin, 2 mM L-glutamine, and 1.25 ug/mL Plasmocin (InvivoGen) and 
grown on tissue culture plates pre-treated with 0.1% gelatin.  All cell lines were grown at 
37°C and maintained in a humidified atmosphere of 5% CO2.  Primary MEFs were 
mitotically inactivated with 10 ug/mL mitomycin C (Sigma) in MEF media for 2 hours at 
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37°C to be used as feeders for ES cells.  All cells were frozen in an equal volume of 2X 
freezing medium, 80% heat-inactivated FBS and 20% dimethylsulfoxide (DMSO). 
 
G.  Molecular analysis 
      G1.  Southern analyses 
      For genotyping by Southern analysis, genomic DNA was prepared from mouse tails, 
embryo yolk sacs, mammary tumor tissues, mammary tumor cells, MEF cells, and ES 
cells by dissolving the tissue or cultured cells in 500 ul of lysis buffer (50 mM Tris-HCL, 
pH 8.0, 0.1 M NaCL, 2 mM EDTA, 1% SDS) containing 200 ug/mL proteinase K 
overnight at 56°C.  Genomic DNA was precipitated with isopropanol, dissolved in 1X TE 
buffer (10 mM Tris-HCL, 1 mM EDTA, pH 8.0), and digested (10 ug DNA) with the 
appropriate restriction enzyme(s) in a volume of 30 ul with 10 units of enzyme.  The 
digested genomic DNA was fractionated on a 0.8% agarose, 1X TAE gel, depurinated in 
0.25 M HCL, denatured in 0.5 M NaOH/1.5 M NaCL and blotted onto a Biodyne B nylon 
membrane (Pall) via an upward capillary transfer for at least 6 hours.  To permanently 
immobilize the DNA to the membrane, the membrane was baked at 80°C for 15 minutes 
and then pre-hybridized with 350 ug of sonicated denatured salmon sperm DNA in 10 
mL Rapid Hybridization buffer (5X SSC, 10% polyethylene glycol MW 8000, 5% 
poly(sodium 4-styrenesulfonate), 0.2% cetylpyridinium chloride monohydrate) for 35 
minutes at 65°C in a rotating hybridization oven.  A [α32P]-dCTP-labeled (Perkin Elmer) 
probe was prepared using the Prime-It II Random Primer Labeling Kit (Agilent 
Technologies).  The 32P-labeled probe was denatured with 250 ug of salmon sperm DNA 
by boiling for 10 minutes at 95°C before being placed on ice and added directly to the 
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blot with pre-hybridization solution for a 2 hour incubation at 65°C.  Following 
hybridization, the membrane was washed sequentially for 12 minutes at 65°C in 500 mL 
of wash 1) 2X SSC, 0.5% SDS, 2) 1X SSC, 0.5% SDS, 3) 0.1X SSC, 0.1% SDS, dried on 
Whatman paper, wrapped in Saran wrap, and exposed to Kodak BioMax MS film with 
two amplifying screens at -80°C overnight. 
      The Ctip+ (7.9 kb), CtipS326A (7.9 kb), Ctip– (6 kb), CtipS326A-neo (5.8 kb), and CtipS326A-
hyg (10.4 kb) alleles were detected by hybridizing PvuII-digested genomic DNA with the 
5’ flanking Ctip probe spanning exon 9 (“Ctip #6”) (Figure 7A).  The Ctip+ (12.7 kb) 
allele was also occasionally detected by hybridizing SpeI-digested DNA with the 5’ 
flanking Ctip probe upstream of exon 1 (“Ctip-2”) (Figure 24A).  This “Ctip-2” probe 
also recognized the CtipCo-neo (8.3 kb) allele in SpeI-digested DNA.  Additionally, the 
Ctip genotype could be determined by digesting the DNA with BglII/NheI and 
hybridizing with a probe (“CtipCo-SmaI”) spanning exon 1 (data not shown).  This 
“CtipCo-SmaI” probe discriminates between the unrecombined CtipCo (5.6 kb) allele and 
the recombined CtipCo-rec (4.2 kb) allele lacking the transcriptional initiator methionine; 
however, both the Ctip+ and Ctip– alleles are recognized as a 3.3 kb band.  Therefore, to 
discriminate between these two alleles, the DNA had to be digested with PvuII and 
hybridized with the exon 9-spanning Ctip probe (“Ctip #6”) (see above, Figure 7A). 
      The Rosa+ (10.5 kb) and the RosaCre (2.8 kb) alleles were detected by digesting the 
DNA with EcoRV and hybridizing with the “Rosa” probe.  EcoRV-digested DNA was 
also hybridized with the “Flpe” probe to identify the presence of Flpe recombinase.  The 
presence of WapCre was detected by digesting the DNA with EcoRI and hybridizing with 
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the “Wap” probe.  A 6.8 kb band represented the Wap+ allele, while a 3.5 kb, 8 kb or 9 kb 
band represented the WapCre allele.  To determine the p53 genotype of various DNA 
samples, the p53+ (4.6 kb), p53Co-rec (4.3 kb) and p53Co (2.5 kb) alleles were 
discriminated by hybridization of EcoRV-digested genomic DNA with the “p53Co” 
probe.  Additionally, the p53 LSL-R270H (6.8 kb) allele was detected following hybridization 
of EcoRV-digested DNA with the “SV40” probe.  To assess amplification of c-Met, the 
DNA samples were digested with EcoRI and hybridized with the “c-Met” probe.  The 
intensity of the bands relative to the amount of DNA loaded on the gel was compared 
across samples using tail DNA, which lacks c-Met amplification, as a control. 
G2.  PCR analysis 
      Polymerase chain reaction (PCR) genotyping was performed on genomic DNA 
prepared from mouse tails, embryo yolk sacs, mammary gland tissue, MEF cells, and ES 
cells as described above.  PCRs were carried out using Taq DNA Polymerase 
(Invitrogen) with 10X PCR buffer (200 mM Tris-HCL (pH 8.4), 500 mM KCL), 50 mM 
MgCl2, a 10 mM dNTP mix, and when necessary, 100% DMSO.  Each PCR reaction 
occurred in a total volume of 25 ul and was run on an Eppendorf Mastercycler Gradient 
PCR machine.  Unless otherwise noted, 1 ul of genomic DNA was amplified per sample 
and oligonucleotide primers were used at a 10 µM concentration. 
      The Ctip+ (350 bp) and CtipS326A (430 bp) alleles were amplified using 1 ul of 1:10 
diluted DNA with primer 1 and primer 2 (see Table 1 below) under the following PCR 
conditions: 94°C 3 min (1 cycle); 94°C 30 sec, 62°C 30 sec, 72°C 30 sec (40 cycles); 
72°C 3 min (1 cycle); 4°C hold.  Using the same PCR conditions and primers 3 and 4, the 
Ctip+ (250 bp) and CtipCo (290 bp) alleles were amplified.  These primers amplify across 
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the single loxP site in intron 1 of Ctip.  The CtipCo-rec (350 bp) allele was amplified in the 
presence of DMSO with primer 3 and primer 5 using the same PCR conditions as above 
except with an annealing temperature of 58°C. 
      To genotype the Abx+ and AbxS404A alleles, primers 6 and 7 were used with 1 ul of 
1:10 diluted DNA in the presence of DMSO under the following PCR conditions: 94°C 3 
min (1 cycle); 94°C 30 sec, 54°C 30 sec, 72°C 30 sec (29 cycles); 72°C 3 min (1 cycle); 
4°C hold.  These primers amplify a 190 bp band for the Abx+ allele and a 250 bp band for 
the AbxS404A allele.  Primers 8 and 9 were used at a 100 µM concentration to amplify the 
Bach1+ (520 bp) and Bach1FH-S994A (350 bp) alleles.  The PCR conditions for this reaction 
were as follows: 94°C 3 min (1 cycle); 94°C 30 sec, 64°C 1 min, 72°C 1 min (34 cycles); 
72°C 3 min (1 cycle); 4°C hold.  Finally, the Ku70+ (450 bp) and Ku70–  (320 bp) alleles 
were amplified in the presence of DMSO using primers 10, 11, and 12 under the 
following conditions: 94°C 3 min (1 cycle); 94°C 30 sec, 57°C 30 sec, 72°C 1 min (34 
cycles); 72°C 5 min (1 cycle); 4°C hold.  All amplified fragments were separated by 2% 









Table 1.  PCR primers. 
Primer # Primer Name Primer Sequence 
1 Ctip-HpaI junction 5’ 5’- GTCCTCAGTGGGCTTCATTTC 
2 Ctip-mct2-Rev 5’- ATGTCTAAGAGAGAGGGGGAG 
3 Ctip-NheI 5’ 5’- GGGCTCAGTTTCTGGGTGCT 
4 Ctip-NheI 3’ 5’- CATGTTGGGCATGGTGACTC 
5 Ctip-EcoRV 3’ 5’- TTGCAGAGAACCAAAGTTCAGC 
6 Abx-Ex 9 Forw 5’- CAGCAGGCACCAAGACAAGG 
7 Abx-3’ UTR Rev 5’- TCTGTGTATTAATCCAGAAGGCAAAGA 
8 Bach1 5’ 5’- GCCAAGTGTCCCAGCTCAAA 
9 Bach1 3’ 5’- TCAGTGTCCCAGGCAACTAAG 
10 Ku70 5’ 5’- ACACGGCTTCCTTAATGTGA 
11 Ku70 3’ 5’- GGCTGGCTTTAGCACTGTCA 
12 Ku70_Loxp1h3 5’- ACGTAAACTCCTCTTCAGACCT 
 
 
H.  Histological analysis 
      Mice were sacrificed and autopsied when they became moribund or had a palpable 
tumor mass.  All major organs and any tumors identified were dissected, fixed overnight 
in 10% buffered formalin, and dehydrated prior to paraffin embedding.  Paraffin blocks 
were sectioned at 4 µm and stained with hematoxylin and eosin for histopathological 
evaluation.  For immunophenotyping, all specimens were labeled with antibodies against 
E-cadherin (BD Pharmingen), vimentin (RDI), CK5 (Covance), CK14 (Covance), ER 
(Santa Cruz) and PR (ABR). 
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I.  Glutathione-agarose affinity chromatography 
     Rosetta(DE3)pLysS competent cells (Novagen) were transformed with <0.5 ug of the 
GST-containing expression plasmid and spread onto an ampicillin/chloramphenicol plate 
(75 ug/mL ampicillin and 38 ug/mL chloramphenicol).  A single colony from the plate 
was inoculated in 3 mL of 1X LB Broth (Difco, BD) media containing ampicillin and 
chloramphenicol throughout the day at 37ºC.  Half of the overday bacterial culture was 
then inoculated overnight at 37ºC.  The next morning, two 1 L flasks were prepared with 
400 mL of 2X LB media, 150 ul of 200 mg/mL ampicillin, 400 ul of 38 mg/mL 
chloramphenicol, and 50 mL of the overnight culture and put to shake at 37ºC until the 
OD600= 0.5 (~ 1.5 hrs), at which point, 160 ul of 1M IPTG was added (final concentration 
is 0.4 mM) to each flask to induce production of the plasmid-encoded protein.  The flasks 
were shaken at 37ºC for an additional 4 hours.  The cells were pelleted by centrifugation 
at 5,000 rpm for 5 minutes at 4ºC and each pellet was resuspended in 8 mL of cold Buffer 
D (50 mM Hepes pH 7.5, 0.4 M NaCL, 0.1 mM EDTA pH 8.0, 0.1% NP40, 10% 
glycerol) supplemented with 1 mM dithiothreitol (DTT) and a complete protease 
inhibitor pellet (Roche).  The resuspended pellets were stored at -80ºC overnight. 
Two hours before use, the glutathione-agarose resin (Sigma) was prepared by adding 
0.3 g of glutathione-agarose resin to 30 mL of cold Buffer E (50 mM Hepes pH 7.5, 0.15 
M NaCL, 0.1 mM EDTA pH 8.0, 10% glycerol).  The resin/buffer was mixed and stored 
at 4ºC until swollen.  Once swollen, the glutathione-agarose resin was equilibrated by 
washing in 20 mL of Buffer D twice.  Between each wash, the resin was centrifuged at 
2,000 rpm for 2 minutes at 4ºC and the supernatant was discarded.  The resin was then 
51 
	  
washed with 10 mL of Buffer D supplemented with 1 mM DTT and a complete protease 
inhibitor pellet (Roche), spun down, and stored at 4ºC until needed. 
      To purify the GST-fusion protein, the cell suspensions were thawed on ice and 
sonicated 15 times with a 30-second burst followed by a 15-second rest.   The culture was 
pelleted and the supernatant was added to the equilibrated glutathione-agarose resin to 
mix for 2 hours at 4ºC.  After mixing, the beads were pelleted and washed two times with 
20 mL of Buffer D supplemented with 1 mM DTT and a protease inhibitor pellet 
(Roche).  Between each wash, the beads were centrifuged at 2000 rpm for 2 minutes at 
4ºC and the supernatant was removed.  These rounds of washes/centrifugation were 
repeated two more times with 20 mL of Buffer E supplemented with 1 mM DTT.  
Following this final spin, ~ 2 mL of the Buffer E wash was left behind.  The resin was 
then transferred into a 5 mL Econo-Column (Bio-Rad).  The GST-fusion protein was 
eluted in cold Elution Buffer (0.1g glutathione dissolved in 50 mL of Buffer E 
supplemented with 1 mM DTT, pH 8.0) made fresh and the eluents were collected in 1 
mL fractions.  The protein concentration was checked in each fraction using the Bio-Rad 
Protein Assay reagent (Bio-Rad). The eluted material was subjected to SDS-PAGE and 
stained with Coomassie blue (Gibco) to estimate the yield of intact fusion protein. 
      I1.  Generation of a mouse-specific Brca1 antibody 
      A cDNA fragment containing amino acids 1484-1812 of murine Brca1 (mBR-SZ) 
was subcloned into the GST-containing expression vector pGEX2.  The glutathione S-
transferase (GST)-Brca1 fusion protein was purified by glutathione-agarose affinity 




J.   Western analysis and antibodies 
J1.  Western blot 
    Cells were scraped in 5 mL of cold 1X PBS and lysed in low salt Nonidet P-40 
(NP40) lysis buffer (10 mM Hepes, pH 7.6, 1 M NaCL, 0.1% NP40, 5 mM EDTA, 10% 
glycerol) supplemented with 1 mM dithiothreitol (DTT), 5 mM sodium fluoride, 0.1 mM 
sodium orthovanadate, and complete protease inhibitor (Roche).  To detect Brca1 
hyperphosphorylation following 1 mM hydroxyurea (Sigma) treatment for 1 hour, cells 
were lysed 1 hour post-drug removal in low salt Nonidet P-40 (NP40) lysis buffer 
supplemented with 1 mM DTT, 25 mM sodium fluoride, 10 mM sodium orthovanadate, 
and complete protease inhibitor (2x concentration).  Lysates were cleared by high-speed 
centrifugation at 4ºC for 10 minutes.  The protein concentration of each sample was 
determined by using the Bio-Rad Protein Assay reagent (Bio-Rad).  Samples were 
prepared for SDS-PAGE by adding 5X protein loading dye (0.313 M Tris-Cl pH 6.8, 
10% SDS, 50% glycerol, 25% 2-mercaptoethanol, 0.05% bromophenol blue) and boiled 
at 150ºC for 4 minutes to elute the proteins.  Samples were fractionated on Tris-glycine 
polyacrylamide gels (6-10%) and transferred onto Optitran nitrocellulose membranes 
(Whatman) in western transfer buffer (25 mM Tris-Cl pH 7.6, 190 mM glycine, 20% 
methanol, 0.04% SDS) overnight at 22 V at room temperature.  Membranes were blocked 
at room temperature for 35 minutes in 10% milk in TBS-T (20 mM Tris-Cl pH 7.6,   
0.137 M NaCL, 0.1% Tween 20), washed for 5 minutes in TBS-T, and then incubated at 
room temperature with the desired dilution of primary antibody in 2% milk in TBS-T for 
2.0-2.5 hours.  The membranes were then washed in TBS-T three times for 10 minutes 
and incubated for 1 hour at room temperature with a 1:10,000 dilution of either HRP-
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conjugated goat anti-mouse (Sigma) or donkey anti-rabbit (Amersham) secondary 
antibodies prepared in 2% milk in TBS-T.  Following incubation and a quick rinse in 
TBS-T, the membranes were washed two times for 10 minutes each in TBS-T.  The 
membranes were incubated with the SuperSignal West Pico Chemiluminescent substrate 
(Pierce) or the more sensitive SuperSignal West Dura Chemiluminescent substrate 
(Pierce) for 4 minutes before exposure of the immobilized proteins on autoradiographic 
film. 
J2.  Antibodies 
     Immunoblotting was performed with a rabbit polyclonal antibody raised against 
amino acids 1484-1812 of mouse Brca1 (mB-57J; 1:2000 dilution) (Section I1) and a 
monoclonal mouse anti-CtIP antibody (14-1; 1:50 dilution) (Yu and Baer, 2000).  Other 
antibodies used include: monoclonal anti-α-tubulin (1:10000 dilution) (DM1A, 
Calbiochem) and polyclonal anti-Na+/K+ ATPase (1:5000 dilution) (RDI Division, 
Fitzgerald Industries). 
 
K.  Co-immunoprecipitation of Ctip with Brca1 
      Cells were scraped in 5 mL of cold 1X PBS and centrifuged at 1200 rpm for 2 
minutes at 4°C.  The cell pellet was lysed in 10 times its volume with freshly made cold 
Buffer A (10 mM Hepes pH 7.9, 10 mM KCl, 0.1 mM EGTA) supplemented with 1 mM 
dithiothreitol (DTT), 5 mM sodium fluoride, 0.1 mM sodium orthovanadate, and 
complete protease inhibitor (Roche).  Following lysis for 15 minutes on ice, a 1/16 
volume of 10% NP40 was added to each sample.  The samples were vortexed vigorously 
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for 10 seconds, set on ice for 5 minutes, and centrifuged at 2000 rpm for 5 minutes at 
4°C.  The supernatant or cytoplasmic fraction was removed while the nuclear pellet was 
resuspended in 1.5 times its volume with freshly made cold Buffer C (20 mM Hepes pH 
7.9, 10% glycerol, 0.4 M NaCL, 0.5 mM EDTA, 0.5 mM EGTA, 0.1% NP40) 
supplemented with 1 mM DTT, 5 mM sodium fluoride, 0.1 mM sodium orthovanadate, 
and complete protease inhibitor (Roche) and put at 4°C to rotate for 15 minutes.  After 
mixing, the samples were spun down at maximum speed for 10 minutes at 4°C.  The 
supernatant or nuclear extract was transferred to a new tube and the protein concentration 
was measured using the Bio-Rad Protein Assay reagent (Bio-Rad). 
      The nuclear extract lysate (~800 ug-1500 ug) was incubated by rotating at 4°C 
overnight with either the mouse-specific Brca1 polyclonal antibody (mB-56F; 1:20 
dilution) or the matched pre-immune serum (mB-56Pre; 1:20 dilution) in a total volume 
of 300 ul.  The next day, 25 ul of protein A sepharose beads (20% slurry; GE Healthcare) 
per sample were prepared by washing the beads four times in 500 ul of cold Buffer C 
supplemented with 1 mM DTT, 5 mM sodium fluoride, 0.1 mM sodium orthovanadate, 
and complete protease inhibitor (Roche) and spinning down at 8000 rpm for 30 seconds 
at 4°C between each wash.  The packed protein A sepharose beads were added to each 
lysate/antibody sample and put to rotate at 4°C for 1 hour.  After incubation, the samples 
were spun down (30 seconds, 8000 rpm, 4°C) and the supernatant/flow-through was 
collected.  The lysate and antibody-bound beads were washed three times with 500 ul of 
cold Buffer C supplemented with 1 mM DTT, 5 mM sodium fluoride, 0.1 mM sodium 
orthovanadate, and complete protease inhibitor (Roche).  After the final wash, as much 
buffer as possible was removed and 40 ul of 2X protein loading dye was added.  These 
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samples were boiled for 4 minutes at 150ºC to elute the bound proteins and fractionated 
on a 6% Tris-glycine polyacrylamide gel set at 95 V.  The gel was transferred overnight 
at 22 V at room temperature and the western blot procedure was followed as described in 
Section J. 
 
L.   Gene-targeting analysis 
       Gene-targeting efficiency at the Pim1 locus was measured by electroporating Ctip+/– 
and CtipS326A/– ES cells with the XhoI-linearized p59xDR-GFP6 DNA targeting vector 
(30 ug of DNA at 0.8 kV/3 µF) (a kind gift of Maria Jasin; Moynahan et al., 2001a), 
selecting for hygromycin resistance, and evaluating the drug-resistant clones for gene 
targeting by Southern analysis.  Genomic DNA of individual hygromycin-resistant clones 
was prepared, digested with HincII, and hybridized with the “P22” probe (see Figure 3 of 
Moynahan et al., 2001a).  A 3.6 kb fragment represents the wildtype Pim1 allele while a 
2.4 kb fragment represents the targeted Pim1 allele.  The p59xDR-GFP6 plasmid contains 
a promoterless hygromycin-resistance marker flanked by targeting arms comprised of 
Pim1 genomic DNA.  Thus, most hygromycin-resistant clones are correctly targeted by 
homologous recombination because hygromycin expression is dependent on the Pim1 
promoter.  However, hygromycin-resistant clones can also arise upon random integration 
of the p59xDR-GFP6 construct adjacent to transcriptional promoters at other genomic 
sites. 
       For assessing the gene-targeting efficiency of Ctip+/– and CtipS326A/– ES cells at the 
Rb locus, ES cells were electroporated with the HpaI-linearized Rb-G (Rb-pgkhyg) 
targeting vector (30 ug of DNA at 0.8 kV/3 µF).  The Rb-G vector was derived by 
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inserting a PGK-hyg cassette into the BglII site within exon 19 of Rb (see Figure 1d of   
te Riele et al., 1992).  ES cells were selected with hygromycin and genomic DNA was 
prepared from the surviving clones.  The gene-targeting efficiency of the ES cells was 
revealed following an EcoRI digest of the genomic DNA and Southern blot hybridization 
analysis with the “p153” probe (same as probe B in Figure 1a of te Riele et al., 1992).  
The wildtype and targeted Rb alleles are 9.7 and 4.9 kb, respectively.  The Rb-pgkhyg 
targeting vector contains the mouse pgk1 (phosphoglycerate kinase) promoter to drive 
expression of the hygromycin-resistance gene.  Therefore, in contrast to the p59xDR-
GFP6 vector, a greater proportion of the hygromycin-resistant clones result from random 
integration of the Rb-G vector and thus, the targeting efficiency with this vector is lower 
overall. 
 
M.  Recombination reporter assays 
       To measure repair of I-SceI-induced chromosomal DNA breaks, each ES clone 
carrying a specific chromosomally integrated GFP recombination reporter was 
trypsinized and seeded in 6-wells of a 12-well gelatinized plate in the absence of a feeder 
layer (~1 x 106 cells/well).  The next day, ES cells (~50% confluent) were provided fresh 
media (ES media minus penicillin/streptomycin, Plasmocin, and LIF) and transfected 
with 2.5 ug of either empty vector (pCAGGS) or the I-SceI expression vector (pCβASce) 
using Lipofectamine 2000 (Invitrogen).  Following a 24 hour incubation, each well of 
transfected cells was washed twice with 1X PBS, trypsinized, and replated in a well of a 
6-well gelatinized plate.  48 hours after replating and 72 hours post-transfection, the cells 
were washed with PBS and trypsinized prior to resuspension in cold 1% FCS/PBS.  
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Samples were placed on ice and protected from light before flow cytometric analysis on 
the FACSCalibur using the CellQuest software (BD Biosciences).  The proportion of 
GFP positive events (at least 70,000 events were scored per sample) provided a measure 
of DSB repair. 
      M1.  Homology-directed repair (HDR) 
 By assessing the gene-targeting efficiency of Ctip+/– and CtipS326A/– ES cells at the 
Pim1 locus, DR-GFP reporter ES cell lines of each genotype were obtained (Section L).  
These correctly targeted Ctip+/– DR-GFP and CtipS326A/– DR-GFP ES clones were 
examined as described above for their ability to repair chromosomal DSBs by HDR. 
      M2.  Single-strand annealing (SSA) 
      Ctip+/– and CtipS326A/– ES cells were electroporated with the SacI/KpnI-linearized 
hprtSAGFP targeting vector (30 ug of DNA at 0.8 kV/3 µF) (a kind gift of Jeremy Stark; 
JS #125; Stark et al., 2004) and plated onto gelatinized-only 10-cm plates.  This targeting 
construct has homology to the Hprt locus and contains a puromycin resistance marker as 
well as the SSA reporter substrate, SA-GFP.  Upon proper integration, the Hprt gene is 
inactivated, rendering the cells resistant to the nucleotide analog 6-thioguanine (6-TG) 
(Pierce et al., 2001; Stark et al., 2004).  Therefore, only correctly targeted clones should 
be resistant to both puromycin and 6-TG.  The ES cells were selected with 1.5 ug/mL 
puromycin for 5 days followed by 10 ug/mL of 6-TG for 4 days (from a stock of 10 
mg/mL in 1N NaOH).  For Southern analysis, genomic DNA was prepared from the 
doubly-resistant ES clones, digested with PstI, and hybridized with the “HPRT-SSA” 
probe, an 800bp iGFP HindIII fragment from the DR-GFP plasmid (a kind gift from 
Jeremy Stark; JS #65).  Since the Southern blot probe (“HPRT-SSA”) was part of the 
58 
	  
targeting construct, only the two GFP repeats were recognized, as 7.5 kb and 3.3 kb 
bands.  Multiple Ctip+/– SA-GFP and CtipS326A/– SA-GFP reporter ES clones were 
obtained and used to compare the SSA repair efficiency among genotypes. 
M3.  Alternative non-homologous end joining (alt-NHEJ) 
To assess the efficiency of DSB repair by alt-NHEJ, Ctip+/– and CtipS326A/– ES cells 
were electroporated with the XhoI-linearized pim-EJ2-GFP-hyg targeting vector (30 ug of 
DNA at 0.8 kV/3 µF) (kindly provided by Jeremy Stark; JS251; Bennardo et al., 2008).  
This targeting vector was generated by cloning the EJ2SceGFP gene into the pim-DR-
GFP vector (Moynahan et al., 2001; Bennardo et al., 2008).  Following electroporation, 
ES cells grown on feeders were selected with hygromycin and genomic DNA was 
prepared from the surviving colonies.  Southern analysis was performed by digesting the 
DNA with HincII and hybridizing with the “P22” probe (see Figure 3 of Moynahan et al., 
2001a).  This probe detects a 3.6 kb HincII fragment on the wildtype Pim1 allele and a 
2.4 kb fragment on targeted alleles generated by proper homologous integration of the 
EJ2-GFP-hyg reporter into the mouse Pim1 locus.  The ability to repair I-SceI-induced 
DSBs by alt-NHEJ was then examined using several correctly targeted Ctip+/– EJ2-GFP 
and CtipS326A/– EJ2-GFP ES clones identified by Southern analysis. 
 
N.  Clonogenic survival assays 
      For each ES cell line, a 90% confluent well of a 6-well plate was trypsinized and the 
live cells were enumerated by counting trypan-blue negative cells.  1000 cells/well (for 
untreated controls) or 5000 cells/well (for drug-treated cultures) were then seeded onto 6-
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well feeder plates pre-coated with gelatin.  Per condition, each ES cell line was plated in 
triplicate.  At 24 hours post-seeding, ES cells were exposed for 24 hours to varying doses 
of camptothecin (CPT dissolved in DMSO, Sigma) (CPT: 0 ng/mL, 20 ng/mL, 40 ng/mL, 
80 ng/mL, and 100 ng/mL) or etoposide (ETO dissolved in DMSO, Sigma) (ETO: 0 
ng/mL, 30 ng/mL, 60 ng/mL, 90 ng/mL, 120 ng/mL, and 150 ng/mL).  At 48 hours post-
seeding, ES cells were exposed for 4 hours to varying doses of mitomycin C (MMC 
dissolved in PBS, Sigma) (MMC: 0 ng/mL, 50 ng/mL, 100 ng/mL, 150 ng/mL, and 200 
ng/mL).  Following drug treatment, all cells were washed twice with 1X PBS, provided 
fresh media, and allowed to grow at 37°C undisturbed for 7-9 days.  Colonies of 
surviving cells were then fixed in 10% buffered formalin for 30 minutes, stained with 
0.5% Crystal violet (Sigma) for 15 minutes, washed in water three times, and then 
counted. 
 
O.  Cytogenetic analysis 
Metaphase spreads were prepared from subconfluent ES cells, primary MEFs, and 
mammary tumor cells treated with or without mitomycin C (MMC 40 ng/mL; Sigma) for 
16 hours.  For ES cells, 0.05 ug/mL of KaryoMAX Colcemid solution (Gibco/Invitrogen) 
was added directly to the culture 4 hours prior to the end of MMC treatment (–/+ MMC).  
In contrast, for primary MEFs and mammary tumor cells, 0.05 ug/mL KaryoMAX 
Colcemid solution (Gibco/Invitrogen) was added 2 hours prior to the end of MMC 
treatment (–/+ MMC).  Since many mitotic cells are among the floating and poorly 
attached cells, at the end of MMC treatment, the media on all cells was collected, as was 
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the 1X PBS wash.  The remaining attached cells were then trypsinized and added to the 
collected media/wash.  The combined cell solution was then centrifuged at 1500 rpm for 
5 minutes.  The ES and primary MEF cell pellets were resuspended by vigorously 
flicking in ~1 mL of 0.56% KCL (w/v) hypotonic solution prepared fresh and pre-
warmed at 37ºC.  The mammary tumor cell pellets on the other hand were dislodged by 
vigorously flicking in pre-warmed 0.38% KCL (w/v) hypotonic solution.  Once the 
pellets were resuspended, the volume in the tube was brought up to 12 mL with the 
appropriate KCL solution (depends on cell type, see above).  The tubes were quickly 
inverted two times and submerged to the level of the KCL solution in a 37ºC water bath 
for 20 minutes (mammary tumor cells) or 30 minutes (ES cells and primary MEFs).  
Following KCL treatment, ~0.5 mL of freshly made pre-chilled (at -20ºC) fixative (3:1 
Methanol/Glacial Acetic Acid) was added dropwise directly to the KCL solution in each 
tube and mixed by gently inverting the tube twice.  An additional 0.5 mL of cold fixative 
was added and mixed before the tubes were centrifuged at 1200 rpm for 5 minutes and 
the supernatant was removed.  The swollen cell pellets were resuspended by adding ~0.5 
mL cold fixative drop by drop to the tube and softly tapping the sides.  The tube was then 
held over a constant gentle vortex while 5 mL of cold fixative was added dropwise.  The 
samples were then spun down at 1500 rpm for 5 minutes. Two additional rounds of the 
cold fixative wash took place before the cells were resuspended in 5 mL of fixative and 
stored at -20ºC overnight.  The next day, the cells were spun down at 1500 rpm for 5 
minutes and washed an additional two times in cold fixative as done the previous day.  
The fixed cell suspensions were then resuspended in ~1 mL of cold fixative and dropped 
onto glass slides.  Gentle blowing across the slide helped to spread the chromosomes.  
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Once dried, the slides were stained with the KaryoMAX Giemsa stain stock solution 
(Gibco/Invitrogen) for 3 minutes.  Excess stain solution was washed away with water and 
an air-stream was used to dry the slides.  At least 15 metaphases were scored per sample. 
 
P.   Proliferation assays 
      The MTT assay was used to evaluate the proliferation rate of early passage primary 
MEFs.  Four 96-well flat bottom gelatinized plates were needed, one for each day of 
measurement (Day 0 – Day 3).  8 wells of each cell line were seeded onto the four 96-
well plates; therefore, each cell line was seeded into 32 wells.  4000 cells/well were 
seeded for each triple ABC mutant cell line, while 2000 cells/well were seeded for the 
control cell lines.  The cells were cultured with MTT/solubilization solution either 24 
hours (Day 0 plate), 48 hours (Day 1 plate), 72 hours (Day 2 plate), or 96 hours (Day 3 
plate) after seeding.  On the appropriate day, the media was discarded from the 96-well 
plate and MTT stock (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; 
Sigma) (5 mg/mL in sterile PBS) diluted in MEF media was added to each well to 
produce a final MTT concentration of 500 ug/mL.  The cells were cultured with MTT for 
4 hours at 37°C to allow the formation of purple formazan crystals from MTT cleavage.  
100 ul of solubilization solution (10% SDS in 0.01 M HCL) was then added directly to 
each well and the cells were cultured at 37°C overnight.  The next day, the intensity of 
the precipitated formazan product was detected by measuring the UV absorbance with the 




Q.   Centrosome staining 
  Primary MEFs were seeded onto Poly-L lysine (Sigma) coated coverslips in a 12-
well plate (~70,000 cells/well) and allowed to attach for 2-3 days until 50% confluent.  
The cells were rinsed twice in 1X PBS before being fixed on ice in cold 100% methanol 
for 10 minutes.  The cells were then incubated in 1X PBS for 5 minutes with gentle 
shaking followed by incubation in serum-free DMEM for 5 minutes again with gentle 
shaking.  Net gel (150 mM NaCL, 5 mM EDTA, 50 mM Tris-Cl, 0.05% NP40, 0.25% 
Gelatin IV bloom 75, Type B (Sigma), 0.02% Na-azide, pH 7.4) was used to rinse the 
cells twice prior to permeabilization with 0.5% Triton-X/net gel at room temperature for 
10 minutes.  The cells were then gently shaken in 5% BSA/PBS blocking solution for 30 
minutes.  Double immunostaining was then performed using a rabbit polyclonal anti-
pericentrin (1:250 dilution) (Abcam) and a mouse monoclonal anti-α-tubulin (1:1000 
dilution) (Calbiochem) antibody diluted in 1% BSA/PBS for 1 hour at room temperature 
on the bench.  The cells were then washed three times for 5 minutes in 1% BSA/PBS 
before being incubated in Alexa Fluor 568 goat anti-rabbit IgG (1:400 dilution) and 
Alexa Fluor 488 goat anti-mouse IgG (1:400 dilution) (Invitrogen) secondary antibodies 
diluted in 1% BSA/PBS for 30 minutes.  Following four 5 minute washes in 1% 
BSA/PBS, the coverslips were stained with 4’, 6-diamidino-2-phenylindole (DAPI) 
(1:20,000 dilution, Sigma) for 5 minutes and mounted with Aqua-Poly/Mount mounting 





R.   Immunofluorescence staining 
 Cells were seeded onto Poly-L lysine (Sigma) coated coverslips in a 6-well plate and 
allowed to attach for 2 days until 50% confluent, at which point, the cells were either 
treated with or without 10 Gys of ionizing radiation (IR) (Gammacell 40).  One hour 
post-IR, the cells were rinsed twice in cold 1X PBS and fixed in freshly made cold 3.7% 
paraformaldehyde/PBS pH 7.4 for 15 minutes at room temperature on the bench.  The 
cells were then washed and incubated for 5 minutes in cold serum-free DMEM.  
Following this incubation, the cells were washed twice with cold 1X PBS, permeabilized 
in cold 0.5% Triton-X/net gel for 10 minutes at room temperature, and washed twice in 
net gel (150 mM NaCL, 5 mM EDTA, 50 mM Tris-Cl, 0.05% NP40, 0.25% Gelatin IV 
bloom 75, Type B (Sigma), 0.02% Na-azide, pH 7.4).  The cells were then blocked in 1% 
BSA/PBS at 4°C for at least 15 minutes.  Once the cells were blocked, they were 
incubated with primary antibody (diluted in 1% BSA/PBS) for 45 minutes at room 
temperature on the bench followed by two rinses and three washes with gentle shaking in 
1% BSA/PBS (5 minutes for the first two washes, 10 minutes for the last).  Next, the cells 
were incubated with the secondary antibody diluted in 1% BSA/PBS for 45 minutes.  
Again, the cells were rinsed and washed in 1% BSA/PBS (four 5-minute washes with 
gentle shaking).  Cold 1X PBS was used to rinse the cells twice before they were stained 
with 4’, 6-diamidino-2-phenylindole (DAPI) (1:20,000 dilution, Sigma) for 5 minutes 






R1.  Antibodies 
Immunofluorescence was performed with a rabbit polyclonal antibody raised against 
amino acids 1484-1812 of mouse Brca1 (mB-57J, 1:500 dilution) (Section I1), a 
monoclonal mouse anti-CtIP antibody (14-1; 1:10 dilution) (Yu and Baer, 2000), a rabbit 
polyclonal anti-Rad51 antibody (1:50 dilution) (Santa Cruz), and an anti-RPA (Ab-3, 
total RPA) mouse monoclonal antibody (1:100 dilution) (Calbiochem).  For staining with 
the anti-RPA mouse monoclonal antibody (Calbiochem), the cells were incubated in cold 
Extraction Buffer (10 mM Pipes pH 6.8, 100 mM Nalco, 300 mM sucrose, 3 mM 
MgCL2, 1 mM EGTA, 0.5% Triton X-100) for 5 minutes at 4°C prior to the two washes 
in 1X PBS and fixation in 3.7% paraformaldehyde/PBS.  Additionally, as a marker of 
DNA damage sites, either a rabbit polyclonal anti-γH2AX antibody (1:50 dilution) (Cell 
Signaling) or a mouse monoclonal anti-γH2AX antibody (JBW301, 1:200 dilution) 
(Millipore) was used.  The secondary antibodies used included Alexa Fluor 488 and 568 
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A.  INTRODUCTION 
      Germline mutations of the BRCA1 tumor suppressor gene are a common cause of 
familial breast and ovarian cancer.  Its protein product has been implicated in a 
remarkably broad spectrum of cellular processes that includes ubiquitination, cell cycle 
checkpoint control, DNA repair, centrosome duplication, and transcriptional regulation 
(reviewed in Deng, C.-X., 2006; Nagaraju and Scully, 2007; Greenberg, R. A., 2008; 
Huen et al., 2010; Moynahan and Jasin, 2010; Roy et al., 2011).  While it remains unclear 
which of these cellular functions are relevant for tumor suppression, the BRCA1 protein 
harbors an N-terminal RING domain which possesses E3 ubiquitin ligase activity and 
two tandem C-terminal BRCT repeats that form a phosphopeptide binding domain (Miki 
et al., 1994; Joazeiro and Weissman, 2000; Hashizume et al., 2001; Manke et al., 2003; 
Yu et al., 2003).  Although most cancer-predisposing mutations involve gross truncations 
of the BRCA1 protein, single amino acid substitutions in the RING or BRCT domains of 
BRCA1 have been found in some familial patients (Miyake et al., 2000).  Therefore, 
these domains are critical for the tumor suppression activity of BRCA1.   
      BRCA1 exerts its pleiotropic functions by interacting with a diverse set of proteins.  
In vivo, most BRCA1 polypeptides interact with the related protein BARD1 to form a 
heterodimer that exhibits ubiquitin E3 ligase activity (Wu et al., 1996; Yu and Baer, 
2000; Hashizume et al., 2001; reviewed in Baer and Ludwig, 2002; Irminger-Finger and 
Jefford, 2006; Huen et al., 2010).  Formation of the BRCA1/BARD1 heterodimer is 
mediated by sequences encompassing their respective RING domains (Wu et al., 1996).  
In addition, the BRCT domains of BRCA1 interact in vivo with phosphorylated isoforms 
of the repair proteins Abraxas/CCDC98, BACH1/BRIP1/FancJ, and CtIP (Wong et al., 
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1998; Yu et al., 1998; Cantor et al., 2001; Magnard et al., 2002; Manke et al., 2003; 
Rodriguez et al., 2003; Yu et al., 2003; Yu et al., 2004; Kim et al., 2007; Liu, Z. et al., 
2007; Wang et al., 2007).  Thus, the BRCA1/BARD1 heterodimer forms a distinct 
complex with each of these BRCT-interacting phosphoproteins, in a mutually exclusive 
manner, to mediate unique aspects of BRCA1 function in response to DNA damage (Yu 
and Chen, 2004; Greenberg et al., 2006; Kim et al., 2007; Liu, Z. et al., 2007; Wang et 
al., 2007; reviewed in Huen et al., 2010; Moynahan and Jasin, 2010).   
      Of the three major BRCT phospho-ligands, CtIP is the only one known to be an 
enzymatic substrate of BRCA1/BARD1’s E3 ligase activity (Yu et al., 2006).  However, 
we recently found that the phosphopeptide binding property of the BRCT repeats, but not 
the E3 ligase activity of the RING domain, is required for BRCA1-mediated tumor 
suppression (Shakya et al., 2011).  Since tumor suppression is dependent on BRCA1 
association with its BRCT phospho-ligands, the CtIP interaction may contribute to 
BRCA1-mediated tumor suppression by promoting genome stability.  Indeed, CtIP plays 
a diverse role in maintaining genome integrity by activating the transient G2/M 
checkpoint (Yu and Chen, 2004) and promoting DNA resection and homology-directed 
repair of DSBs (Sartori et al., 2007).  Moreover, site-specific mutations designed to 
ablate phosphorylation of human CtIP (S327A) are known to disrupt its interaction with 
BRCA1 (Yu and Chen, 2004).  Indeed, a peptide competition assay performed by Yu and 
Chen (2004) showed that only the phosphorylated CtIP-S327 peptide, but not the 
unphosphorylated control peptide, competed with endogenous CtIP for binding to the 
BRCA1 BRCT domains.   
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      Therefore, to elucidate the role of the BRCA1-CtIP interaction in genome stability 
and tumor suppression, we examined murine cells that express Ctip polypeptides (Ctip-
S326A) that fail to interact with Brca1.  Using embryonic stem (ES) cell technology we 
generated the CtipS326A knock-in allele and introduced it into the mouse germline.  
Isogenic subclones of ES cells and mouse embryonic fibroblasts (MEFs) that express 
either the wildtype Ctip+ or mutant CtipS326A allele were then used to examine the genome 
stability functions of the Brca1-Ctip interaction.  In addition, we have assessed tumor 














B.  RESULTS 
B1. The Ctip-S326A knock-in targeting constructs 
      To knock the S326A missense mutation into the Ctip gene of murine ES cells, we 
produced two targeting constructs: CtipS326A-neo and CtipS326A-hyg.  For the CtipS326A-neo 
construct, we introduced the S326A mutation into the coding sequence of exon 11 and a 
loxP-flanked PGK promoter-driven neomycin gene cassette into the adjacent upstream 
intron (Figure 7B).  Additionally, a gene cassette encoding HSV thymidine kinase (HSV-
TK) was included in the targeting construct as a negative selection marker.  To target 
cells already carrying neomycin resistance, we also prepared an analogous CtipS326A-hyg 
targeting construct by replacing the loxP-flanked neomycin resistance cassette in 
intron 10 with a loxP-flanked hygromycin selection marker (data not shown).  
 
B2. Generation of CtipS326A mutant ES cells 
      To assess whether the Brca1-Ctip interaction is required for ES cell viability, we 
electroporated the CtipS326A-hyg targeting construct into neomycin-resistant Ctip+/– ES 
cells, which are heterozygous for a Ctip null allele (Ctip–) (unpublished data; Ludwig, 
Baer, and Efstratiadis) (Section A1 of Chapter II).  If the CtipS326A-hyg targeting construct 
recombines with the endogenous Ctip+ allele of the heterozygous ES cells, then the 
resulting cells should solely express Ctip-S326A polypeptides that fail to interact with 
Brca1.  Indeed, Southern analysis of the hygromycin-resistant colonies identified several 
independent subclones that had undergone homologous recombination at the Ctip+ allele 





Figure 7.  Design of the mutant CtipS326A allele.  A map of the wildtype Ctip locus 
encompassing exons 9-14 is shown (A), along with a diagram of the targeting vector (B), 
and maps of the Ctip locus after homologous recombination (CtipS326A-neo) (C) and cre-
mediated recombination (CtipS326A) (D).  To prepare the targeting vector, a neomycin 
expression cassette flanked by loxP signals (closed triangles) was inserted into the HpaI 
site of intron 10 and both an AgeI restriction site and the CtipS326A mutation (asterisk) 
were introduced into exon 11 by site-directed mutagenesis.  The Pgk promoter of the 
expression cassette controls transcription of the neo gene.  A gene cassette encoding HSV 
thymidine kinase (HSV-TK) was included as a negative selection marker.  The wavy line 
represents plasmid sequences of the targeting vector.  Relevant restriction enzyme sites 
are: PvuII (P), EcoRI (E), HpaI (H), and AgeI (A).  The position of a Ctip probe (“Ctip 
#6”) for Southern analysis is shown, together with the PvuII fragments recognized by this 
probe.  An analogous CtipS326A-hyg targeting construct was prepared by replacing the loxP-
flanked neomycin resistance cassette in intron 10 with a loxP-flanked hygromycin 
selection marker. (Note that the hygromycin gene cassette lacks a PvuII restriction 
enzyme site). 
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Figure 8.  Identification of properly targeted CtipS326A-hyg/– ES cells.  The CtipS326A-hyg 
targeting construct was electroporated into neomycin-resistant Ctip+/– ES cells, and 
PvuII-digested genomic DNAs from hygromycin-resistant clones were evaluated by 
Southern hybridization using a 5’ flanking Ctip probe (“Ctip #6”; Figure 7A).  The 10.4 
kb PvuII fragment represents the targeted Ctip allele, while the 7.9 kb and 6 kb fragments 
represent the wildtype (Ctip+) and null (Ctip–) alleles, respectively.  Properly targeted ES 




















from the knock-in allele, the targeted ES cells were transiently transfected with the 
Adeno-cre virus and properly recombined CtipS326A/– ES clones (Figure 7D) were 
identified by Southern analysis and confirmed by sequence analysis (data not shown).  
The fact that CtipS326A/– subclones were readily generated indicates that the Brca1-Ctip 
interaction is not required for the viability of ES cells, despite the fact that Brca1 
(McCarthy et al., 2003; Reid et al., 2008) and Ctip (data not shown) are individually 
required.  Thus, the interaction with Brca1 is not essential for all cellular functions of 
Ctip.  The Ctip+/– and CtipS326A/– clones, which represent isogenic ES cell lines expressing 
either wildtype or S326A-mutant Ctip, were then used in our studies of cellular Ctip 
function (see below). 
 
B3. Generation of CtipS326A mutant MEFs 
      To produce isogenic MEF lines that express either wildtype or S326A-mutant Ctip, 
129/Sv ES cells were electroporated with the CtipS326A-neo targeting construct and selected 
for neomycin-resistance.  Genomic DNAs prepared from the surviving drug-resistant ES 
cell subclones were digested with the PvuII restriction endonuclease and analyzed by 
Southern blotting with a 5’ flanking genomic Ctip probe spanning exon 9 (“Ctip #6”) 
(Figure 7A).  Several independent neomycin-resistant CtipS326A-neo/+ ES cells were 
identified (Figure 9), and the presence of the S326A mutation was confirmed by sequence 
analysis (data not shown). 
     Two independently derived CtipS326A-neo/+ 129/Sv ES clones were then injected into 






	  	  	  	  	  	  	  	    
 
 
Figure 9.  Identification of properly targeted CtipS326A-neo/+ ES cells.  129/Sv ES cells 
were electroporated with the CtipS326A-neo targeting construct (Figure 7B), and PvuII-
digested genomic DNAs from the neomycin-resistant ES clones were evaluated by 
Southern hybridization using a 5’ flanking Ctip probe (“Ctip #6”; Figure 7A).  The 7.9 kb 
PvuII fragment represents the wildtype Ctip locus (Figure 7A) while the 5.8 kb fragment 
represents the targeted Ctip allele (Figure 7C).  Properly targeted ES clones are seen in 













male CtipS326A-neo/+ mice were mated with females carrying a ubiquitously expressed Cre 
transgene driven by the mouse Rosa26 gene promoter (RosaCre) (provided by Dr. Thomas 
Ludwig, Columbia University) to excise the loxP-flanked neomycin expression cassette 
from the targeted allele (Figure 7C) and produce offspring expressing the CtipS326A allele 
(Figure 7D).  Significantly, when heterozygous CtipS326A/+ mice were intercrossed, 
CtipS326A/S326A pups were born at the expected (25%) Mendelian ratio, indicating that the 
S326A mutation does not appreciably affect embryonic development.  For confirmation, 
pregnant females from this intercross were sacrificed on E13.5 to isolate homozygous 
CtipS326A/S326A embryos.  Unlike animals homozygous for either the Brca1- or Ctip-null 
allele, which undergo embryonic lethality prior to gastrulation (precluding the generation 
of MEFs) (Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Chen, P.-L. et al., 
2005), homozygous CtipS326A/S326A embryos were viable and observed at the expected 
Mendelian frequency at E13.5 (data not shown).  For studies of cellular Ctip functions in 
MEFs, primary Ctip+/+, CtipS326A/+, and CtipS326A/S326A MEFs were prepared from day 
E13.5 embryos, and isogenic MEF lines were established by immortalization with Simian 
virus 40 large-T antigen (Schuermann M., 1990).   
 
B4. The CtipS326A mutation is sufficient to ablate the Brca1-Ctip interaction 
       Importantly, the mutant Ctip protein of CtipS326A/S326A MEFs is expressed at normal 
levels (Figure 10), indicating that the amino acid substitution did not affect the stability 
of the Ctip protein.  Previous studies have shown the corresponding S327A mutation of 
human CtIP abolishes its association with BRCA1 in human cells (Yu and Chen, 2004). 





	   	   
	  
Figure 10.  Co-immunoprecipitation of Ctip with a Brca1-specific antibody.  Ctip-
S326A (SA) polypeptides do not interact with Brca1 in vivo.  Brca1 and Ctip levels were 
examined by immunoblotting nuclear extracts of Ctip+/+, CtipSA/+ and CtipSA/SA MEFs 
(left).  Nuclear extracts were also immunoblotted with antibodies specific for α-tubulin as 
a loading control.  Note that a non-specific band runs just below Brca1 in extracts of each 
genotype.  To evaluate the Brca1-Ctip interaction, the extracts were immunoprecipitated 
with mouse Brca1-specific antiserum (B1) or the corresponding pre-immune serum (Pre) 
and immunoblotted with CtIP-specific monoclonal antibodies (right).  The input (left) 
represents 6.25% of the protein amount used for immunoprecipitation (right).     
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Ctip polypeptides of CtipS326A/S326A MEFs interact with murine Brca1.  Nuclear extracts of 
Ctip+/+, CtipS326A/+, and CtipS326A/S326A immortalized MEFs were immunoprecipitated with 
a mouse Brca1-specific antiserum (B1) or the corresponding pre-immune serum (Pre) and 
immunoblotted with CtIP-specific monoclonal antibody 14-1 (Yu and Baer, 2000).  As 
shown in Figure 10, Ctip was efficiently co-immunoprecipitated from both wildtype 
Ctip+/+ and heterozygous CtipS326A/+ MEFs with the Brca1 antiserum.  In contrast, Ctip 
failed to co-immunoprecipitate with Brca1 from homozygous CtipS326A/S326A MEFs 
(Figure 10), indicating that Ctip-S326A polypeptides do not interact with Brca1 in vivo.   
 
B5. The effect of the Brca1-Ctip interaction on gene-targeting efficiency  
      B5a.  CtipS326A mutant cells are more efficient in gene targeting than control cells 
      Given the known requirements for BRCA1 and CtIP individually in homology-
directed repair (HDR) (Moynahan et al., 1999; Moynahan et al., 2001; Sartori et al., 
2007; Bennardo et al., 2008), we sought to determine whether the BRCA1-CtIP 
interaction is also required for this process.  To do this, we first used gene-targeting 
assays to measure the ability of isogenic Ctip+/– and CtipS326A/– ES cells to homologously 
integrate exogenous DNA.  Although the relationship between homologous integration 
and HDR is unclear, deficiencies in gene targeting are often attributed to cellular defects 
in homologous recombination (Moynahan et al., 1999; Snouwaert et al., 1999; Moynahan 
et al., 2001).  To measure homologous integration at the Pim1 locus, Ctip+/– and 
CtipS326A/– ES cells were electroporated with p59xDR-GFP6, a DNA construct that 
contains the DR-GFP recombination substrate (described below) and a promoterless 
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hygromycin-resistance marker flanked by targeting arms comprised of mouse Pim1 
genomic DNA (Moynahan et al., 2001a).  After hygromycin selection, the drug-resistant 
subclones were examined for homologous integration at the Pim1 locus by Southern 
analysis (Moynahan et al., 2001a).  Surprisingly, Pim1 targeting was observed in 96% of 
the hygromycin-resistant CtipS326A/– clones and 46% of the drug-resistant Ctip+/– clones 
(Figure 11A; Table 2).  A similar two-fold increase in gene-targeting efficiency was also 
observed in CtipS326A/– cells electroporated with the Rb-G targeting vector designed for 
homologous integration at the Rb chromosomal locus (Figure 11B; Table 2) (te Riele et 
al., 1992).  Thus, in the absence of the Brca1-Ctip interaction, cells reproducibly display 
a greater capacity to support homologous integration.    
 
B6. Recombination reporter assays to measure HDR, SSA, and alt-NHEJ 
      B6a. The Brca1-Ctip interaction is not required for DSB repair by homology- 
              directed repair (HDR) 
       The HDR of DSBs at a defined chromosomal locus was also examined by using an 
integrated DR-GFP recombination substrate (Pierce et al., 2001).  The DR-GFP substrate 
consists of two defective GFP genes: SceGFP, which contains the cleavage site for the 
rare-cutting I-SceI endonuclease; and iGFP, which lacks the N- and C-terminal coding 
sequences of GFP.  I-SceI endonuclease expression triggers cleavage of SceGFP, 
resulting in a chromosomal DSB at the I-SceI site.  Proficient repair of this DSB by HDR 
using iGFP as a template will generate a functional GFP gene, an event which can be 
quantified by flow cytometry (Pierce et al., 2001).  Since the p59xDR-GFP6 targeting 

















Figure 11.  Gene-targeting efficiency of Ctip+/– and CtipS326A/– ES cells at the Pim1 
and Rb loci.  (A) Gene-targeting was measured at the Pim1 locus by electroporating 
Ctip+/– and CtipS326A/– ES cells with linearized p59xDR-GFP6 targeting vector DNA, 
selecting for hygromycin resistance, and evaluating the drug-resistant clones for gene 
targeting by Southern analysis.  A 3.6 kb fragment represents the wildtype Pim1 allele 
while a 2.4 kb fragment represents the targeted Pim1 allele.  (B)  Ctip+/– and CtipS326A/– 
ES cells were also electroporated with linearized Rb-G (Rb-pgkhyg) targeting vector 
DNA.  ES cells were selected with hygromycin and genomic DNA was prepared from the 
surviving clones for Southern analysis.  The wildtype and targeted Rb alleles are 9.7 kb 







































Gene-targeting efficiencies were determined by Southern analysis for the Pim1 and Rb 





















subclones that arose upon homologous integration of this construct (Figure 11A; Table 2) 
possess the DR-GFP substrate at identical positions in the Pim1 locus.    
      To measure HDR of an induced chromosomal DSB, Ctip+/– DR-GFP and CtipS326A/–
DR-GFP subclones were evaluated for the appearance of GFP-positive cells after 
transient transfection with an expression vector encoding the I-SceI endonuclease 
(pCβASce).  In the absence of I-SceI expression, GFP-positive cells were seldom 
detected (<0.02%) in cell lines of either Ctip genotype (Figure 12), indicating that 
spontaneous intrachromosomal gene conversion is rare.  As expected, I-SceI expression 
induced the HDR of chromosomal DSBs within the integrated DR-GFP substrate in 
control Ctip+/– ES cells, as reflected by the increased percentage of GFP-positive cells 
(2.4%-2.74%) (Figure 12, A and B).  Surprisingly, I-SceI expression induced similar 
proportions of CtipS326A/– GFP-positive cells (2.13%-2.26%) (Figure 12, C and D), 
suggesting that the Brca1-Ctip interaction is not required for proficient HDR.  Consistent 
with previous reports (Moynahan et al., 1999; Snouwaert et al., 1999; Moynahan et al., 
2001), a subclone of the Brca1-null ES cell line 236.44 (Brca1∆223-763/∆223-763) with the 
DR-GFP substrate integrated at the same position in the Pim1 locus, displayed 
significantly reduced HDR efficiency (0.64%) (Figure 12E).  Thus, as with gene 
targeting, HDR of an induced chromosomal break is not diminished in CtipS326A/– ES 
cells.  Although Brca1 and, more specifically, its BRCT phospho-recognition binding 
property are required for HDR of chromosomal DNA breaks (Moynahan et al., 1999; 
Moynahan et al., 2001; Shakya et al., 2011), the Brca1-Ctip interaction appears to be 
dispensable.  Furthermore, since HDR of a DSB is dependent on DNA resection, these 









Figure 12.  Cells lacking the Brca1-Ctip interaction are proficient for HDR of DSBs.  
Several control Ctip+/– (clones A and B) and mutant CtipS326A/– (clones C and D) ES 
subclones containing the direct repeat-green fluorescent protein (DR-GFP) substrate 
integrated into the Pim1 locus were transfected with either an I-SceI expression vector or 
empty vector (pCAGGS).  GFP-positive cells were rarely generated on transfection with 
the empty vector.  In contrast, I-SceI expression strongly induced the proportion of GFP-
positive Ctip+/– cells (clones A and B) and CtipS326A/– cells (clones C and D), indicating 
efficient homology-directed repair (HDR).  Additionally, a subclone of the Brca1-mutant 
ES cell line 236.44 (Brca1∆223-763/∆223-763) with the DR-GFP substrate integrated at the 
same position in the Pim1 locus, denoted here as Brca1–/– (clone E), was used as a control 
since it is known to be deficient in HDR (Moynahan et al., 1999).  Each ES subclone was 
assayed in triplicate with three independent transfections, and the error bars represent SE 
of the mean.  Similar results were also observed in separate experiments using additional 
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     B6b. The Brca1-Ctip interaction is not required for DSB repair by single-strand   
              annealing (SSA) 
     Single-strand annealing (SSA) is another DSB repair pathway initiated by DNA 
resection.  In the SSA pathway, complementary sequences (>30 bp) within the ssDNA 
overhangs of both DSB ends anneal with one another, allowing ligation of the ends and 
deletion of the intervening sequences (Stark et al., 2004; Bennardo et al., 2008; McVey 
and Lee, 2008; Huertas, P., 2010).  Although both BRCA1 and CtIP promote SSA of 
DSBs (Stark et al., 2004; Bennardo et al., 2008), it is unclear whether the BRCA1-CtIP 
interaction is required for this repair pathway.  To explore this possibility, isogenic 
Ctip+/– and CtipS326A/– ES cells were electroporated with the hprtSAGFP targeting 
construct (Stark et al., 2004), and subclones that carry an SA-GFP recombination 
substrate integrated into the Hprt locus were derived.   
      Like the DR-GFP recombination substrate, the SA-GFP substrate consists of two non-
functional GFP fragments (5’GFP and SceGFP3’) (Stark et al., 2004).  A DSB triggered 
by I-SceI cleavage of SceGFP3’ can be repaired by SSA when a DNA strand from 
SceGFP3’ anneals to the complementary strand of 5’GFP, resulting in formation of a 
functional GFP gene and deletion of the intervening sequence (Stark et al., 2004).  
Importantly, HDR of the SA-GFP reporter does not restore a functional GFP gene (Stark 
et al., 2004); therefore, GFP positive products are specifically produced by SSA.  In 
addition to the SA-GFP reporter, the hprtSAGFP targeting construct also has homology 
to the Hprt locus and contains a puromycin resistance marker (Stark et al., 2004).  Upon 
proper integration of the hprtSAGFP targeting construct into Ctip+/– and CtipS326A/– ES 
cells, the Hprt gene is inactivated, rendering the cells resistant to the nucleotide analog 6-
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thioguanine (6-TG) (Stark et al., 2004; Pierce et al., 2001).  Therefore, only correctly 
targeted clones should be resistant to both puromycin and 6-TG.  We prepared genomic 
DNA from the doubly-resistant ES clones for Southern analysis and identified multiple 
Ctip+/– SA-GFP and CtipS326A/– SA-GFP reporter ES subclones (data not shown). 
      To analyze the SSA efficiency of Ctip+/– and CtipS326A/– ES subclones bearing the 
integrated SA-GFP substrate, we transiently transfected these cells with an I-SceI 
expression vector (pCβASce) or the empty vector (pCAGGS) alone.  The experiments 
were performed in triplicate with three independent transfections and all cells were 
examined 72 hours post-transfection by flow cytometry.  Very few GFP-positive cells 
were detected (< 0.01%) in any of the cell lines in the absence of I-SceI expression 
(Figure 13).  After transfection with the I-SceI expression vector, however, GFP-positive 
cells were readily detected in both Ctip+/– (0.76%-1.13%) and CtipS326A/– (1.07%-1.40%) 
cells (Figure 13, A-E).  Thus, although Brca1 and Ctip are both essential for SSA at 
chromosomal DSBs (Stark et al., 2004; Bennardo et al., 2008), the Brca1-Ctip interaction 
appears to be dispensable for this mode of DSB repair.   
 
      B6c. The Brca1-Ctip interaction is not required for DSB repair by alternative non-  
               homologous end joining (alt-NHEJ) 
     Unlike HDR and SSA, non-homologous end joining (NHEJ) ligates DSB ends without 
a requirement for extensive sequence homology (reviewed in Haber, J. E., 2000; Karran, 
P., 2000).  NHEJ appears to be comprised of two subpathways: classical-NHEJ and 
alternative-NHEJ (alt-NHEJ) (Bennardo et al., 2008; McVey and Lee, 2008).  Classical-
























Figure 13.  Cells lacking the Brca1-Ctip interaction are proficient for SSA of DSBs.  
Several control Ctip+/– (clones A and B) and mutant CtipS326A/– (clones C to E) ES 
subclones containing the SA-GFP reporter substrate integrated into the Hprt locus were 
transfected with either an I-SceI expression vector or empty vector (pCAGGS).  GFP-
positive cells were rarely generated on transfection with the empty vector.  I-SceI 
expression induced a similar number of GFP-positive Ctip+/– cells (clones A and B) and 
CtipS326A/– cells (clones C to E).  Thus, the Brca1-Ctip interaction is not required for DSB 
repair by single-strand annealing (SSA).  Each ES subclone was assayed in triplicate with 
three independent transfections, and the error bars represent SE of the mean.   


























C D E 
85 
	  
key NHEJ factors, including the Ku70/80 (Ku) heterodimer, XRCC4, DNA Ligase IV 
and DNA-PKcs (reviewed in Haber, J. E., 2000; Karran, P., 2000).  In contrast, alt-NHEJ 
is independent of these factors.  Instead, alt-NHEJ appears to be mediated by the 
annealing of short homology stretches or microhomologies (usually 2-3 bp) which are 
exposed at the DSB ends by DNA resection (Bennardo et al., 2008; McVey and Lee, 
2008, Huertas, P., 2010).  Thus, like HDR and SSA, alt-NHEJ is suppressed by Ku 
binding and promoted by CtIP-mediated DSB end resection (Bennardo et al., 2008).   
      To examine whether the BRCA1-CtIP interaction is required for alt-NHEJ, we 
electroporated isogenic Ctip+/– and CtipS326A/– ES cells with the pim-EJ2-GFP-hyg 
targeting vector, which contains the EJ2-GFP recombination substrate and genomic 
sequences for targeting the Pim1 locus.  The EJ2-GFP reporter consists of an N-terminal 
tag fused to GFP which is disrupted by an 8 nucleotide microhomology repeat that flanks 
an I-SceI site and an in-frame stop codon (Bennardo et al., 2008).  If alt-NHEJ occurs by 
annealing of the microhomology repeats, the intervening 35 nucleotide sequence is 
deleted, the coding frame between the N-terminal tag and GFP is restored, and a 
functional GFP-positive gene is reconstructed (Bennardo et al., 2008).  Following 
electroporation with the pim-EJ2-GFP-hyg targeting vector, Ctip+/– and CtipS326A/– ES 
cells were selected with hygromycin and DNA was prepared from the surviving colonies.  
Southern analysis revealed proper homologous integration of the EJ2-GFP reporter into 
the mouse Pim1 locus of several Ctip+/– and CtipS326A/– ES subclones (data not shown). 
      To measure alt-NHEJ of an induced chromosomal DSB, Ctip+/– EJ2-GFP and 
CtipS326A/– EJ2-GFP subclones were transiently transfected with an expression vector 
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encoding I-SceI and evaluated for the appearance of GFP-positive cells by flow 
cytometry.  GFP expression as a result of spontaneous intrachromosomal gene conversion 
events was rare, as very few GFP-positive cells were detected (< 0.05%) in Ctip+/– and 
CtipS326A/– ES clones transfected with the empty vector (Figure 14).  Following 
transfection with the I-SceI expression vector, Ctip+/– and CtipS326A/– ES clones exhibited 
a comparable percentage of GFP-positive cells, 0.64%-0.71% and 0.62%-0.64%, 
respectively (Figure 14, A-D).  Thus, as with the other resection-dependent repair 
pathways (HDR and SSA), the Brca1-Ctip interaction appears to be dispensable for alt-
NHEJ repair of chromosomal DSBs. 
 
B7.  Immunofluorescent analyses of nuclear recombination foci 
        B7a.  The Brca1-Ctip interaction is not required for Ctip, Brca1, RPA or Rad51   
                 focus formation in S-phase and IR-treated cells 
 
        In cells subjected to ionizing radiation (IR), protein accumulation at sites of DNA 
damage can take the form of cytologically discernible foci, as observed for the repair 
proteins CtIP, BRCA1, RPA, and Rad51 (Haaf et al., 1995; Scully et al., 1997b; 
Choudhary and Li, 2002; Yu et al., 2006; Sartori et al., 2007).  The formation of IR-
induced foci (IRIFs) of CtIP, which can be visualized by immunofluorescent microscopy, 
may reflect the role of CtIP in resection of DSB ends (Yu et al., 2006; Sartori et al., 2007; 
You et al., 2009).  In human cells, CtIP localization to IRIFs appears to require the 
BRCA1-CtIP interaction, as CtIP IRIFs fail to form in HCC1937 cells, which express a 
C-terminally truncated BRCA1 polypeptide that lacks the BRCT repeat, or in 293T cells 
























Figure 14.  Cells lacking the Brca1-Ctip interaction are proficient for alt-NHEJ of 
DSBs.  Several control Ctip+/– (clones A and B) and mutant CtipS326A/– (clones C and D) 
ES subclones containing the EJ2-GFP reporter substrate integrated into the Pim1 locus 
were transfected with either an I-SceI expression vector or empty vector (pCAGGS).  
Very few GFP-positive cells were detected in Ctip+/– and CtipS326A/– ES clones following 
transfection with the empty vector.  I-SceI expression induced a similar number of GFP-
positive cells in both Ctip+/– cells (clones A and B) and CtipS326A/– cells (clones C and D) 
indicating efficient alternative non-homologous end joining (alt-NHEJ).  Each ES 
subclone was assayed in triplicate with three independent transfections, and the error bars 
represent SE of the mean.  Similar results were also observed in separate experiments 
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2006).  In contrast, however, we observed comparable recruitment of Ctip to IRIFs in 
CtipS326A/S326A and Ctip+/+ immortalized MEFs (Figure 15).  This result is consistent with 
our data showing that resection-dependent repair (i.e., HDR, SSA, and alt-NHEJ) is 
proficient in CtipS326A/– ES cells (Figures 12-14).  Thus, the Brca1-Ctip interaction is not 
required for recruitment of Ctip to sites of DNA damage in murine cells.  Moreover, Ctip 
recruitment to the S-phase nuclear foci of unstressed cells also appears to be unaffected 
by the S326A mutation (Figure 15).  This result is consistent with published data that 
amino acid residues 505-546 of CtIP are necessary and sufficient for targeting CtIP to S-
phase replication foci in human cells (Gu and Chen, 2009).     
      Similarly, we observed comparable recruitment of Brca1 polypeptides to both S-
phase nuclear foci and IRIFs in Ctip+/+ and CtipS326A/S326A MEFs (Figure 16).  This result 
is consistent with the normal BRCA1 focus formation reported for human cells 
expressing S327A-mutant Flag-tagged CtIP (Yu et al., 2006).  Therefore, although the 
BRCT phosphopeptide binding property of Brca1 is required for proper formation of 
Brca1 foci after DNA damage (Shakya et al., 2011), Brca1’s interaction with the BRCT 
phospho-ligand Ctip is not essential for Brca1 localization.  Instead, BRCA1 recruitment 
is reported to require its BRCT phospho-dependent interaction with the Abraxas/RAP80 
complex, as cells bearing the Abraxas-S406A mutation, which ablates the BRCA1-
Abraxas interaction, fail to target BRCA1 to sites of DNA damage (Kim et al., 2007; Kim 
et al., 2007a; Liu, Z. et al., 2007; Sobhian et al., 2007; Wang et al., 2007; Wang and 




























Figure 15.  Proper Ctip focus formation in the absence of the Brca1-Ctip 
interaction.  (A)  Ctip+/+ and CtipS326A/S326A immortalized MEFs were either untreated to 
assess S-phase focus formation or exposed to IR (10 Gy) to assess IRIF formation.  
Immunostaining with CtIP-specific antibodies occurred 1 hour post-irradiation.  Ctip-
containing S-phase foci and IRIFs were counted in 300 cells of two independent MEF 
lines for each genotype, and the error bars represent SE of the mean.  Ctip S-phase foci 
and IRIF formation was comparable in Ctip+/+ and CtipS326A/S326A MEFs. (B)  
Representative image of Ctip mobilization to IRIFs in CtipS326A/S326A MEFs.  4’, 6-






















Figure 16.  Proper Brca1 focus formation in the absence of the Brca1-Ctip 
interaction.  Ctip+/+ and CtipS326A/S326A immortalized MEFs were either untreated to 
assess S-phase focus formation or exposed to IR (10 Gy) to assess IRIF formation.  The 
cells were immunostained at 1 hour post-irradiation with a mouse-specific Brca1 
antibody.  Brca1-containing S-phase foci and IRIFs were counted in 300 cells of two 
independent MEF lines for each genotype, and the error bars represent SE of the mean.  
Brca1 was efficiently recruited to the S-phase foci and IRIFs in CtipS326A/S326A MEFs, 
indicating that the Brca1-Ctip interaction is dispensable for Brca1 focus formation.  (B)  
Representative image of Brca1 mobilization to IRIFs in CtipS326A/S326A MEFs.  4’, 6-
diamidino-2-phenylindole (DAPI) was used for nuclear staining. 
        
 
 

























     The role of BRCA1, once at sites of DNA damage, remains unclear.  One attractive 
notion, given that BRCA1, CtIP, and MRN form a discrete protein complex in vivo 
(BRCA1 complex C), is that BRCA1 is required for the DNA resection activities ascribed 
to CtIP and MRN (Greenberg et al., 2006; Chen et al., 2008).  Of note, efficient 
association of BRCA1 with MRN appears to require the BRCA1-CtIP interaction (Chen 
et al., 2008).  To determine whether the BRCA1-CtIP interaction is essential for DNA 
resection, we examined RPA focus formation in isogenic Ctip+/+ and CtipS326A/S326A 
immortalized MEFs.  Upon DNA resection, RPA is rapidly loaded onto the nascent 
single-stranded DNA (ssDNA), an event which can be observed cytologically by the 
formation of nuclear foci that stain with RPA-specific antibodies.  By immunofluorescent 
microscopy, we observed indistinguishable levels of RPA-staining of S-phase foci and 
IRIFs in both CtipS326A/S326A and Ctip+/+ MEFs (Figure 17).  This result suggests that the 
Brca1-Ctip interaction is dispensable for DNA resection, and that CtIP and MRN likely 
mediate DNA resection independently of BRCA1.  This observation is also consistent 
with the fact that resection-dependent repair (i.e., HDR, SSA, and alt-NHEJ) is proficient 
in CtipS326A/– ES cells (Figures 12-14). 
      We also examined the effect of the Ctip-S326A mutation on localization of the 
recombination protein Rad51.  At chromosomal breaks, Rad51 can displace RPA from 
resected ssDNA tails to form a nucleoprotein filament that mediates the search for a 
homologous DNA template.  A requirement for the BRCT phosphopeptide binding 
property of BRCA1 in this process was established by the fact that Rad51 accumulation 






















Figure 17.  Proper RPA focus formation in the absence of the Brca1-Ctip 
interaction.  Ctip+/+ and CtipS326A/S326A immortalized MEFs were either untreated to 
assess S-phase focus formation or exposed to IR (10 Gy) to assess IRIF formation.  Foci 
formation was assessed 1 hour post-irradiation by immunostaining with RPA-specific 
antibodies.   RPA-containing S-phase foci and IRIFs were counted in 300 nuclei of two 
independent MEF lines for each genotype, and the error bars represent SE of the mean.  
RPA S-phase foci and IRIF formation was comparable in Ctip+/+ and CtipS326A/S326A 
MEFs; thus, the Brca1-Ctip interaction is not required for RPA recruitment to sites of 
DNA damage.  (B)  Representative image of RPA mobilization to IRIFs in CtipS326A/S326A 
MEFs.  4’, 6-diamidino-2-phenylindole (DAPI) was used for nuclear staining. 
 























Brca1+/+ MEFs (Shakya et al., 2011).  To determine whether the Brca1-Ctip interaction is 
required for proper Rad51 recruitment, we compared the assembly of Rad51 in the S-
phase foci and IRIFs of Ctip+/+ and CtipS326A/S326A immortalized MEFs.  As shown in 
Figure 18, the levels of Rad51-staining S-phase foci and IRIFs were comparable in MEFs 
expressing either the wildtype or S326A-mutant Ctip polypeptide.  Thus, Rad51 
recruitment to sites of DNA damage, a key step in DSB repair by homologous 
recombination, depends on the BRCT phospho-recognition property of Brca1, but not its 
interaction with the phospho-ligand Ctip.    
 
B8.  Clonogenic survival 
        B8a.  CtipS326A mutant cells are resistant to MMC-induced genotoxic stress 
        In clonogenic survival assays, cells lacking the BRCT phosphopeptide binding 
property of Brca1 (Brca1S1598F/S1598F) are hypersensitive to mitomycin C (MMC), a DNA 
cross-linking agent that can potentiate DSB formation (Shakya et al., 2011).  To ascertain 
whether Brca1’s interaction with the BRCT phospho-ligand Ctip mediates its cellular 
resistance to MMC, we used a clonogenicity assay to evaluate the response of isogenic 
Ctip+/– and CtipS326A/– ES cells to this genotoxic agent.  As shown in Figure 19, the MMC 
survival curves of two CtipS326A/– ES clones completely overlap with those of the Ctip+/– 
and Brca1+/– control cells.  In parallel, we also analyzed homozygous Brca1-null ES cells 
(Brca1∆223-763/∆223-763).  In accord with published data (Moynahan et al., 2001; Reid et al., 
2008), we found that these cells, unlike CtipS326A/– cells, display a pronounced 
hypersensitivity to MMC (Figure 19).  Thus, the Brca1-Ctip interaction is not required 



















Figure 18.  Proper Rad51 focus formation in the absence of the Brca1-Ctip 
interaction.  Ctip+/+ and CtipS326A/S326A immortalized MEFs were either untreated to 
assess S-phase focus formation or exposed to IR (10 Gy) to assess IRIF formation.  Foci 
formation was assessed 1 hour later by immunostaining with Rad51-specific antibodies.   
Rad51-containing S-phase foci and IRIFs were counted in 300 nuclei of two independent 
MEF lines for each genotype, and the error bars represent SE of the mean.  The levels of 
Rad51-staining S-phase foci and IRIFs were comparable in MEFs expressing either the 
wildtype or Ctip-S326A mutant polypeptides.  (B)  Representative image of Rad51 
mobilization to IRIFs in CtipS326A/S326A MEFs.  4’, 6-diamidino-2-phenylindole (DAPI) 






























Figure 19.  CtipS326A/– ES cells are resistant to MMC-induced genotoxic stress.  
Isogenic Ctip+/– and CtipS326A/– ES cells were examined for mitomycin C (MMC) 
sensitivity in clonogenic survival assays, together with ES cells homozygous for the 
hypomorphic Brca1Δ223-763 mutation (denoted here as Brca1–/–), and control ES cells 
(Brca1+/–).  Cells were plated and treated with various concentrations of MMC for 4 
hours.  After 7-9 days, the surviving colonies were stained with Crystal violet and 
counted.  Survival is calculated as a percentage of colonies in the mock-treated plates.  
Each subclone was tested in triplicate, and the error bars represent the SE of the mean of 
survival for each subclone.  Similar results were also observed in separate experiments 
















     B8b.  CtipS326A mutant cells are slightly sensitive to camptothecin and etoposide 
        Additionally, we investigated the role of the Brca1-Ctip interaction in the cellular 
response to the topoisomerase I inhibitor camptothecin (CPT) and the topoisomerase II 
inhibitor etoposide (ETO).  CPT and ETO stabilize their respective Topo-cleavage 
complexes by preventing DNA religation, thereby inducing DSBs predominantly in S-
phase (for CPT) or throughout the cell cycle (for ETO) (Pommier, Y., 2006; Sartori et al., 
2007; Nitiss, J. L., 2009; Nakamura et al., 2010).  Importantly, repair of CPT- and ETO-
induced DSBs requires removal of the covalently-bound polypeptides from the DNA 
ends (Nakamura et al., 2010).  Since cellular resistance to CPT and ETO depends on 
some aspect of CtIP function (Sartori et al., 2007), we assessed whether the Brca1-Ctip 
interaction is required for resistance to these topoisomerase inhibitors.  
      To this end, Ctip+/– and CtipS326A/– ES clones were exposed for 24 hours to varying 
doses of CPT and ETO and allowed to recover for 7-9 days.  As shown in Figure 20A, 
two independent CtipS326A/– ES clones exhibit slight sensitivity to the topoisomerase I 
inhibitor CPT relative to control Ctip+/– cells.  For both mutant clones, the apparent 
difference in sensitivity is only observed at the two highest CPT doses (Figure 20A).  
Similarly, although we observe clonal variation, in response to the topoisomerase II 
inhibitor ETO, CtipS326A/– cells display a slight decrease in survival compared to control 
Ctip+/– cells (Figure 20B).  In contrast, ES cells homozygous for the Brca1∆223-763 
hypomorphic allele show significant hypersensitivity to CPT (Figure 20A) and a modest 


























Figure 20.  CtipS326A/– ES cells are slightly sensitive to CPT- and ETO-induced 
genotoxic stress.  Ctip+/– and CtipS326A/– ES cells were examined for (A) camptothecin 
(CPT) and (B) etoposide (ETO) sensitivity in clonogenic survival assays, together with 
ES cells homozygous for the hypomorphic Brca1Δ223-763 mutation (denoted here as   
Brca1–/–).  Cells were plated and exposed for 24 hours to varying doses of CPT and ETO 
and allowed to recover for 7-9 days.  The surviving colonies were stained with Crystal 
violet and counted.  Survival is calculated as a percentage of colonies in the mock-treated 
plates.  Each subclone was tested in triplicate, and the error bars represent the SE of the 
mean of survival for each subclone.     
 




















required for some, but not all, of the cellular resistance mediated by Brca1 in response to 
the topoisomerase inhibitors CPT and ETO. 
 
B9.  Cytogenetic analysis 
        B9a.  CtipS326A mutant cells can suppress both spontaneous and MMC-induced   
                  chromosomal rearrangements 
      Deficiencies in DSB repair can give rise to chromosomal instability, which may in 
turn promote tumorigenesis.  Consistent with this, Brca1S1598F/S1598F cells, which express 
Brca1 polypeptides that lack BRCT phospho-recognition, display HDR defects and 
marked chromosomal instability (Shakya et al., 2011).  To determine whether the Brca1-
Ctip interaction is required for Brca1-mediated chromosome maintenance, we examined 
the metaphase spreads of several early passage Ctip+/+ and CtipS326A/S326A primary MEF 
subclones.  As shown in Figure 21A and Table 3, CtipS326A/S326A MEFs display low levels 
of spontaneous chromosomal rearrangements, comparable with those of wildtype Ctip+/+ 
MEFs.  Thus, in the absence of exogenous DNA damage, the Brca1-Ctip interaction is 
dispensable for Brca1-mediated suppression of spontaneous chromosomal instability.  
      In addition, CtipS326A/S326A MEFs also display normal resistance to MMC-induced 
chromosomal rearrangements, as these cells accumulate cytogenetic defects to the same 
extent as Ctip+/+ MEFs when subjected to DNA damage by MMC exposure (Figure 21B; 
Table 3).  As shown in Table 3, the types of spontaneous and MMC-induced 
chromosomal rearrangements observed in cells of either Ctip genotype are predominantly 






















Figure 21.  Low levels of spontaneous and MMC-induced chromosomal aberrations 
in CtipS326A/S326A primary MEFs.  Primary Ctip+/+ and CtipS326A/S326A MEFs were cultured 
in the (A) absence or (B) presence of MMC (40 ng/mL, 16 h) and subjected to karyotype 
analysis.  Following colcemid treatment, exposure to a hypotonic solution, and 
methanol/acetic acid fixation, the cell suspensions were dropped onto glass slides and 
stained with Giemsa.  Twenty-five metaphase spreads per cell line were examined for 
each treatment condition for numerical and structural chromosomal aberrations.   
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Table 3.  Spontaneous and induced chromosomal aberrations in primary MEFs 










MMC, mitomycin C / Chr, chromosome / Cht, chromatid     
 
The percentage of metaphases containing one or more aberrations and a breakdown of 
aberration-type is shown for each primary MEF cell line in both the absence (–) and 













exchanges.  Moreover, aneuploidy was not observed in the spreads of CtipS326A/S326A cells, 
which contained on average the expected 40 mouse chromosomes (data not shown).  
Therefore, although Brca1 suppresses both spontaneous and MMC-induced chromosomal 
instability (Moynahan et al., 2001; Reid et al., 2008), its interaction with Ctip is not 
required for these functions.     
      Since undifferentiated ES cells and MEFs sometimes manifest different DNA damage 
responses (Moynahan et al., 2001), we also examined the karyotypes of several Ctip+/– 
and CtipS326A/– ES subclones.  Like the CtipS326A/S326A MEFs, CtipS326A/– ES cells also 
accumulate spontaneous and MMC-induced chromosomal aberrations at the same rate as 
control (Ctip+/– ES) cells (Figure 22, A and B).  Thus, regardless of the cell type, and 
consistent with our observation of proficient DSB repair in CtipS326A/– ES cells (Figures 
12-14), chromosomal stability is maintained in the absence of the Brca1-Ctip interaction.  
Overall, these results indicate that significant aspects of BRCA1 and CtIP function in 
genome maintenance are independent of the BRCA1-CtIP interaction.   
 
B10.  Viability and IR sensitivity of CtipS326A mice 
         B10a.  CtipS326A mutant mice are viable, healthy, fertile, and resistant to IR   
          To evaluate whether the Brca1-Ctip interaction is required for animal development 
and tumor suppression, we examined mice that solely express mutant Ctip-S326A 
polypeptides which fail to interact with Brca1 (i.e., CtipS326A/S326A and CtipS326A/– mice).  
In contrast to the early embryonic lethality of Ctip- and Brca1-null animals (Hakem et al., 



























Figure 22.  Low levels of spontaneous and MMC-induced chromosomal aberrations 
in CtipS326A/– ES cells.  Metaphase spreads were prepared from (A) untreated or (B) 
MMC-treated (40 ng/mL, 16 h) isogenic Ctip+/– and CtipS326A/– ES subclones.  Following 
colcemid treatment, exposure to a hypotonic solution, and methanol/acetic acid fixation, 
the cell suspensions were dropped onto glass slides and stained with Giemsa.  For each 
treatment condition, at least twenty-five metaphase spreads per ES subclone were 
examined for numerical and structural chromosomal aberrations.   
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Karyotype of ES cells: MMC (-)


















CtipS326A/– mice were born at the expected Mendelian ratios, survived to adulthood, were 
fertile, and otherwise appeared to be indistinguishable from their littermate controls (data  
not shown).  The viability of CtipS326A/S326A and CtipS326A/– mice again indicates that the 
Brca1-Ctip interaction is not essential for all Brca1 and all Ctip functions.   
      To assess whether the Brca1-Ctip interaction is required for in vivo resistance to 
genotoxic stress, we tested the sensitivity of CtipS326A/S326A mice to whole-body ionizing 
radiation (IR).  Homozygous (CtipS326A/S326A) mutant mice and control mice (CtipS326A/+ 
and Ctip+/+) at two months of age were exposed to a sublethal dose of 8 Gys of gamma 
irradiation.  While 10 out of 11 control mice survived at least 6 weeks post-irradiation, 11 
out of 12 CtipS326A/S326A mutant mice also survived (data not shown).  Thus, CtipS326A/S326A 
mutant mice are resistant to whole-body IR, suggesting that the Brca1-Ctip interaction is 
not essential for in vivo resistance to genotoxic stress.  
 
B11.  Whole-body tumor formation 
         B11a.   Ablation of the Brca1-Ctip interaction does not enhance spontaneous tumor   
                    formation 
 
      Although Ctip is reported to serve as a tumor suppressor (Chen, P.-L. et al., 2005), it 
is not known whether this function reflects its activity in the BRCA1 pathway and, as 
such, would be relevant to human breast and ovarian cancer.  Therefore, to ascertain 
whether the BRCA1-CtIP interaction is required for BRCA1-mediated tumor 
suppression, we monitored CtipS326A/S326A and CtipS326A/– mice for whole-body tumor 
development over a 24-month observation period.  As shown in Figure 23, CtipS326A/S326A 
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and CtipS326A/– mutant mice (n=40) developed tumors at a very advanced age.  The 
frequency and kinetics of spontaneous tumor formation in these mutant mice were 
comparable with those of control mice (n=47; Ctip+/+, Ctip+/–, and CtipS326A/+) (Figure 
23).  Thus, consistent with the observed genomic stability of mutant Ctip-S326A ES cells 
and MEFs, ablation of the Brca1-Ctip interaction does not enhance spontaneous tumor 
formation in mice.  Moreover, although the ability of the BRCT domain to bind its 
phospho-ligands is critical for BRCA1 tumor suppression (Shakya et al., 2011), the tumor 
suppression function of BRCA1 is not dependent on its interaction with the phospho-































Figure 23.  The Brca1-Ctip interaction is dispensable for tumor suppression.  
Kaplan-Meier tumor-free survival curves of control Ctip+/+, +/–, SA/+ (orange curve; n = 47) 
mice compared with CtipSA/SA, SA/– (purple curve; n = 40; P = 0.2249) mice.  Significance 
was estimated with the log-rank test using Graph-Pad Prism (version 4) software.  Values 
































C.  DISCUSSION 
      Although the mechanisms of BRCA1 tumor suppression are not understood, the 
tumor suppressor activity of BRCA1 is thought to derive, at least in part, from its ability 
to promote genomic integrity (reviewed in Scully and Livingston, 2000; Jasin, M., 2002; 
Deng, C.-X., 2006; Nagaraju and Scully, 2007).  Consistent with this, a BRCT phospho-
recognition mutant of Brca1 (Brca1-S1598F) fails to suppress both chromosomal 
instability in cells and tumor formation in animals (Shakya et al., 2011).  Notably, the 
BRCT sequences of BRCA1 preferentially bind the phosphorylated isoforms of repair 
proteins Abraxas/CCDC98, BACH1/BRIP1/FancJ, and CtIP to mediate BRCA1 function 
in response to DNA damage (Greenberg et al., 2006; reviewed in Huen et al., 2010; 
Moynahan and Jasin, 2010).  Given that CtIP has prominent functions in genome stability 
and is the only known BRCT phospho-ligand that is also an enzymatic substrate of 
BRCA1/BARD1’s E3 ligase activity, we sought to determine whether CtIP’s interaction 
with BRCA1 mediates its genome maintenance and tumor suppression functions.   
      To this end, we introduced the S326A mutation into the mouse Ctip gene of ES cells 
by homologous recombination.  Previous studies have established that the in vivo 
association of human CtIP and BRCA1 requires phosphorylation of CtIP at residue S327, 
which corresponds to Ctip residue S326 in mice (Yu and Chen, 2004).  Thus, the Ctip-
S326A missense mutation prevents phosphorylation of Ctip residue S326 and, as 
anticipated, it ablates the Brca1-Ctip interaction (Figure 10).  Surprisingly, we found that 
the BRCA1-CtIP interaction is dispensable for mammalian cell viability, critical aspects 
of BRCA1 function in genome stability, and BRCA1-mediated tumor suppression. 
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      Individually, BRCA1 and CtIP are each essential for the viability of mammalian cells 
(Elledge and Amon, 2002; Chen, P.-L. et al., 2005; Reid et al., 2008).  This is consistent 
with the early embryonic lethality of mice bearing homozygous-null mutations of either 
Brca1 (Hakem et al., 1996; Ludwig et al., 1997) or Ctip (Chen, P.-L. et al., 2005), the 
inability to culture MEFs from Brca1-null (Hakem et al., 1996; Ludwig et al., 1997) or 
Ctip-null (Chen, P.-L. et al., 2005) embryos, and the failure to generate viable ES cells by 
targeted inactivation of both alleles of either Brca1 (McCarthy et al., 2003) or Ctip 
(unpublished data).  In contrast, with relative ease we were able to generate mice, MEFs, 
and ES cells that solely express mutant Ctip-S326A polypeptides.  Thus, our data indicate 
that the Brca1-Ctip interaction is dispensable for mammalian cell viability and that the 
interaction is not required for all Brca1 or all Ctip functions.  In accord with these 
findings, Ctip-null mice die at an earlier stage of embryogenesis than Brca1-null mice, 
suggesting that Ctip likely executes at least some functions independent of Brca1 (Chen, 
P.-L. et al., 2005).       
      CtIP initiates HDR of DSBs through its role in DNA resection, a process in which the 
5’ strand of a DSB end is degraded to yield 3’ single-stranded DNA (ssDNA) overhangs 
(Sartori et al., 2007; Bennardo et al., 2008; Yun and Hiom, 2009; reviewed in Symington 
and Gautier 2011).  Although a specific biochemical function for BRCA1 in HDR has yet 
to be elucidated, the discovery of the BRCA1-CtIP interaction raised the possibility that 
BRCA1 collaborates with CtIP to resect DSB ends.  Consistent with this hypothesis, 
biochemical studies show that the BRCA1, CtIP, and MRN polypeptides form a discrete 
protein complex in vivo (Greenberg et al., 2006; Chen et al., 2008), and BRCA1 appears 
to function at an upstream stage of the HDR pathway (Stark et al., 2004).  To address 
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whether BRCA1 modulates DNA resection through its interaction with CtIP, we 
examined the ability of Ctip-S326A mutant cells to repair DSBs through several 
resection-dependent pathways and recruit the ssDNA-binding protein RPA to sites of 
DNA damage.    
      Cells bearing mutations in certain DSB repair genes often display defects in both 
gene targeting and HDR, although the relationship between the two processes is not fully 
understood (Moynahan et al., 1999; Snouwaert et al., 1999; Moynahan et al., 2001).  
Gene targeting with an exogenous DNA fragment involves two distal recombination 
reactions in which the one-ended DSB intermediates of the linearized targeting construct 
invade a chromosome with homologous sequences (Pierce et al., 2001).  HDR, on the 
other hand, occurs through a single recombination reaction that involves two proximal 
DSB ends preferentially invading an intact sister chromatid (Pierce et al., 2001).  Since 
BRCA1 and CtIP are individually required for HDR (Moynahan et al., 1999; Moynahan 
et al., 2001; Sartori et al., 2007; Bennardo et al., 2008) we used two distinct assays to 
ascertain whether the BRCA1-CtIP interaction is required for this process. 
      First, gene-targeting assays were used to measure the efficiency by which transfected 
DNA fragments are integrated homologously at two independent chromosomal loci in 
isogenic Ctip+/– and CtipS326A/– ES cells.  Surprisingly, at both the Pim1 and Rb loci, we 
observed a 2-fold increase in the gene-targeting efficiency of CtipS326A/– cells relative to 
control Ctip+/– cells.  Additionally, when HDR was measured using an integrated DR-
GFP recombination substrate, we observed equivalent levels of HDR in ES cells that do 
or do not allow the Brca1-Ctip interaction.  Thus, these results suggest that the BRCA1-
CtIP interaction is not required for HDR of chromosomal DNA breaks.  Because HDR 
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requires DNA resection, these results further suggest that the BRCA1-CtIP interaction is 
dispensable for DSB end processing.  
      Recently, two independent groups using chicken DT40 cells and an I-SceI-induced 
reporter assay published conflicting results on the role of the BRCA1-CtIP interaction in 
HDR.  Yun and Hiom (2009) reported that CtIP-null chicken DT40 cells reconstituted 
with an exogenous cDNA expression vector encoding human S327A mutant CtIP      
(CtIP–/–/– + hCtIP-S327A) were defective for HDR.  On this basis, they concluded that 
the BRCA1-CtIP interaction is required for DNA resection and, in turn, HDR.  In 
contrast, a second group observed normal levels of HDR in CtIP-S332A mutant 
(CtIPS332A/–/–) DT40 clones (note: the chicken CtIP-S332A mutation is equivalent to the 
murine Ctip-S326A and human CtIP-S327A mutations) (Nakamura et al., 2010).  
Although the cause of these discrepant results remains unclear, Nakamura et al. (2010) 
argue that their approach, in which the S332A mutation was knocked into the endogenous 
chicken CtIP gene, is more physiological as it should preserve normal regulation of CtIP 
gene expression.  Like Nakamura et al. (2010), we used a knock-in approach to introduce 
the S326A mutation into the mouse Ctip gene and found proficient HDR in the absence 
of the Brca1-Ctip interaction.  Using this approach, expression of the Ctip-S326A mutant 
is controlled by the endogenous Ctip promoter, allowing for proper cell-cycle dependent 
regulation (Yu and Baer, 2000).   
      In addition to HDR, CtIP promotes DSB repair by SSA and alt-NHEJ, two distinct 
pathways that also require DNA resection (Bennardo et al., 2008).  To determine the role 
of the BRCA1-CtIP interaction in these pathways, we generated isogenic Ctip+/– and 
CtipS326A/– ES cell subclones containing the SSA or alt-NHEJ recombination substrate 
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integrated into the Hprt or Pim1 locus, respectively.  Following I-SceI endonuclease 
expression, we observed proficient repair of an induced DSB through either SSA or alt-
NHEJ in the absence of the Brca1-Ctip interaction.  Thus, although CtIP promotes 
resection-dependent repair by HDR, SSA, and alt-NHEJ (Bennardo et al., 2008), the 
BRCA1-CtIP interaction appears to be dispensable for these repair pathways. 
      Consistent with proficient DSB repair in the absence of the Brca1-Ctip interaction, 
we observed proper recruitment of several DNA repair proteins to sites of DNA damage 
in CtipS326A/S326A MEFs.  For example, both Brca1 and Ctip readily accumulate into IR-
induced foci (IRIFs) in these cells.  Moreover, RPA recruitment to IRIFs was normal in 
CtipS326A/S326A MEFs, suggesting that resection-dependent formation of ssDNA occurs in 
the absence of the Brca1-Ctip interaction.  The Rad51 protein was also efficiently loaded 
onto resected DNA in CtipS326A/S326A cells.  Taken together, these data indicate that the 
BRCA1-CtIP interaction is not required for CtIP-mediated DNA resection.   
      Prior to these studies, the data regarding the role of BRCA1 in DNA resection was 
limited and in some respects contradictory.  On one hand, Chen et al. (2008) reported that 
RPA recruitment to IRIFs is impaired in HCC1937, a breast tumor cell line that expresses 
C-terminally truncated BRCA1 polypeptide lacking the BRCT repeats.  On the other 
hand, Zhao et al. (2007) found normal IR-induced RPA focus formation in HeLa cells 
after siRNA-mediated BRCA1 depletion.  Moreover, proper laser-induced RPA 
accumulation and IR-induced Rad51 focus formation was observed in the absence of the 
BRCA1-CtIP interaction in CtIPS332A/–/– DT40 cells (Nakamura et al., 2010).  The 
discrepant results obtained from different laboratories may reflect differences in the 
approach to gene modulation (e.g., gene targeting vs. siRNA knockdown) and/or the 
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limitations inherent in using RPA accumulation as a downstream measure of DNA 
resection.  Importantly, when our group and Nakamura et al. (2010) used a gene knock-in 
approach to ablate the BRCA1-CtIP interaction, we both found proficient recruitment of 
RPA and Rad51 to sites of DNA damage.   
       Given that resection-dependent DSB repair appears to be proficient in the absence of 
the Brca1-Ctip interaction, it is not surprising that we observed normal suppression of 
spontaneous and MMC-induced chromosomal rearrangements in Ctip-S326A mutant 
cells, as well as normal cellular tolerance to MMC treatment.  Interestingly, however, 
CtipS326A/– ES cells show a slight sensitivity to the topoisomerase inhibitors CPT and 
ETO, both of which stabilize the Topo-DNA cleavage complex.  This suggests that the 
Brca1-Ctip interaction facilitates cellular tolerance to topoisomerase inhibitors, perhaps 
by mediating the removal of covalently-bound polypeptides from DSB ends.  In fact, a 
requirement for the BRCA1-CtIP interaction in CPT and ETO resistance was 
demonstrated in CtIPS332A/–/– chicken DT40 cells (Nakamura et al., 2010).  However, 
unlike the modest effects observed in mammalian cells, CtIPS332A/–/– DT40 cells displayed 
marked hypersensitivity to both CPT and ETO (Nakamura et al., 2010).  Thus, the extent 
to which the BRCA1-CtIP interaction is involved in the removal of topoisomerases from 
DNA may differ between species.   
     In summary, we have demonstrated that the BRCA1-CtIP interaction is not required 
for all functions of either BRCA1 or CtIP in cell viability and genome maintenance.  In 
mammalian cells, the BRCA1-CtIP interaction is dispensable for resection-dependent 
DSB repair, RPA focus formation, suppression of spontaneous and MMC-induced 
chromosomal rearrangements, and cellular resistance to MMC.  However, the Ctip-
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S326A mutation does have a slight effect on the clonogenic survival of cells to 
topoisomerase inhibitors CPT and ETO.  Therefore, we examined the role of the BRCA1-
CtIP interaction in BRCA1-mediated tumor suppression by monitoring spontaneous 
tumor formation in mice that express the Ctip-S326A mutant.  Interestingly, these mice 
were not tumor prone.  Thus, although BRCA1 tumor suppression depends on BRCT 
phosphoprotein binding (Shakya et al., 2011), it does not depend specifically on its 
interaction with the phospho-ligand CtIP.  Given that BRCA1 also forms distinct protein 
complexes based on BRCT-mediated interactions with the repair proteins 
Abraxas/CCDC98 and BACH1/BRIP1/FancJ, it will be important to determine if one of 
these interactions (and/or others yet to be discovered) mediates the tumor suppression 
function of BRCA1.  It is also conceivable that a combination of BRCT-mediated 
interactions may be required for BRCA1 tumor suppression.  Although CtIP is not 
required for BRCA1-mediated tumor suppression, future studies should resolve whether 
CtIP has functions relevant to tumor suppression independent of its interaction with 




































A.  INTRODUCTION 
      Given its pivotal role in the DNA damage response and its in vivo association with 
several established tumor suppressors, CtIP was itself proposed to function as a tumor 
suppressor (Chen, P.-L., et al., 2005; Chinnadurai, G., 2006).  Although mutational 
screening of cDNA sequences from 89 human tumor cell lines did not detect 
homozygous deletions within the CtIP gene, five missense mutations in the coding region 
were observed in cell lines derived from breast, ovarian, pancreas, and colon carcinomas 
(Wong et al., 1998).  Interestingly, the wildtype CtIP allele was absent in a pancreatic 
carcinoma cell line with a non-conservative K337E missense mutation, suggesting 
possible loss of heterozygosity (Wong et al., 1998).  Although the K337E variant did not 
ablate the BRCA1-CtIP interaction, it could conceivably affect other aspects of CtIP 
function (Wong et al., 1998).   
      CtIP was also identified as a target gene for microsatellite instability in colorectal 
cancer (Vilkki et al., 2002).  Microsatellite instability (MSI) occurs when microsatellites 
or simple tandem repeat sequences are mutated at high frequency due to defects in 
mismatch DNA repair (Chinnadurai, G., 2006).  A screen of 109 colorectal cancers 
revealed that an A9 mononucleotide repeat was mutated on one allele of the CtIP gene 
(one base-pair deletion) at a high rate (22.9%) compared to control intronic 
mononucleotide repeats (Vilkki et al., 2002).  This lesion alters the reading frame such 
that CtIP would encode a grossly truncated polypeptide lacking the C-terminal 540 amino 
acids (Vilkki et al., 2002).  Nevertheless, biallelic lesions of the CtIP gene were not 
observed in these tumors (Vilkki et al., 2002).      
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      The possibility that CtIP acts as a tumor suppressor was further suggested by an 
analysis of mutant mice carrying a null Ctip allele (Chen, P.-L. et al., 2005).  The null 
allele (Ctip–) was generated by inserting a pgkneopA cassette into exon 5 of Ctip.  While 
homozygous (Ctip–/–) animals died in early embryogenesis, heterozygous (Ctip+/–) mice 
were healthy, but developed tumors, primarily lymphomas, at an increased rate (average 
tumor latency T50 = 625 days) relative to Ctip+/+ mice (T50 = 780 days) (Chen, P.-L. et al., 
2005).  Importantly, tumor cells retained the wildtype Ctip allele and tumor tissue stained 
positively for Ctip.  On this basis, Chen, P.-L. et al. (2005) proposed that monoallelic 
Ctip lesions can promote tumor formation by haploid insufficiency.   
      Although a potential role for CtIP in tumor suppression is suggested, these studies do 
not address whether CtIP serves as a tumor suppressor in mammary epithelial cells, an 
intriguing possibility given its interaction with BRCA1.  To determine whether CtIP is 
required for tumor suppression in mammary epithelial cells, and if so, whether this 
activity is epistatic with BRCA1-mediated tumor suppression, we used a Cre-loxP gene 
targeting system to generate mice that inactivate Ctip in a mammary-specific fashion.  To 
bypass the early embryonic lethality of Ctip-nullizygous (Ctip–/–) mice (Chen, P.-L. et al., 
2005), we bred mice to carry a Ctip conditional-null allele (CtipCo) and the mammary-
specific WapCre transgene.  Since this is the same Cre transgene used to induce mammary 
tumors in conditional Brca1-null mice (Shakya et al., 2008), the tumorigenic 





B.  RESULTS 
B1. Generation of the Ctip conditional-null (CtipCo) knock-in targeting construct 
       To generate the Ctip conditional-null allele (CtipCo), we constructed a targeting 
vector in which exon 2 of Ctip is flanked by two loxP recombination sites (Figure 24B).  
Consequently, this exon, which encodes the N-terminal 36 amino acids of Ctip, including 
the initiator methionine, can be deleted upon Cre-mediated recombination.  In addition, a 
PGK promoter-driven neomycin expression cassette flanked by FRT (Flpe recombinase 
target) sites was positioned adjacent to the downstream loxP signal in intron 2.  An HSV 
thymidine kinase (HSV-TK) gene cassette was also included in the targeting vector for 
negative selection.   
 
B2. Identification of properly targeted ES clones 
      129/Sv ES cells were electroporated with the Ctip conditional-null (CtipCo-neo) 
targeting construct and selected for neomycin resistance.  Genomic DNA prepared from 
the surviving drug-resistant ES cell clones was digested with SpeI and analyzed by 
Southern blotting with a 5’ flanking Ctip probe (“Ctip-2”) located upstream of exon 1 
(Figure 24).  In this manner, several independent neomycin-resistant ES clones harboring 
the CtipCo-neo knock-in allele were identified (Figure 25). 
 
B3. The Cre-recombined product of the conditional CtipCo allele is functionally null           
      Two independent CtipCo-neo/+ 129/Sv ES clones were injected into C57BL/6J 














































Figure 24.  Design of the conditional-null CtipCo allele.  A map of the wildtype Ctip 
locus encompassing exons 1 and 2 is shown (A), followed by a diagram of the targeting 
vector (B), and maps of the Ctip locus after homologous recombination (CtipCo-neo) (C), 
Flpe-mediated recombination (CtipCo) (D), and cre-mediated recombination (CtipCo-rec) 
(E).  The coding sequence of Ctip exons are represented by closed rectangles while non-
coding sequences are depicted by open rectangles.  (Note that the initiator methionine is 
located in exon 2).  To prepare the targeting vector, a single loxP recombination signal 
(closed triangle) was inserted into the NheI restriction site of intron 1, while a second 
loxP signal, together with a neomycin expression cassette flanked by FRT signals (open 
triangles), were inserted into the EcoRV site of intron 2.  The Pgk promoter of the 
expression cassette controls transcription of the neo gene.  An HSV thymidine kinase 
(HSV-TK) gene cassette was also included in the targeting vector for negative selection.  
The wavy line represents plasmid sequences of the targeting vector.  Relevant restriction 
enzyme sites are: NheI (N), EcoRV (V), and SpeI (S).  The position of the 5’ flanking 
Ctip probe (“Ctip-2”) used for Southern analysis and the sizes of the SpeI fragments 













Figure 25.  Identification of properly targeted CtipCo-neo/+ ES cells.  129/Sv ES cells 
were electroporated with the conditional CtipCo-neo targeting construct (Figure 24B), and 
SpeI-digested genomic DNAs from the neomycin-resistant ES clones were evaluated by 
Southern hybridization using a 5’ flanking Ctip probe (“Ctip-2”; Figure 24).  The 12.7 kb 
SpeI fragment represents the wildtype Ctip locus (Figure 24A) while the 8.3 kb fragment 
represents the targeted Ctip allele (Figure 24C).  Properly targeted ES clones are seen in 










the neomycin expression cassette from the targeted allele (Figure 24C), CtipCo-neo/+ 
heterozygous mice were mated with Flpe-expressing mice to produce offspring in which 
the FRT-flanked neomycin cassette has been removed, converting the CtipCo-neo allele 
into the desired CtipCo allele (Figure 24D).  These animals were then intercrossed to 
obtain homozygous CtipCo/Co mice (Figure 26).  In contrast to the early lethality of Ctip-
nullizygous embryos (Chen, P.-L. et al., 2005), homozygous CtipCo/Co mice were viable, 
healthy, fertile, and had a normal lifespan, indicating that the two loxP sites and single 
FRT site of the conditional CtipCo allele (Figure 24D) did not interfere with normal gene 
function.  
     CtipCo/Co mice were mated with animals that carry a ubiquitously expressed Cre 
transgene (RosaCre) driven by the mouse Rosa26 gene promoter (provided by Dr. Thomas 
Ludwig, Columbia University) to obtain heterozygous CtipCo-rec/+/RosaCre/+ animals 
(Figure 24E).  To assess the function of the Cre-recombined product (CtipCo-rec) of the 
CtipCo allele, these mice were intercrossed and their progeny identified by genotyping. 
Although wildtype and heterozygous pups appeared at the expected 1:2 ratio, 
homozygous CtipCo-rec/Co-rec offspring (0 out of 113 viable pups) were not obtained from 
this intercross, suggesting an early embryonic death (data not shown).  Furthermore, to 
analyze the stage of lethality, embryos from heterozygous CtipCo-rec/+/RosaCre/+ 
intercrosses were genotyped and the gross morphologies of the embryos and histological 
sections of dissected deciduas were examined at embryonic day 7.5.  As expected, we 
observed 5 homozygous CtipCo-rec/Co-rec embryos out of 16 total embryos examined 














Figure 26.  Identification of homozygous CtipCo/Co mice.  PCR genotyping of 
homozygous CtipCo/Co mice was performed on genomic DNA prepared from mouse tails.  
Using primers 3 and 4 listed in Table 1, the CtipCo allele is amplified as a 290 bp band 
while the Ctip+ allele is amplified as a 250 bp band.  Homozygous CtipCo/Co mice are 
shown in lanes 1, 2 and 3, along with a heterozygous CtipCo/+ mouse (lane 4) and a 










and heterozygous CtipCo-rec/+) embryos examined at E7.5 had gastrulated to form a third 
(mesodermal) germ layer.  In contrast, none of the CtipCo-rec/Co-rec embryos developed past 
the egg cylinder stage (Figure 27, B and D).  Therefore, CtipCo-rec/Co-rec mutant embryos 
display severe growth and morphogenic defects by the onset of gastrulation and die prior 
to E7.5.  This phenotype is remarkably similar to that reported for Ctip–/– nullizygous 
embryos (Chen, P.-L. et al., 2005), confirming that the Cre-recombined product of the 
conditional CtipCo allele is functionally null.    
  
B4. The embryonic lethal phenotype of Ctip-null embryos is not ameliorated by  
       concomitant loss of Ku70 
      Although DSB repair by non-homologous end joining (NHEJ) can proceed with little 
or no nucleolytic processing, other modes of DSB repair, such as homology-directed 
repair (HDR), are highly dependent on DNA resection of the DSB ends.  NHEJ is 
initiated by the recognition and binding of broken DNA ends by the Ku70/Ku80 
heterodimer.  Once bound, Ku protects the ends from degradation and mediates the 
recruitment of downstream NHEJ factors (Daley et al., 2005).  HDR, on the other hand, is 
initiated by the 5’ to 3’ resection of DSBs to generate single stranded DNA (ssDNA) 
overhangs.  Recent studies have shown that CtIP and its orthologs regulate the initial 
stage of DNA resection, where it functions together with the MRN complex to process 
DSB ends into the 3’-ssDNA tails required for ATR checkpoint signaling and homology-
directed repair (Limbo et al., 2007; Penkner et al., 2007; Sartori et al., 2007; Gravel et al., 




















Figure 27.  Embryonic lethality of CtipCo-rec/Co-rec embryos.  Hematoxylin- and eosin-
stained sagittal sections of wildtype (A and C) and CtipCo-rec/Co-rec (B and D) embryos at 
E7.5 are shown.  (A and C) Normal (Ctip+/+,Co-rec/+) post-gastrulation embryos with three 
distinct germ layers.  (B and D) Developmentally retarded homozygous CtipCo-rec/Co-rec 
mutant embryos.  am, amnion; ep, ectoplacental cone; r, Reichardt’s membrane; y, yolk 





















     In S. cerevisiae, the initial step of DNA resection mediated by MRX-Sae2 creates a 
less appealing substrate for Ku binding, committing cells to extensive resection and HDR 
(Mimitou and Symington, 2010).  Mutants lacking Sae2 or any component of the MRX 
complex are highly sensitive to IR (Ivanov et al., 1992; Tsubouchi and Ogawa, 1998; 
Bressan et al., 1999; Moreau et al., 2001; Mimitou and Symington, 2010).  Notably, the 
IR sensitivity of the mre11Δ (Bressan et al., 1999) and sae2Δ (Mimitou and Symington, 
2010) mutants is highly suppressed by deletion of yeast Ku70.  The increased IR 
resistance of mre11Δ/yku70Δ and sae2Δ/yku70Δ double mutants is thought to be the 
result of DNA resection occurring in the absence of Mre11 or Sae2 due to the loss of 
DNA end protection by Ku (Mimitou and Symington, 2010).  
     Given these results, we sought to determine whether loss of Ku70 can mitigate the 
early embryonic lethality phenotype of CtipCo-rec/Co-rec mutant embryos.  To this end, 
CtipCo-rec/+ mice were crossed with Ku70–/– mice (provided by Dr. Shan Zha, Columbia 
University) to generate CtipCo-rec/+/Ku70+/– animals.  These mice were subsequently 
intercrossed to obtain the desired CtipCo-rec/Co-rec/Ku70–/– genotype at an expected 
Mendelian ratio of 1:16.  Embryos from this intercross were isolated and analyzed at E9.5 
of gestation.  76 total embryos were genotyped by PCR and all 9 genotypes were 
identified.  Among the 76 embryos, 54 were live and 22 were in resorption.  As expected, 
no viable CtipCo-rec/Co-rec mutant embryos were identified at E9.5 in a Ku70 wildtype or 
Ku70 heterozygous background.  Additionally, no CtipCo-rec/Co-rec/Ku70–/– mutant embryos 
survived until E9.5, indicating that the Ku70 mutation does not rescue, or even partially 





Table 4.  The Ku70 mutation does not rescue Ctip-null lethality. 
 
a  Among the 76 embryos, 22 were in resorption at E9.5.  Homozygous CtipCo-rec/Co-rec   
   mutants die before E7.5 (Figure 27, B and D) much like Ctip-null mice (Chen, P.-L. et     
   al., 2005).  
 
b  Ku70-nullizygosity does not rescue, or even partially rescue, the Ctip-null early    
   embryonic lethality, as viable CtipCo-rec/Co-rec /Ku70–/– embryos were not observed at    











B5.  Mammary epithelial cell-specific inactivation of Ctip 
       B5a.  Generating a cohort of CtipCo/–,Co/Co/WapCre/+ females for tumor monitoring 
        To evaluate whether Ctip affects tumor suppression, we applied a mouse model of 
familial breast cancer in which the WapCre transgene elicits mammary-specific 
inactivation of the conditional-null CtipCo allele (Ludwig et al., 2001a; Shakya et al., 
2008).  Therefore, homozygous CtipCo/Co mice were crossed with Ctip+/– mice that harbor a 
Cre transgene knocked into the whey acidic protein (Wap) locus, expression of which is restricted 
to mammary epithelial cells during late pregnancy and lactation (Ludwig et al., 2001a).  This 
cross generated control (CtipCo/+/WapCre/+) and experimental (CtipCo/–/WapCre/+) females 
for tumor analysis.  Also, additional experimental CtipCo/Co/WapCre/+ females were 
derived by intercrossing CtipCo/+/WapCre/+ mice.  All female mice appeared normal in that 
they were fertile, had normal litter sizes, and were able to nurse their pups.   
 
       B5b.  Cre-dependent recombination of CtipCo in mammary epithelial cells 
        To demonstrate the activity of the WapCre allele, we examined recombination of the 
conditional CtipCo allele in the mammary glands of experimental CtipCo/Co/WapCre/+ 
females at various time points throughout pregnancy.  Importantly, the endogenous Wap 
gene is expressed specifically in mammary epithelial cells at high levels only for a time 
period that includes late pregnancy and lactation (Robinson et al., 1995).  Although 
limited Wap expression also occurs in some fraction of the putative stem cell population, 
Cre-mediated deletion persists despite massive apoptotic loss of epithelial cells during 
gland involution (Ludwig et al., 2001a).  Notably, one round of pregnancy is necessary 
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and sufficient for Cre-mediated recombination (Ludwig et al., 2001a).  Therefore, we 
prepared genomic DNA from pregnant (E13.5 and E18.5), lactating (10 days 
postpartum), and involuted (10 days post-wean) mammary glands of experimental 
CtipCo/Co/WapCre/+ female mice.  As a control, genomic DNA was also prepared from each 
female’s tail.  Additionally, tail and mammary gland DNA was prepared from 
CtipCo/Co/Wap+/+ females that lack the WapCre transgene.  As expected, PCR analysis 
identified the Cre-recombined Ctip product only in the E18.5 and lactating mammary 
glands of experimental (CtipCo/Co/WapCre/+) females (Figure 28).  Thus, Cre expression 
following pregnancy and lactation renders the mammary epithelial cells of 
CtipCo/Co/WapCre/+ females genotypically Ctip-null (CtipCo-rec/Co-rec).    
 
       B5c.  Mammary-specific inactivation of Ctip does not induce breast carcinogenesis    
                in mice 
      If CtIP is required for tumor suppression in mammary epithelial cells, then 
mammary-specific inactivation of the murine Ctip gene should elicit breast tumors.  
Moreover, if the tumor suppression activities of Ctip and Brca1 are epistatic, then these 
tumors should closely resemble the basal-like mammary carcinomas that arise upon 
mammary-specific ablation of Brca1 (Shakya et al., 2008).  To test this hypothesis, the 
experimental cohort of conditional Ctip (n=21; 14 CtipCo/Co/WapCre/+ and 7 CtipCo/–
/WapCre/+) females was mated to induce at least one round of pregnancy and lactation, 
and then monitored for tumor formation.  Unlike conditional Brca1Co/Co/WapCre/+ females 






















Figure 28.  Cre-mediated CtipCo recombination in E18.5 and lactating mammary 
glands.  Genomic DNA was prepared from pregnant (E13.5 and E18.5), lactating (10 
days postpartum), and involuted (10 days post-wean) mammary glands of control 
CtipCo/Co/Wap+/+ females that lack the WapCre transgene (–), and experimental 
CtipCo/Co/WapCre/+ females that carry the WapCre transgene (+).  As a control, genomic 
DNA was also prepared from the tail of each female.  PCR analysis was performed on 
tail (T) and mammary gland (M) DNA using primers 3 and 5 listed in Table 1.  The 
CtipCo-rec allele is amplified as a 350 bp band.  The PCR product of the recombined 
CtipCo-rec allele is only observed in the mammary glands of E18.5 and lactating 
CtipCo/Co/WapCre/+ experimental females. x, empty lane; H, water lane; C, positive control 









(Shakya et al., 2008), all conditional Ctip experimental animals remained tumor-free over 
an entire 24-month observation period (Figure 29), as did the control animals (n=10; 
CtipCo/+/WapCre/+) (data not shown).  Thus, Ctip appears to be dispensable for tumor 
suppression in this breast cancer model.      
 
     B5d.  Assessing the tumor suppression function of Ctip in tumor-prone settings 
                B5di.  Ctip inactivation increases the latency of breast tumor formation induced   
                           by mammary-specific inactivation of the p53 gene  
      The experiment shown in Figure 29 indicates that conditional inactivation of Ctip 
does not elicit breast tumors in mice.  However, it is possible that Ctip has only a weak 
tumor suppression activity (relative to Brca1) such that its inactivation does not 
appreciably affect the kinetics of breast cancer formation in our mouse model.  Therefore, 
before concluding that Ctip is unnecessary for tumor suppression in mammary epithelial 
cells, we also examined its activity in a tumor-prone setting using a p53 conditional-null 
mutation (p53flex7, which will be designated herein as “p53Co” for clarity; Chen, Z. et al., 
2005).  The rationale for this strategy is based on the well-established observation that 
p53 deficiency accelerates tumor formation in animals bearing Brca1 mutations, 
including various conditional Brca1-null mouse models (Brodie and Deng, 2001; Ludwig 
et al., 2001; Moynahan, M. E., 2002; Evers and Jonkers, 2006; Shakya et al., 2011).  
Therefore, if Ctip suppresses tumor formation, we would expect tumors to develop with a 
shorter latency in Ctip/p53 double-deficient mice compared to p53-deficient alone mice.  


















Figure 29.  Normal suppression of mammary tumorigenesis in the absence of Ctip.  
Kaplan-Meier survival curves of Brca1Co/Co/WapCre/+ (orange curve; n=33; T50 = 512 
days) females (Shakya et al., 2008) compared with CtipCo/–,Co/Co/WapCre/+ (green curve; 
n=21; P < 0.0001) females.  Significance was estimated with the log-rank test using 
Graph-Pad Prism (version 4) software.  Values were considered statistically significant at 
P < 0.05.   

































double-deficient mice should develop tumors with the same latency and penetrance as 
p53-deficient alone animals. 
     To assess tumor development in this sensitized background, we generated WapCre 
females carrying either one or two alleles of the p53 conditional-null mutation (p53Co) 
(Chen, Z. et al., 2005) together with the conditional-null Ctip (CtipCo) allele.  
Specifically, we produced two experimental cohorts (CtipCo/–,Co/Co/p53Co/Co/WapCre/+ and 
CtipCo/–,Co/Co/p53Co/+/WapCre/+) and two corresponding control cohorts 
(CtipCo/+,+/+/p53Co/Co/WapCre/+ and CtipCo/+,+/+/p53Co/+/WapCre/+).  These female mice were 
all healthy, fertile, and able to properly lactate and nurse normal-size litters.  As shown in 
Figure 30 (A and B), mammary tumors occurred in the two control cohorts with average 
latencies of 309 days (CtipCo/+,+/+/p53Co/Co/WapCre/+ mice; n=38) and 330.5 days 
(CtipCo/+,+/+/p53Co/+/WapCre/+ mice; n=10), respectively.  These results are consistent with 
previous studies of mammary-specific p53 inactivation (Wijnhoven et al., 2005).  
Surprisingly, however, tumor formation was dramatically delayed by mammary-specific 
Ctip inactivation in both experimental cohorts: CtipCo/–,Co/Co/p53Co/Co/WapCre/+ (T50 = 605 
days; n=11) (Figure 30A) and CtipCo/–,Co/Co/p53Co/+/WapCre/+ (T50 = not applicable; n=24) 
(Figure 30B).  Thus, in contrast to our expectation that Ctip inactivation would potentiate 
tumorigenesis, we observed that loss of Ctip function markedly inhibits breast cancer 
formation in p53-deficient mice. 
 
























Figure 30.  Loss of Ctip function markedly inhibits breast cancer formation in p53-
deficient mice.  (A)  Kaplan-Meier survival curves of CtipCo/+,+/+/p53Co/Co/WapCre/+ (blue 
curve; n=38; T50 = 309 days) females compared with CtipCo/–,Co/Co/p53Co/Co/WapCre/+ (pink 
curve; n=11; T50 = 605 days; P < 0.0001) females.  (B)  Kaplan-Meier survival curves of 
CtipCo/+,+/+/p53Co/+/WapCre/+ (light blue curve; n=10; T50 = 330.5 days) females compared 
with CtipCo/–,Co/Co/p53Co/+/WapCre/+ (red curve; n=24; P < 0.0001) females.  Significance 
was estimated with the log-rank test using Graph-Pad Prism (version 4) software.  Values 
were considered statistically significant at P < 0.05. 
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                 B5dii.  Ctip inactivation also increases the latency of breast tumor formation    
                              induced by mammary-specific expression of mutant p53  
     Since missense mutations in p53 are among the most common genetic lesions 
associated with human cancer, we also examined the effect of Ctip inactivation on 
tumorigenicity in mice bearing the conditional p53LSL-R270H point mutation (Olive et al., 
2004).  This gain-of-function mutation in murine p53 corresponds to the human R273H 
hotspot mutation often associated with breast cancer (Olive et al., 2004; Wijnhoven et al., 
2005).  Importantly, the mutant p53 allele was designed such that expression of the 
p53R270H polypeptide is blocked until removal of a Lox-STOP-Lox (LSL) cassette by Cre 
recombinase (Olive et al., 2004; Tuveson et al., 2004).  Thus, the unrecombined p53 LSL-
R270H allele is functionally null.   
     To examine the tumor suppression function of Ctip in this tumor-prone setting, we 
generated WapCre females that carry both the conditional p53LSL-R270H point mutation 
(Olive et al., 2004) and the conditional-null Ctip (CtipCo) allele.  Thus, homozygous 
CtipCo/Co mice were crossed with p53LSL-R270H/+/WapCre/+ mice to produce control 
CtipCo/+/p53LSL-R270H/+/WapCre/+ females.  These animals were subsequently mated with 
CtipCo/+ mice to yield the experimental cohort of CtipCo/Co/p53LSL-R270H/+/WapCre/+ females, 
as well as additional control Ctip+/+/p53 LSL-R270H/+/WapCre/+ females.  Following at least 
one complete round of pregnancy to induce Cre-dependent mammary-specific 
inactivation of Ctip and expression of the p53R270H point mutant, the control and 
experimental mice were monitored for tumor formation.  Consistent with previous studies 
(Wijnhoven et al., 2005; Shakya et al., 2011), mammary tumors developed in control 
CtipCo/+,+/+/p53LSL-R270H/+/WapCre/+ females (n=38) with an average latency of 400 days 
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(Figure 31).  Notably, the kinetics of tumor development was significantly slower upon 
conditional Ctip inactivation in the CtipCo/Co/p53LSL-R270H/+/WapCre/+ experimental females 
(n=26; T50 = not applicable) (Figure 31).  Furthermore, inactivation of Ctip and 
expression of the dominant-negative p53R270H allele resulted in an extremely low 
incidence (8.3%; 2/24) of invasive breast tumors.  Of note, the final two experimental 
CtipCo/Co/p53LSL-R270H/+ WapCre/+ females of the cohort are still alive at 510 days old.           
      Interestingly, while control CtipCo/+,+/+/p53LSL-R270H/+/WapCre/+ females developed 
breast tumors before an osteosarcoma could develop, 13 out of 24 CtipCo/Co/p53LSL-
R270H/+/WapCre/+ experimental females succumbed to osteosarcomas.  This predominant 
tumor type was rarely observed in the females of the p53 conditional-null cohort (p53Co) 
due to a difference in the design of the unrecombined p53LSL-R270H and p53Co alleles.  The 
control and experimental females in the p53 conditional-null cohort are in essence p53+/+ 
throughout their entire body (Chen, Z. et al., 2005), while the p53LSL-R270H allele is 
functionally null, rendering the p53 point mutant control and experimental females p53+/– 
throughout their entire body (Olive et al., 2004; Tuveson et al., 2004).  With this in mind, 
our results are consistent with the well-established reports indicating that osteosarcomas 
are the predominant spontaneous tumor type of p53+/– mice (Harvey et al., 1993).  
Nonetheless, as observed with the p53 conditional-null mutation (Figures 30, A and B), 
Ctip loss also inhibited mammary tumor induction by a dominant-negative p53 missense 



















Figure 31.  Ctip loss inhibits mammary tumor induction by a dominant-negative 
p53 missense mutation.  Kaplan-Meier tumor-free survival curves of CtipCo/+,+/+/p53LSL-
R270H/WapCre/+ (green curve; n=38; T50 = 400 days) females compared with 
CtipCo/Co/p53LSL-R270H/WapCre/+ (red curve; n=26; P < 0.0001) females.  Significance was 
estimated with the log-rank test using Graph-Pad Prism (version 4) software.  Values 
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B6.  Analysis of the mammary tumor phenotype 
     The mammary tumors that arose in the conditional Ctip/p53-mutant females were 
invasive adenocarcinomas with a predominantly solid-glandular or solid-nodular primary 
pattern.  Widespread or multifocal ductal carcinoma in situ (DCIS) was detected both 
adjacent and distal to many of the invasive carcinomas examined, and within separate 
mammary glands, suggesting that one or more of these pre-invasive foci likely 
progressed to form the invasive carcinoma.  DCIS was rarely observed, however, in the 
mammary glands of the Ctip/p53-deficient animals that remained mammary tumor free. 
      The solid-glandular or solid-nodular patterns observed in the Ctip/p53-deficient 
mammary tumors were quite uniform and resembled the histological patterns of breast 
tumors that develop following mammary-specific co-inactivation of Brca1 and p53 
(personal communication with Dr. Thomas Ludwig, Columbia University).  This pattern 
was in stark contrast to the sarcomatous or spindle-like pattern observed in the breast 
tumors of p53-deficient alone mice.   
      Furthermore, by immunohistochemistry, most Ctip/p53-deficient invasive neoplasms 
stained for the cytoskeletal markers of basal-like breast cancer, including CK5 (6 of 10 
tumors), CK14 (10 of 10), and vimentin (5 of 10) (Figure 32, A, B, and C; respectively).  
These tumors retained the E-cadherin staining (9 of 10) typical of normal epithelial cells 
(Figure 32D), and most were estrogen receptor (ER) (7 of 10) and progesterone receptor 
(PR) (9 of 10) negative (Figure 32, E and F; respectively).  Therefore, on this basis, a 
majority of the Ctip/p53-deficient mammary tumors were characterized as basal-like 




       
 
Figure 32.  The immunohistochemical phenotype of Ctip/p53-deficient mammary 
carcinomas.  Ctip/p53-deficient mammary carcinomas (CtipCo/–,Co/Co/p53Co/+,Co/Co 
/WapCre/+) exhibit a basal-like phenotype, a characteristic shared with Brca1/p53-
deficient mammary tumors that includes strong immunolabeling for CK5 (A), CK14 (B), 
and vimentin (C), retention of E-cadherin (D) expression, and negative staining for the 
estrogen (ERα) (E) and progesterone receptors (PR) (F).        	  	  





      Although the Brca1/p53-deficient and Ctip/p53-deficient mammary tumors exhibited 
a similar basal-like phenotype, their incidence and latency differed dramatically (Shakya 
et al., 2011), as co-inactivation of Ctip and p53 resulted in a low incidence (33%; 8/24 in 
the p53Co/+state and 55%; 6/11 in the p53Co/Co state) of breast tumors that developed after 
a long latency, longer in fact than p53 inactivation alone (recall Figure 30).  Moreover, 
unlike the Brca1/p53-deficient tumors (data not shown), both p53- and Ctip/p53-deficient 
mammary tumors exhibited amplification of the proto-oncogene c-Met (Figure 33).  
Therefore, to summarize, the Ctip/p53-deficient mammary tumors shared characteristics 
of both Brca1/p53-deficient tumors (basal-like features) and p53-deficient alone tumors 
(c-Met amplification), while having their own unique tumor incidence and latency. 
 
B7.  Assessing the role of Ctip in genome stability with mammary tumor cells 
       B7a.  Analysis of the mammary tumor cells 
        Mammary carcinoma cell lines were derived from several independent breast tumors 
of both the control (CtipCo/+/p53Co/+/WapCre/+) and experimental (CtipCo/–
/p53Co/+/WapCre/+) cohorts, and genomic DNA from each line was examined by Southern 
analysis to assess Cre-mediated conversion of the conditional CtipCo allele to the 
recombined CtipCo-rec null allele.  As shown in Figure 34, we observed full recombination 
of the conditional CtipCo allele, with retention of the wildtype Ctip+ and null Ctip– alleles, 



















Figure 33.  c-Met amplification in p53- and Ctip/p53-deficient mammary tumors.   
Control CtipCo/+/p53Co/+/WapCre/+ (1) and experimental CtipCo/–/p53Co/+/WapCre/+ (2) tail 
(T), mammary tumor tissue (M), and mammary tumor cell line (C) genomic DNA was 
prepared for Southern analysis.  The DNA (left) was hybridized with a “c-Met” probe 
(right).  The intensity of the bands relative to the amount of DNA loaded on the gel was 
compared across samples using the corresponding tail DNA, which lacks c-Met 
amplification, as a control.  c-Met amplification is observed in both control p53-deficient 
(1) and experimental Ctip/p53-deficient (2) mammary tumor tissue (M) and mammary 
tumor cells (C).  Similar results were observed in the Ctip/p53-deficient mammary 









































Figure 34.  Southern blot analysis of CtipCo recombination in mammary tumor cells.  
Control CtipCo/+/p53Co/+/WapCre/+ (1) and experimental CtipCo/–/p53Co/+/WapCre/+ (2) tail 
(T), mammary tumor tissue (M), and mammary tumor cell line (C) genomic DNA was 
prepared for Southern analysis.  BglII/NheI-digested DNA was hybridized with the 
“CtipCo-SmaI” probe spanning exon 1.  The 5.6 kb BglII/NheI fragment represents the 
unrecombined (CtipCo) allele while the 4.2 kb fragment represents the recombined 
(CtipCo-rec) allele.  The wildtype (Ctip+) and null (Ctip–) alleles cannot be discriminated 
and are recognized as a 3.3 kb band.  In both control (CtipCo-rec/+) (1) and experimental 
(CtipCo-rec/-) (2) mammary tumor cells (C) there is complete recombination of the CtipCo 








Moreover, lysates were prepared from several mammary tumor cell lines to examine Ctip 
protein expression.  By immunoblotting with a CtIP-specific antibody, we observed 
endogenous Ctip protein in the control, but not in the experimental, mammary tumor cell 
lines (Figure 35).  Surprisingly, therefore, the experimental mammary tumor cells (CtipCo-
rec/–), unlike normal ES cells and MEFs (Chen, P.-L. et al., 2005), are viable despite the 
complete absence of Ctip expression.  Southern analysis also showed complete 
recombination of the conditional p53Co allele, as well as loss of the wildtype p53+ allele, 
in both the control and experimental mammary tumor lines (Figure 36).  Thus, we 
successfully generated mammary tumor lines that are either double Ctip/p53-null (from 
the experimental cohort or p53-null alone (from the control cohort).  Hereafter, for 
simplicity, these cells will be referred to as CtipCo-rec/– and CtipCo-rec/+, respectively. 
 
       B7b. Analysis of CtipCo-rec/– mammary tumor cells by immunofluorescence  
                  B7bi.  S-phase and IR-treated CtipCo-rec/– mammary tumor cells lack Ctip  
                             nuclear foci 
        To confirm the absence of Ctip expression in CtipCo-rec/– mammary tumor cells, we 
used immunofluorescent microscopy to visualize S-phase and IR-induced nuclear foci 
(IRIFs).  In unstressed cells, CtIP localizes to DNA replication foci during S-phase (Gu 
and Chen, 2009).  However, in response to DNA damage, CtIP disperses from S-phase 
foci and re-emerges to form IRIFs with several other repair proteins (Yu et al., 2006; 
Sartori et al., 2007).  As expected, proficient formation of Ctip-staining S-phase foci and 
IRIFs were observed in CtipCo-rec/+ mammary tumor cells, but Ctip recruitment to nuclear 















Figure 35.  Ctip protein expression in mammary tumor cells.  Whole cell lysates were 
prepared from several independent control CtipCo-rec/+ (lanes 1 and 2) and experimental 
CtipCo-rec/– (lanes 3-5) mammary tumor cell lines.  The cell lysates were then fractionated 
by PAGE and immunoblotted with antibodies specific for CtIP or α-tubulin.  The 
experimental CtipCo-rec/– mammary tumor cells (lanes 3-5) lack endogenous Ctip protein 
expression.  Similar results were also observed in separate experiments using 



































Figure 36.  Southern blot analysis of p53Co recombination and loss of wildtype p53+ 
in mammary tumor cells.  Control CtipCo/+/p53Co/+/WapCre/+ (1) and experimental 
CtipCo/–/p53Co/+/WapCre/+ (2) tail (T), mammary tumor tissue (M), and mammary tumor 
cell line (C) genomic DNA was prepared for Southern analysis.  EcoRV-digested DNA 
was hybridized with the “p53Co” probe, which recognizes the wildtype p53+ (4.6 kb), 
recombined p53Co-rec (4.3 kb) and unrecombined p53Co (2.5 kb) alleles.  In both control 
(1) and experimental (2) mammary tumor cells (C) there is complete recombination of 
the p53Co allele as well as loss of the wildtype p53+ allele; therefore, these cells are p53-








































Figure 37.  Ctip focus formation is absent in CtipCo-rec/– mammary tumor cells.     
CtipCo-rec/+ and CtipCo-rec/– mammary tumor cells were subjected to 10 Gy of IR or left 
untreated; 1 hour later, cells were fixed and stained with CtIP-specific antibodies.  Ctip-
containing S-phase foci and IRIFs were counted in 300 cells of two independent 
mammary carcinoma cell lines for each genotype, and the error bars represent SE of the 
mean.  Ctip S-phase foci and IRIF formation was absent in CtipCo-rec/– mammary 
carcinoma cells, consistent with the lack of endogenous Ctip protein expression in these 






























accord with the immunoblotting data (Figure 35), immunofluorescent staining of Ctip is 
not observed in CtipCo-rec/– mammary tumor cells. 
 
                  B7bii. Brca1, RPA, and Rad51 polypeptides are recruited normally to S-phase   
                             foci and IRIFs in CtipCo-rec/– mammary tumor cells  
      Given the viability of CtipCo-rec/– mammary tumor cells, we were able to evaluate 
whether Ctip is required for the localization of other repair proteins (e.g., Brca1, RPA, 
and Rad51) to both S-phase foci and IRIFs.  Although we and others have observed 
proper Brca1 focus formation in the absence of the Brca1-Ctip interaction (Yu et al., 
2006; Section B7a of Chapter III), these data do not rule out the possibility that Ctip 
indirectly recruits Brca1 to sites of DNA damage.  Nevertheless, as shown in Figure 38, 
Brca1 was properly recruited to S-phase foci and IRIFs in both control CtipCo-rec/+ and 
Ctip-deficient CtipCo-rec/– mammary tumor cells. 
     To ascertain whether loss of Ctip affects DNA resection, we examined IR-induced 
focus formation by the RPA complex. Since RPA readily coats the ssDNA tracts 
generated by 5’ to 3’ resection to form RPA/ssDNA nucleoprotein filaments, RPA 
recruitment to sites of DNA damage is commonly used as an indirect readout of DNA 
resection.  Although CtIP is reported to promote ssDNA formation (Sartori et al., 2007; 
Chen et al., 2008; Nakamura et al., 2010), we observed normal RPA localization to IRIFs 
in both control CtipCo-rec/+ and Ctip-deficient CtipCo-rec/– mammary tumor cells (Figure 
39).  The levels of RPA assembly at S-phase nuclear foci were also comparable in CtipCo-
















Figure 38.  Proficient formation of Brca1 foci in CtipCo-rec/– mammary tumor cells.  
Primary CtipCo-rec/+ and CtipCo-rec/– mammary carcinoma cells were either untreated to 
assess S-phase foci formation or exposed to IR (10 Gy) to assess IRIF formation.  1 hour 
post-irradiation the cells were immunostained with a mouse-specific Brca1 antibody.  
Brca1-containing S-phase foci and IRIFs were counted in 300 cells of two independent 
mammary tumor cell lines for each genotype, and the error bars represent SE of the 
mean.  Brca1 was efficiently recruited to both S-phase foci and IRIFs in Ctip-deficient 












































Figure 39.  Proficient formation of RPA foci in CtipCo-rec/– mammary tumor cells.  
CtipCo-rec/+ and CtipCo-rec/– mammary carcinoma cells were either untreated to assess S-
phase foci formation or exposed to IR (10 Gy) to assess IRIF formation.  Foci formation 
was assessed 1 hour post-irradiation by immunostaining with RPA-specific antibodies.   
RPA-containing S-phase foci and IRIFs were counted in 300 nuclei of two independent 
mammary tumor cell lines for each genotype. The error bars represent SE of the mean.  
RPA localization to S-phase foci and IRIFs was comparable in CtipCo-rec/+ and CtipCo-rec/– 
































formation by end resection may be independent of Ctip in CtipCo-rec/– mammary tumor 
cells. 
      During the DNA damage response, the Rad51 recombination protein can displace 
RPA from RPA/ssDNA filaments to form a Rad51/ssDNA nucleoprotein filament that 
initiates strand invasion and homologous recombination.  To determine if Rad51 
recruitment to sites of DNA damage is dependent on Ctip, we assessed Rad51 focus 
formation in CtipCo-rec/– mammary tumor cells.  As shown in Figure 40, we observed 
proficient formation of Rad51-staining S-phase foci and IRIFs in CtipCo-rec/– cells.  Rad51 
was recruited to these nuclear structures with the same efficiency as observed in the 
control CtipCo-rec/+ cells (Figure 40).  Thus, Ctip is not required for the localization of 
Rad51 to sites of DNA damage.  Since these nuclear structures likely reflect the assembly 
of Rad51/ssDNA nucleofilaments, this result indirectly suggests that DNA resection can 
take place in the absence of Ctip.  Overall, Ctip may be dispensable for DNA resection 
and HDR given the proper recruitment of Brca1, RPA, and Rad51 to DSB sites in Ctip-
deficient cells.  
  
       B7c. Cytogenetic analysis of chromosomal stability 
                  B7ci.  CtipCo-rec/– mammary tumor cells suppress both spontaneous and MMC-  
                             induced chromosomal rearrangements 
 
        Next we used cytogenetic analysis to assess the ability of Ctip-deficient cells to 
suppress spontaneous and MMC-induced chromosomal rearrangements.  Interestingly, 
low levels of spontaneous chromosomal rearrangements were observed in metaphase 
















Figure 40.  Proficient formation of Rad51 foci in CtipCo-rec/– mammary tumor cells.  
CtipCo-rec/+ and CtipCo-rec/– mammary tumor cells were subjected to 10 Gy of IR or left 
untreated; 1 hour later, the cells were fixed and stained with Rad51-specific antibodies.   
Rad51-containing S-phase foci and IRIFs were counted in 300 nuclei of two independent 
mammary tumor cell lines for each genotype.  The error bars represent SE of the mean.  
Rad51 localization to S-phase foci and IRIFs was comparable in mammary tumor cells of 

































result indicates that Ctip-deficient cells display normal resistance to spontaneous 
chromosomal instability.  We also compared metaphase spreads from CtipCo-rec/– and 
CtipCo-rec/+ cells treated for 16 hours with 40 ng/mL of the DNA interstrand crosslinking 
agent mitomycin C (MMC).  In response to MMC, the CtipCo-rec/– mammary tumor cells 
again accumulated cytogenetic defects at a similar rate to control CtipCo-rec/+ cells (Figure 
41B) suggesting that Ctip is not required for the suppression of MMC-induced 
chromosomal aberrations.  The types of spontaneous and MMC-induced chromosomal 
rearrangements observed in the CtipCo-rec/– and CtipCo-rec/+ cells were predominantly 
chromatid/chromosome breaks and gaps, as opposed to complex rearrangements or 
exchanges (Table 5).  Furthermore, pronounced aneuploidy was not observed in the 
CtipCo-rec/– mammary tumor cells relative to CtipCo-rec/+ cells (data not shown).  Thus, in 
these tumor lines, Ctip appears to be dispensable for recruitment of key repair proteins 
(Brca1, RPA, and Rad51) to sites of DNA damage and for suppression of spontaneous 




























Figure 41.  Low levels of spontaneous and MMC-induced chromosomal aberrations 
in CtipCo-rec/– mammary tumor cells.  Primary CtipCo-rec/+ and CtipCo-rec/– mammary 
carcinoma cells were cultured in the (A) absence or (B) presence of MMC (40 ng/mL, 16 
hours) and subjected to karyotype analysis.  Following colcemid treatment, exposure to a 
hypotonic solution, and methanol/acetic acid fixation, the cell suspensions were dropped 
onto glass slides and stained with Giemsa.  For each treatment condition, at least twenty 
metaphase spreads per cell line were examined for numerical and structural chromosomal 
aberrations.   
 
 





































Table 5.  Spontaneous and induced chromosomal aberrations in mouse mammary 












MMC, mitomycin C / Chr, chromosome / Cht, chromatid     
 
The percentage of metaphases containing one or more aberrations, as well as a 
breakdown of aberration-type, is shown for each mammary carcinoma cell line in both 












C.  DISCUSSION 
      Apart from an amino-terminal coiled-coil domain that is now known to mediate 
protein homodimerization (Dubin et al., 2004), the amino acid sequence of CtIP does not 
harbor obvious structural features.  Thus, the first clues to the biological function of CtIP 
were provided by the identification of CtIP-interacting partners.  CtIP contains several 
short sequence motifs required for its interaction with the transcriptional co-repressor 
CtBP (Schaeper et al., 1998), the tumor suppressor Rb (Fusco et al., 1998), and the tumor 
suppressor BRCA1 (Wong et al., 1998; Yu et al., 1998).  These interactions are thought 
to mediate CtIP function in transcriptional regulation, the DNA damage response, and 
cell cycle checkpoint control (Meloni et al., 1999; Li et al., 2000; Yu and Chen, 2004; 
Chen, P.-L. et al., 2005; Liu and Lee, 2006).   
      Further studies also raised the possibility that CtIP may itself serve as a tumor 
suppressor.  Monoallelic genetic alterations of the CtIP gene have been identified in some 
human tumor cells, including mismatch repair-deficient colorectal carcinomas (Wong et 
al., 1998; Vilkki et al., 2002).  Furthermore, heterozygous Ctip+/– mice develop tumors at 
an increased rate relative to wildtype Ctip+/+ mice, suggesting that haploid insufficiency 
of Ctip can lead to tumorigenesis (Chen, P.-L. et al., 2005).  However, none of these 
studies addressed whether CtIP exerts tumor suppression activity in mammary epithelial 
cells, an intriguing possibility given that CtIP interacts with the BRCA1 tumor 
suppressor.   
      To test this hypothesis, we generated a conditional-null Ctip (CtipCo) allele in ES cells 
and introduced it into the mouse germline.  Importantly, we showed that the CtipCo-rec 
allele that arises upon Cre-mediated recombination of CtipCo is non-functional.  
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Therefore, by restricting Cre expression to mammary epithelial cells, we were able to 
inactivate the CtipCo allele in a mammary-specific fashion.  This strategy mimics the 
approach used to demonstrate the tumor suppressor activity of Brca1 (Shakya et al., 
2008), and thus the tumorigenic consequences of Ctip and Brca1 inactivation could be 
directly compared.  
      Conditional inactivation of Brca1 elicits mammary carcinomas that phenotypically 
resemble the basal-like breast tumors of human BRCA1 mutation carriers (Shakya et al., 
2008).  In contrast, we report here that mammary-specific Ctip inactivation does not 
generate breast tumors in mice.  Although BRCA1 and CtIP are both essential for the 
viability of non-malignant mammalian cells, such as ES cells and MEFs (Elledge and 
Amon, 2002; Chen, P.-L. et al., 2005; Reid et al., 2008), the embryonic lethality 
phenotype of Ctip-null embryos is reported to be more severe than that of Brca1 
nullizygotes (Chen, P.-L. et al., 2005).  By PCR analysis, we were able to detect the 
recombined CtipCo-rec allele in the mammary glands of experimental pregnant (E18.5) and 
lactating females (Figure 28), suggesting that Ctip-nullizygous mammary epithelial cells 
are not eliminated immediately by cell death upon Cre-mediated recombination of the 
CtipCo allele.  Nevertheless, unlike the Brca1-null cells produced by mammary-specific 
inactivation of Brca1Co (Shakya et al., 2008), Ctip-null cells did not give rise to 
mammary tumors.  
     Since p53 mutations are prevalent in BRCA1-associated tumors (Crook et al., 1997; 
Xu et al., 1999a), we examined the effect of Ctip conditional inactivation in a tumor-
prone setting using a p53 conditional-null mutation.  Strikingly, we observed an increased 
latency and a reduced incidence of mammary tumor development upon conditional co-
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inactivation of Ctip and p53, relative to conditional p53 inactivation alone.  This result 
indicates not only that Ctip inactivation fails to potentiate p53-induced mammary tumor 
formation, but that Ctip loss actually provides a protective effect against tumorigenesis in 
this setting.  This phenomenon was observed whether p53 deficiency was achieved by 
monoallelic or biallelic p53 gene inactivation or by expression of a dominant-negative 
p53 mutant polypeptide.  Thus, our results challenge the assumption that Ctip acts as a 
tumor suppressor and question whether the monoallelic mutations of human CtIP 
observed in mismatch repair-deficient colorectal carcinomas are truly oncogenic.   
      Several possible explanations can be invoked to account for the prolonged tumor 
latency observed following conditional inactivation of Ctip.  First, loss of Ctip may 
inhibit tumor development by reducing the viability of precancerous cells.  It should be 
noted, however, that mammary tumors are readily generated by a similar protocol of 
Brca1 inactivation, despite the fact that Brca1-null ES cells and MEFs are also inviable 
(Elledge and Amon, 2002; Reid et al., 2008).  Second, Ctip loss may delay tumorigenesis 
by preventing the formation of oncogenic chromosome translocations (Zhang and Jasin, 
2011).  This intriguing possibility emerged from a recent study which implicated CtIP-
mediated alt-NHEJ, a resection-dependent repair process, in the formation of tumor-
associated chromosomal translocations (Zhang and Jasin, 2011).  Third, CtIP is reported 
to relieve an Rb-mediated G1 restraint, since Ctip depletion arrests Rb+/+, but not Rb–/–, 
MEFs in the G1 phase of the cell cycle (Chen, P.-L. et al., 2005; Chinnadurai, G., 2006).  
As such, loss of CtIP may inhibit tumor formation by allowing Rb-dependent cell cycle 
arrest.  This notion is attractive because the CtIP protein (also called RBBP8) harbors an 
LxCxE motif that is reported to bind the interaction pocket of the Rb tumor suppressor 
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(Fusco et al., 1998).  However, inspection of the GenBank database reveals that the motif 
is poorly conserved; thus, while LxCxE is present in the mouse and rat orthologs of CtIP, 
it has diverged in many other mammals, including orangutans, dogs, cows, horses, and 
platypuses. 
      Interestingly, the mammary tumors that arise upon co-inactivation of Ctip and p53 are 
phenotypically distinct from those obtained by either Brca1/p53 co-inactivation or by p53 
inactivation alone.  Specifically, like Brca1/p53-deficient mammary tumors, the 
Ctip/p53-deficient neoplasms display a solid-glandular and solid-nodular histopathology, 
stain for the basal cytokeratins CK5 and CK14, and lack expression of the estrogen and 
progesterone receptors.  However, in contrast to Brca1/p53-deficient tumors, the 
Ctip/p53-deficient tumors show amplification of the c-Met proto-oncogene, a common 
feature of p53-deficient alone tumors (Rong et al., 1995).  Thus, the Ctip/p53-deficient 
tumors appear to incorporate different phenotypic features of the Brca1/p53-deficient and 
p53-deficient tumors. 
      Although Ctip-nullizygous mouse ES cells and MEFs are not viable (Chen, P.-L. et 
al., 2005), we were able to generate permanent cell lines from the mammary tumors of 
experimental CtipCo/–/p53Co/+/WapCre/+ mice.  As such, these represent the first 
mammalian Ctip-null cells to be cultured in vitro.  Southern analysis established that 
these cells are genetically null for Ctip (CtipCo-rec/–), and Western analysis confirmed the 
absence of Ctip protein expression.  Although we do not know the mechanism by which 
these cells retain viability in the absence of Ctip expression, as malignant cells, they may 
harbor additional genetic lesions that compensate for the absence of Ctip.   
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      There is substantial evidence that CtIP is required for maintenance of genomic 
stability, at least in part through its role in resection and repair of DSBs (Sartori et al., 
2007; Bennardo et al., 2008).  Nevertheless, we found that the levels of spontaneous and 
genotoxin-induced chromosomal rearrangements were indistinguishable in mammary 
carcinoma cell lines that did (CtipCo-rec/+) or did not (CtipCo-rec/–) express Ctip.  In 
addition, immunofluorescent microscopy revealed that essential components of the HDR 
machinery, including Brca1 and Rad51, were proficiently recruited to sites of DNA 
damage in the absence of Ctip.  We also observed normal assembly of IR-induced RPA 
foci, suggesting that Ctip is not essential for the formation of ssDNA ends by resection in 
CtipCo-rec/– cells.  These results are in stark contrast to previous studies, in which siRNA-
mediated knockdown of CtIP disrupted both RPA focus formation and an anti-BrdU 
staining of ssDNA foci in genotoxic-treated human tumor lines (Sartori et al., 2007; Chen 
et al., 2008). 
      Although we do not know the mechanisms by which CtipCo-rec/– mammary tumor cells 
retain chromosomal stability in the absence of Ctip, one can envision scenarios in which 
an additional genetic lesion might compensate for loss of Ctip.  For example, one 
untested, but plausible, possibility would be a defect in the function of the Ku70/Ku80 
heterodimer, a critical upstream factor in the NHEJ pathway of DSB repair.  A two-stage 
DSB resection process has been identified in yeast and mammalian cells (Gravel et al., 
2008; Mimitou and Symington, 2008; Raynard et al., 2008; Zhu et al., 2008), whereby 
MRN(MRX) and CtIP(Sae2) generate minimally resected DSB intermediates to recruit 
nucleases/helicases that catalyze extensive and processive resection.  In S. cerevisiae, the 
initial processing of a DSB end by MRX-Sae2 creates a less appealing substrate for 
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binding of the Ku70/Ku80 complex (Mimitou and Symington, 2010).  Interestingly, yeast 
sae2Δ mutants are highly sensitive to IR, presumably because DNA-bound Ku70/Ku80 
blocks end resection (Mimitou and Symington, 2010), but deletion of Ku70 rescues the 
IR sensitivity phenotype of sae2Δ mutants.  This observation suggests that loss of end 
protection by Ku70/Ku80 allows extensive resection by the processive 
nucleases/helicases to occur in the absence of Sae2 (Mimitou and Symington, 2010).  
Perhaps, therefore, an analogous loss of Ku70/Ku80 function would allow CtipCo-rec/– 
tumor cells to execute DNA resection and other aspects of the DNA damage response 
without Ctip function.  Clearly, further studies will be required to ascertain the 
mechanisms of DSB repair in CtipCo-rec/– tumor cells.   
      In summary, CtipCo-rec/– mammary tumor cells appear to resect DSB ends and respond 
to DNA damage properly.  This is further supported by the ability of these cells to 
suppress both spontaneous and MMC-induced chromosomal aberrations.  Thus, key 
aspects of genomic stability are maintained in the CtipCo-rec/– mammary tumor cells.  
Remarkably, the in vivo inactivation of Ctip provided a protective effect against the 
development of mammary tumors due to p53 deficiency.  Understanding how loss of Ctip 



















THE ROLE OF THE BRCT PHOSPHO-LIGANDS OF BRCA1 















A.  INTRODUCTION 
      The two BRCA1 carboxy-terminal (BRCT) motifs of BRCA1 form a phosphoprotein 
recognition domain (Koonin et al., 1996; Manke et al., 2003; Yu et al., 2003) that 
preferentially binds the pSer-x-x-Phe motif (Manke et al., 2003; Rodriguez et al., 2003) 
of three known repair proteins, Abraxas/CCDC98, BACH1/BRIP1/FancJ, and CtIP 
(reviewed in Huen et al., 2010; Moynahan and Jasin, 2010).  Importantly, the phospho-
recognition surface of tandem BRCT motifs can only accommodate one phospho-ligand 
at a time; therefore, a single BRCA1 polypeptide will bind Abraxas, BACH1, or CtIP in a 
mutually exclusive manner (Yu and Chen, 2004; Greenberg et al., 2006; Kim et al., 2007; 
Liu, Z. et al., 2007; Wang et al., 2007).  Thus, BRCA1 forms a distinct complex with 
each of these BRCT-interacting phosphoproteins to mediate unique aspects of its function 
in response to DNA damage (Greenberg et al., 2006; reviewed in Huen et al., 2010).   
      Since the phosphopeptide binding property of the BRCT repeats is critical for 
BRCA1 tumor suppression (Shakya et al., 2011), we, in collaboration with Dr. Thomas 
Ludwig (Columbia University), sought to determine which phosphoprotein interaction 
mediates this function.  To do this, single amino acid (serine-to-alanine) substitutions 
were made in Abraxas, BACH1, and CtIP to ablate the phosphoprotein interaction with 
the BRCT domain of BRCA1.  As described earlier in this thesis, mice bearing the Ctip-
S326A mutation are not tumorigenic and thus, BRCA1 tumor suppression is not mediated 
exclusively by its interaction with CtIP (Section B11a of Chapter III).  Similarly, tumor 
formation was not observed in mice harboring either the Abraxas-S404A or the Bach1-
S994A point mutation (data not shown).  Therefore, BRCA1 tumor suppression is not 
dependent on its individual interaction with the phospho-ligands Abraxas, BACH1, or 
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CtIP.  Instead tumor suppression may require the interaction of BRCA1 with two or more 
of these phosphoproteins (and/or other as yet undiscovered phosphoproteins). 
      To determine if BRCA1 tumor suppression is mediated by the interaction of BRCA1 
with two of its known BRCT phospho-ligands, we generated each of the three 
combinations of double homozygous mutant mice (AbxS404A/S404A/Bach1FH-S994A/FH-S994A, 
AbxS404A/S404A/CtipS326A/S326A, and Bach1FH-S994A/FH-S994A/CtipS326A/S326A) and monitored them 
for tumor development.  For convenience, these animals will be referred to as “AB”, 
“AC”, and “BC” mice, respectively.  Additionally, we bred triple homozygous mutant 
mice (AbxS404A/S404A/Bach1FH-S994A/FH-S994A/CtipS326A/S326A; “ABC” mice) to determine if 
BRCA1 tumor suppression requires BRCA1’s association with all three BRCT-
interacting phosphoproteins.  Since the genome maintenance functions of BRCA1 are 
thought to be critical for its tumor suppression activity, we also examined chromosomal 













B.  RESULTS 
B1.  Genome stability and tumor suppression in double mutant (AB, AC, and BC)  
       cells and animals  
 
       B1a.  Generation of AB, AC, and BC double mutant MEFs  
       Mouse embryonic fibroblasts (MEFs) derived from tumor-prone Brca1S1598F/S1598F 
mice display a genomic instability phenotype that includes chromosomal abnormalities 
and defective DNA damage responses (Shakya et al., 2011).  Since the Brca1-S1598F 
mutation ablates the phospho-recognition property of the BRCT domain, these results 
indicate that the genome stability functions of BRCA1 are mediated by its interaction 
with one or more of its BRCT phospho-ligands.  Since CtipS326A/S326A MEFs do not display 
a comparable genomic instability phenotype, this aspect of BRCA1 function is not solely 
dependent on the Brca1-Ctip interaction (Chapter III of this thesis).  Likewise, this 
genomic instability phenotype is also not observed in either AbxS404A/S404A or Bach1FH-
S994A/FH-S994A MEFs (data not shown).  Therefore, we sought to determine whether genome 
stability is maintained when the interactions of BRCA1 with two of its known BRCT 
phospho-ligands are simultaneously ablated.   
      To this end, we crossed homozygous CtipS326A/S326A mice with homozygous 
AbxS404A/S404A or Bach1FH-S994A/FH-S994A mice (kindly provided by Dr. Thomas Ludwig, 
Columbia University) to produce double heterozygous mutant animals which, when 
intercrossed, would yield the desired double homozygous mutant AC 
(AbxS404A/S404A/CtipS326A/S326A) and BC (Bach1FH-S994A/FH-S994A/CtipS326A/S326A) mice.  In a 
similar fashion, we also generated double homozygous mutant AB 
(AbxS404A/S404A/Bach1FH-S994A/FH-S994A) mice.  Notably, the double homozygous mutant 
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mice of each genotype (AB, AC, and BC) were viable, healthy, fertile, and 
indistinguishable from their littermate controls.     
      Due to the viability of the double homozygous mutant mice, cultured MEFs of each 
genotype were readily established.  Matings were set up and E13.5 day embryos were 
aseptically dissected from the pregnant mother mouse and minced under sterile 
conditions to generate primary MEFs.  The phenotypes of the double homozygous AB, 
AC, and BC mutant MEFs were then examined.  
 
      B1b.  AB, AC, and BC double mutant MEFs proliferate normally 
      Brca1S1598F/S1598F cells, which express a Brca1 polypeptide that fails to interact with its 
BRCT phospho-ligands, display a marked proliferation defect which may be triggered by 
their inability to mount normal cellular responses to DNA damage (Shakya et al., 2011).  
Therefore, we examined the proliferation rate of early passage primary AB, AC, and BC 
double mutant MEFs using the MTT assay.  As shown in Figure 42, the proliferation 
rates of AB and BC double mutant MEFs were comparable to those of heterozygous 
control MEFs (AbxS404A/+/Bach1FH-S994A/+/CtipS326A/+).  Additionally, we observed normal 
proliferation rates for the AC double mutant MEFs (data not shown).    
 

















Figure 42.  Double mutant BRCT phospho-ligand MEFs proliferate normally.  The 
cellular proliferation of double homozygous AB (A/A B/B) and BC (B/B C/C) early 
passage primary MEFs was measured and compared to the proliferation rate of control 
(A/+ B/+ C/+) MEFs.  Cells were seeded on 96-well plates at a density of 2000 cells per 
well.  At the indicated time points, cell numbers were determined using an MTT assay.  
Values on the Y-axis represent folds of increase in cell numbers.  The error bars represent 
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      B1c.  The IR sensitivity of AB, AC, and BC double mutant mice 
      One of the hallmarks of a defective DNA damage response is increased radiation 
sensitivity. As described in Section B10a of Chapter III, loss of the Brca1-Ctip 
interaction did not render CtipS326A/S326A mice hypersensitive to ionizing radiation (IR).  
Furthermore, normal IR resistance was also observed in homozygous AbxS404A/S404A and 
Bach1FH-S994A/FH-S994A mice (data not shown).  Thus, the interaction of BRCA1 with each 
of these three BRCT phospho-ligands is not individually required for IR resistance.  To 
determine whether the interaction with a combination of these phospho-ligands is 
required for resistance to IR, we irradiated AB, AC, and BC double mutant mice at two 
months of age with a sublethal dose of 8 Gys.  Strikingly, all mice (n=10 for each 
genotype) survived at least 6 weeks post-irradiation (data not shown).  In contrast, 100% 
of Bach1-null mice (n=22) died by 20 days post-irradiation (unpublished data).  This 
result suggests that the AB, AC, and BC double mutant mice retain a sufficient DNA 
damage response to allow resistance to whole-body IR. 
 
      B1d.  The tumor susceptibility of AB, AC, and BC double mutant mice 
      Since BRCA1 tumor suppression requires the phosphopeptide binding property of the 
BRCT repeats (Shakya et al., 2011), but not its individual interaction with the phospho-
ligands Abraxas, BACH1, or CtIP (Figure 23, Section B11a of Chapter III; and data not 
shown), we asked whether simultaneous disruption of two or more of these interactions 
affects BRCA1-mediated tumor suppression.  First, we assessed whole-body tumor 
development in AB, AC, and BC double mutant mice.  Although whole-body tumor 
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monitoring of homozygous Brca1S1598F/S1598F mice revealed highly penetrant tumor 
development with an average latency (T50) of 575 days (Shakya et al., 2011), the kinetics 
of tumor development in BC (n=9) double mutant mice was significantly slower (P = 
0.0032) and indistinguishable from that of control Bach1+/+/Ctip+/+ mice (P = 0.8786) 
(Figure 43).  Thus, disrupting the interaction of Brca1 with Bach1 and Ctip 
simultaneously does not render mice susceptible to tumor formation.  At present, whole-
body tumor monitoring of AB (n=20) and AC (n=23) double mutant mice is ongoing.  
Mice of each genotype have remained tumor-free for over a year (data not shown).    
  
B2.  The phenotype of triple mutant (ABC) cells  
        
	  
       B2a.  Generation of ABC triple mutant MEFs  
      	  	  Given that AB, AC, and BC double mutant cells appeared to be normal for all 
parameters tested, we next examined the phenotype of ABC triple mutant MEFs.  To 
obtain these cells, we first mated homozygous AB and BC mice to produce animals 
bearing a total of four mutant alleles (e.g., AbxS404A/+/Bach1FH-S994A/FH-S994A/CtipS326A/+).  
These mice were then intercrossed to generate progeny bearing five mutant alleles.  
Assuming complete viability, crosses of the latter mice should yield pups with the desired 
ABC genotype (AbxS404A/S404A/Bach1FH-S994A/FH-S994A/CtipS326A/S326A) at a frequency of 25%.  
Therefore, we sacrificed pregnant females from these crosses on day E13.5.  Importantly, 
viable ABC triple mutant E13.5 embryos were obtained at the expected Mendelian 












Figure 43.  BC double mutant mice are not tumorigenic.  Kaplan-Meier tumor-free 
survival curves of Bach1+/+/Ctip+/+ (blue curve; n=47) mice compared with Bach1FH-
S994A/FH-S994A/CtipS326A/S326A (green curve; n=9; P = 0.8786) and Brca1S1598F/S1598F (purple 
curve; n=72; T50=575 days; P < 0.0001) mice.  Statistical significance was estimated with 
the log-rank test using Graph-Pad Prism (version 4) software.  Values were considered 














































Figure 44.  ABC triple mutant embryos are viable at E13.5.  PCR analysis of E13.5 
embryos from a five mutant allele cross (e.g., A/+ B/B C/C and A/A B/B C/+).  The 
Abraxas (top), Bach1 (middle), and Ctip (bottom) mutant-specific PCRs were used to 
genotype the DNA isolated from yolk sacs at E13.5.  All four expected offspring 
genotypes were observed, including A/A B/B C/C (triple ABC mutant (*); lanes 4 and 6), 
A/+ B/B C/+ (lanes 2 and 7), A/+ B/B C/C (lanes 3 and 5), and A/A B/B C/+ (lane 1).  
Additionally, control A/+ B/+ C/+ DNA was loaded in lane C.                                           




















a  Matings were set up between A/+ B/B C/C females and A/A B/B C/+ males.   
    A = AbraxasS404A; B = Bach1FH-S994A; C = CtipS326A   
 
b  Among the 15 embryos examined, 4 were triple ABC mutant (A/A B/B C/C).   
   Thus, at E13.5 ABC triple mutant embryos are viable and obtained at the  
   expected Mendelian frequency.         
 











Number of E13.5 embryos 
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and some exhibited exencephaly, a neural tube defect in which the brain is located 
outside the skull (Figure 45).  The modest phenotypic variation observed between 
different ABC embryos may reflect the mixed genetic background (C57Bl6 x 129Sv) of 
the offspring.  In any case, we were able to successfully generate primary and SV40-
immortalized MEFs from ABC triple mutant embryos, and compare their phenotype with 
those of control MEFs, as well as Brca1S1598F/S1598F MEFs that express a Brca1 
polypeptide that fails to interact with its BRCT phospho-ligands. 
 
      B2b.  ABC triple mutant MEFs have a proliferation defect 
      To assess the proliferative potential of ABC triple mutant cells, we examined primary 
MEFs at passage 1 using the MTT assay.  As shown in Figure 46A, by the second day in 
culture the proliferation rate of ABC primary MEFs was significantly reduced compared 
to that of primary MEFs derived from either littermate controls, or from AB, AC, and BC 
double mutant mice (Figure 42, Section B1b of Chapter V).  Similar results were 
obtained using additional independently-derived primary MEF subclones at passage 2 
(Figure 46B).  Notably, the proliferation rate of ABC cells was reduced to the same 
extent as that of Brca1S1598F/S1598F cells (data not shown), which express a Brca1 
polypeptide that lacks BRCT phospho-recognition.  These results indicate that in the 
absence of one or two of the three known BRCT phospho-ligand interactions, the other 
known phospho-ligand interactions can compensate to allow normal cell proliferation.  
Thus, proliferation is not appreciably diminished unless all three known BRCT phospho- 














Figure 45.  Exencephaly of some ABC triple mutant embryos at E13.5.  The neural 
tube has failed to close in this E13.5 ABC triple mutant embryo (left).  This is in contrast 

































Figure 46.  Reduced proliferation in ABC triple mutant MEFs.  To evaluate the 
proliferation rate of (A) passage 1 and (B) passage 2 control (A/+ B/B C/+, A/A B/B C/+, 
and A/+ B/B C/C) and ABC triple mutant (A/A B/B C/C) MEFs, cells were trypsinized, 
counted, and seeded on 96-well plates.  4000 cells per well were seeded for each ABC 
triple mutant line while 2000 cells per well were seeded for the control lines.  At the 
indicated time points, cell numbers were quantified using an MTT assay.  Values on the 
Y-axis represent folds of increase in cell numbers.  The error bars represent the mean ± 
SD of triplicate samples.  A = AbraxasS404A; B = Bach1FH-S994A; C = CtipS326A  
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potential of Brca1 is ablated entirely (as in Brca1S1598F/S1598F MEFs).   
 
      B2c.  ABC triple mutant MEFs exhibit centrosome amplification 
      Supernumerary centrosomes (>2 centrosomes/cell) are frequently observed in cells 
that display genetic instability due to defects in the DNA damage response.  Indeed, 
centrosome amplification can lead to the formation of multiple spindle poles during 
mitosis, which may in turn promote chromosomal aneuploidy, genomic instability, and 
ultimately tumorigenesis (Deng, C.-X., 2002).  Since centrosome amplification is 
observed in Brca1S1598F/S1598F MEFs, the BRCT phospho-recognition property of Brca1 is 
required to maintain normal centrosome duplication (Shakya et al., 2011).  To examine 
whether the interaction of BRCA1 with its three known BRCT phospho-ligands is 
required for control of centrosome duplication, immunofluorescent staining with a 
pericentrin-specific antibody was used to compare centrosome numbers in passage 3 
ABC triple mutant MEFs and control MEFs.  While one or two centrosomes were 
commonly detected in control cells at interphase and at various stages of M phase, ~35% 
of ABC MEFs contained more than two centrosomes (Figure 47A).  A similar result was 
observed when pericentrin staining was performed on passage 4 ABC and control MEFs 
(Figure 47B).  In the most extreme case, one ABC cell was found to contain 10 
centrosomes (data not shown).  Therefore, ABC cells undergo centrosome amplification 






























































































Figure 47.  Centrosome amplification in ABC triple mutant MEFs.  Primary control 
(A/+ B/B C/C) and ABC triple mutant (A/A B/B C/C) MEFs at (A) passage 3 and (B) 
passage 4 were immunostained with anti-pericentrin and anti-α-tubulin and stained with 
4’, 6-diamidino-2-phenylindole (DAPI).  The number of centrosomes per cell was 
determined by immunofluorescent microscopy of 300 cells of each genotype.  The mean 
value from two cell lines of each genotype is presented; error bars indicate the standard 
error of mean (S.E.M).  (C)  Representative images of control (top row) and ABC mutant 
(bottom row) MEFs immunostained with anti-pericentrin (red) and anti-α-tubulin (green) 
and then stained with DAPI (blue) for visualization of nuclei.  A = AbraxasS404A; B = 
Bach1FH-S994A; C = CtipS326A  







      B2d.  Impaired recruitment of repair proteins to the S-phase foci and IRIFs of ABC   
               triple mutant MEFs  
      The localization of BRCA1 to damaged DNA is reportedly mediated, at least in part, 
by its interaction with the BRCT phospho-ligand Abraxas (Kim et al., 2007a; Liu, Z. et 
al., 2007; Sobhian et al., 2007; Wang et al., 2007).  Abraxas bridges the association 
between BRCA1 and RAP80, a nuclear protein that harbors a ubiquitin-interacting motif 
(UIM).  In turn, the UIM of RAP80 recognizes and binds the ubiquitinated histones at 
DNA damage sites, thereby bringing Abraxas-bound BRCA1 polypeptides to damaged 
DNA (Kim et al., 2007a; Liu, Z. et al., 2007; Sobhian et al., 2007; Wang et al., 2007).  By 
immunofluorescent microscopy, we observed a reduction in Brca1 recruitment to S-phase 
foci and IR-induced foci (IRIFs) of immortalized AbraxasS404A/S404A MEFs relative to 
control cells (data not shown).  Since BRCA1 foci still form, albeit at reduced levels, in 
the absence of the Brca1-Abraxas interaction, these results suggest that BRCA1 
recruitment to S-phase foci and IRIFs is not solely dependent on its association with 
Abraxas.  Importantly, Brca1 focus formation was normal in Bach1FH-S994A/FH-S994A (data 
not shown) and CtipS326A/S326A (Section B7a of Chapter III) MEFs.   
      Surprisingly, when we examined ABC MEFs, we observed a marked reduction in 
Brca1 recruitment to the S-phase foci relative to AbxS404A/S404A MEFs (Figure 48).  This 
result suggests that Bach1 and/or Ctip, through their interactions with Brca1, provide a 
compensatory mechanism to recruit Brca1 in the absence of the Brca1-Abraxas 
interaction.  Notably, Brca1 focus formation was not completely absent in ABC triple 
mutant MEFs, suggesting the existence of yet another mechanism(s) for Brca1 
















Figure 48.  ABC triple mutant MEFs display a reduction in Brca1 recruitment to S-
phase foci relative to AbxS404A/S404A MEFs.  Bach1FH-S994A/FH-S994A (A/+ B/B C/+), 
AbraxasS404A/S404A (A/A B/+ C/+), and triple ABC (A/A B/B C/C) primary MEFs were 
immunostained with a mouse-specific Brca1 antibody.  Brca1-containing S-phase foci 
were counted in 400 nuclei of two independent Bach1FH-S994A/FH-S994A and ABC MEF lines 
and a single AbraxasS404A/S404A MEF line.  The error bars represent SE of the mean.  
Relative to control Bach1FH-S994A/FH-S994A MEFs, the number of Brca1-staining S-phase 
foci was reduced in AbraxasS404A/S404A MEFs, and even further reduced in ABC MEFs.    































phosphopeptide binding since Brca1 focus formation was also reduced, but detectable, in 
Brca1S1598F/S1598F MEFs (Shakya et al., 2011).      
      Next, we assessed the effects of ionizing radiation (IR) on BRCA1 localization in 
ABC triple mutant MEFs.  Control Bach1FH-S994A/FH-S994A single mutant and ABC triple 
mutant cells were either untreated or treated with 10 Gys of IR and allowed to recover for 
one hour.  As shown in Figure 49A, Brca1 recruitment to both S phase foci and IRIFs 
was dramatically reduced in ABC MEFs relative to Bach1FH-S994A/FH-S994A control MEFs.  
Thus, ABC cells display a defect in Brca1 focus formation similar to that reported for 
Brca1S1598F/S1598F MEFs (Shakya et al., 2011).  We also examined the localization of 
Rad51, a key homologous recombination protein, to S-phase foci and IRIFs in ABC triple 
mutant MEFs.  Importantly, normal Rad51 focus formation was observed in cells 
homozygous for each of the individual BRCT phospho-ligand mutants (i.e., 
AbxS404A/S404A; Bach1FH-S994A/FH-S994A; and CtipS326A/S326A MEFs) (Section B7a of Chapter 
III, and data not shown).  Significantly, however, Rad51 accumulation at both S-phase 
foci and IRIFs was dramatically diminished in ABC triple mutant MEFs (Figure 49B), in 
a manner reminiscent of Brca1S1598F/S1598F MEFs (Shakya et al., 2011).  
 
      B2e.  Levels of spontaneous and damage-induced chromosomal abnormalities are  
               elevated in ABC triple mutant MEFs 
 
      Given the impaired recruitment of Brca1 and Rad51 to sites of DNA damage in ABC 
triple mutant MEFs, we examined whether chromosomal aberrations accumulate in these 
cells.  To assay for chromosome defects, we examined the karyotypes of ABC passage 3 






















Figure 49.  ABC MEFs are deficient for assembly of Brca1 and Rad51 S-phase foci 
and IRIFs.  Control Bach1FH-S994A/FH-S994A (A/+ B/B C/+) and ABC triple mutant (A/A 
B/B C/C) primary MEFs were exposed to 10 Gy of IR or left untreated; 1 hour later, the 
cells were fixed and stained with (A) Brca1- and (B) Rad51-specific antibodies.  Brca1- 
and Rad51- containing S-phase foci and IRIFs were counted in 200 nuclei of two 
independent ABC MEF lines and a single Bach1FH-S994A/FH-S994A MEF line.  The error bars 
represent SE of the mean.  A = AbraxasS404A; B = Bach1FH-S994A; C = CtipS326A 
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independent MEF cultures derived from different ABC embryos, as well as a culture of 
isogenic control (AbxS404A/+/Bach1FH-S994A/FH-S994A/CtipS326A/+) MEFs.  As shown in Figure 
50A, significantly increased levels of spontaneous chromosomal rearrangements were 
observed in the ABC MEFs relative to control MEFs.  Thus, ABC cells display 
heightened chromosomal instability in the absence of exogenous DNA damage.   
      As shown in Figure 50B, ABC cells also accumulate cytogenetic defects at high rates 
relative to control cells in response to the DNA interstrand cross-linking agent mitomycin 
C (MMC).  Indeed, in both the presence and absence of MMC, the percentage of ABC 
cells with aberrant metaphases was double that of control MEFs (Table 7).  The 
abnormalities of ABC cells include chromatid and chromosome breaks and gaps, as well 
as a high frequency of exchanges, including triradial and quadriradial chromosomes 
(Table 7).  Aneuploidy, however, was not increased in the triple ABC mutant cells (data 
not shown).  Therefore, normal suppression of spontaneous and MMC-induced 
chromosomal instability is abrogated when the phospho-dependent BRCT interactions of 
BRCA1 with Abraxas, BACH1, and CtIP are simultaneously disrupted.    
 
 
      B2f.  Brca1 is efficiently hyperphosphorylated in response to HU in ABC cells 
      BRCA1 is phosphorylated by the ATR kinase in response to the DNA replication 
inhibitor hydroxyurea (HU) (Tibbetts et al., 2000).  To examine whether HU-induced 
Brca1 hyperphosphorylation requires the interaction of Brca1 with its three known BRCT 






















Figure 50.  Elevated levels of spontaneous and MMC-induced chromosomal 
aberrations in ABC MEFs.  Metaphase spreads were prepared from (A) untreated or (B) 
MMC-treated (40 ng/mL, 16 h) control (A/+ B/B C/+) and ABC triple mutant (A/A B/B 
C/C) passage 3 primary MEFs.  Following colcemid treatment, exposure to a hypotonic 
solution, and methanol/acetic acid fixation, the cell suspensions were dropped onto glass 
slides and stained with Giemsa. At least fifteen metaphase spreads per cell line were 
examined for each treatment condition for numerical and structural chromosomal 
aberrations.  A = AbraxasS404A; B = Bach1FH-S994A; C = CtipS326A   
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Table 7.  Spontaneous and induced chromosomal aberrations in ABC triple mutant 









MMC, mitomycin C / Chr, chromosome / Cht, chromatid     
 
The percentage of metaphases containing one or more aberrations and a breakdown of 
aberration-type is shown for each primary MEF cell line in both the absence (–) and 
presence (+) of MMC.  A = AbraxasS404A; B = Bach1FH-S994A; C = CtipS326A    
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     (- MMC)                                                       (- MMC) 
 
Representative examples of Giemsa-stained metaphase spreads of control (A/+ B/B C/+) 
and ABC (A/A B/B C/C) MEFs in the absence of MMC treatment.  Arrows point to a 
number of spontaneous chromosomal aberrations, including an exchange (*) observed in 






and cell lysates were immunoblotted with an antiserum raised against mouse Brca1.  
Additionally, we also examined HU-induced Brca1 hyperphosphorylation in MEFs 
homozygous for two different BRCT phospho-recognition mutations (Brca1S1598F/S1598F 
and Brca1M1717R/M1717R).  As shown in Figure 51, the Brca1 polypeptides of both wildtype 
and ABC MEFs displayed electrophoretic mobility shifts indicative of 
hyperphosphorylation.  In contrast, HU-induced Brca1 hyperphosphorylation was 
impaired in two different BRCT phospho-recognition mutants (Brca1S1598F/S1598F and 
Brca1M1717R/M1717R) (Figure 51).  These results suggest that HU-induced phosphorylation 
of BRCA1 is dependent on its BRCT phosphopeptide binding activity, but not its BRCT 
phospho-dependent interactions with Abraxas, BACH1, and CtIP.   
 
 
B3.  The phenotype of triple mutant (ABC) mice 
        
 
       B3a.  ABC mice are viable, but are born at a lower than expected frequency 
      	  	  To assess the phenotype of ABC triple mutant mice, we intercrossed animals bearing 
five mutant alleles (i.e., AbxS404A/+/Bach1FH-S994A/FH-S994A/CtipS326A/S326A or 
AbxS404A/S404A/Bach1FH-S994A/FH-S994A/CtipS326A/+) on a mixed genetic background (C57Bl6 x 
129Sv) to generate ABC (AbxS404A/S404A/Bach1FH-S994A/FH-S994A/CtipS326A/S326A) triple mutant 
mice.  Although the expected Mendelian yield of ABC mice from this intercross is 25%, 
























Figure 51.  HU-induced Brca1 hyperphosphorylation in ABC triple mutant MEF 
lysate.  Immortalized MEFs were treated with 1 mM hydroxyurea (HU) for 1 hour or left 
untreated; 1 hour post-drug removal, lysates were prepared from wildtype (+/+; lanes 1 
and 2), ABC (lanes 3 and 4), Brca1M1717R/M1717R (B1MR; lanes 5 and 6) and 
Brca1S1598F/S1598F (B1SF; lanes 7 and 8) cells.  The cell lysates were then fractionated by 
SDS-PAGE and immunoblotted with antibodies specific for mouse Brca1 or, as a loading 








      Since ABC embryos were present at the expected Mendelian frequency on day E13.5 
(Figure 44 and Table 6; Section B2a of Chapter V), most ABC mutants likely die 
immediately before (perinatally) or just after (postnatally) birth.  Consistent with this, we 
observed some ABC embryos at E13.5 with the embryonic lethal condition exencephaly 
(Figure 45) as well as some ABC mutants that were dead within hours after delivery (data 
not shown).  Perhaps the variation in viability among different ABC mice is due in part to 
the mixed genetic background (C57Bl6 x 129Sv) of these animals.  In any case, the 
viability of ABC mice is significantly reduced relative to each of the double mutant (i.e., 
AB, AC, and BC) mice.  We do not understand how simultaneous disruption of these 
three BRCT phospho-ligand interactions affects animal viability.  Surprisingly, mice that 
are homozygous (Brca1S1598F/S1598F) for a mutation that presumably ablates the interaction 
of BRCA1 with all of its (known and unknown) BRCT phospho-ligands are born at the 
expected Mendelian ratio (Shakya et al., 2011).   
 
      B3b.   ABC mice have a developmental defect 
      An equal number of male and female ABC mice survive to adulthood (data not 
shown). Compared to their littermate controls, these mice exhibit numerous 
developmental defects of variable severity.  In particular, ABC mice are ~30% smaller 
than same-sex littermate controls for the first four postnatal weeks (Figure 52, A and B) 
and throughout adulthood (data not shown).  Furthermore, ABC mice have characteristic 
white hind feet (Figure 52B) and an occasional white belly spot (Figure 52C).  These 















Figure 52.  The developmental defects of ABC triple mutant mice.  (A) ABC triple 
mutant mice are growth retarded.  The weight of an ABC triple mutant male mouse and a 
male littermate control was measured at different time points during postnatal growth.  
(B) Representative image of an ABC mutant and same-sex littermate control animal 
showing growth retardation and white hind feet (arrow) of the ABC mutant.  (C) An ABC 
triple mutant mouse with a white belly spot (arrow) and (D) kinked tail (arrow) is also 










which renders the extremities and midline devoid of pigment cells (Gilbert, S. F., 2003; 
Oliver et al., 2004).  ABC mice also display skeletal abnormalities in the form of kinked 
tails (Figure 52D).  Notably, Brca1S1598F/S1598F mice exhibit these same developmental 
defects (data not shown). 
 
      B3c.  ABC mice show reduced fertility 
      Homozygous Brca1S1598F/S1598F mice display male, but not female, sterility (Shakya et 
al., 2011).  To assess the fertility of ABC animals, a 10-week-old ABC male mouse was 
mated with three wildtype C57BL6 females of the same age, and the females were 
monitored daily for the presence of a vaginal plug.  The time when the vaginal plug was 
detected was denoted as 0.5 dpc (days post copulation).  On E9.5, the uterus was 
removed from the mated females and the number of implantation sites was determined.  
Notably, we observed a reduced number (average of 2.7 per mouse) of implantation sites 
(data not shown).  In contrast, an average of 6.6 implantation sites per mouse were 
obtained when wildtype females were mated with a wildtype male (data not shown).  
Furthermore, two additional ABC males were setup with multiple wildtype females and 
allowed to mate for 6 months.  During this time, not a single female produced a litter, 
suggesting a more severe fertility phenotype in these ABC mutant males.  Despite the 
observed variability, ABC triple mutant males appear to be sub-fertile.  
       We also assessed the fertility of several ABC females by mating them with wildtype 
males.  The ABC females are fertile in the sense that they can carry their pups to term 
and produce viable offspring.  However, their litter sizes were small, perhaps as a 
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consequence of their low body weight or a reduced fertility (further investigation 
needed).  Overall, the observed phenotype of the triple ABC mutant animals indicates 
that the interaction of BRCA1 with its three known BRCT phospho-ligands is necessary 
for optimal fertility. 
 
      B3d.  Whole-body tumor formation in ABC mice 
      To ascertain whether the phenotypic defects associated with ABC cells and mice are 
relevant for BRCA1-mediated tumor suppression, it will be important to compare tumor 
development in ABC animals with control animals, including double mutant (AB, AC, or 
BC) animals (Section B1d of Chapter V) and Brca1S1598F/S1598F mice, which develop 
tumors with an average latency (T50) of 575 days (Shakya et al., 2011).  Therefore, we 
plan to monitor a cohort of ABC animals for whole-body tumor formation over a 24-
month observation period.  At present, our oldest ABC mouse is 450 days old (~15 
months), but as yet shows no signs of distress or tumor development.   
      If ABC triple mutant mice develop tumors with increased kinetics (penetrance and 
latency) relative to control animals, we will conclude that tumor susceptibility arises 
when the interactions of BRCA1 with each of its three known BRCT phospho-ligands 
(Abraxas, Bach1, and Ctip) are ablated simultaneously.  On one hand, if these mice 
develop tumors with the same kinetics as Brca1S1598F/S1598F mice, we will further conclude 
that the tumor suppression activity of Brca1 is mediated primarily through these three 
BRCT interactions.  On the other hand, if other as yet unidentified BRCT phospho-
ligands also contribute to the tumor suppression activity of Brca1, then tumor formation 
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in the triple ABC mutant mice may be increased with respect to control mice, but reduced 
(longer latency and/or lower frequency) with respect to Brca1S1598F/S1598F mice.  Given the 
long latency for tumor development in the Brca1S1598F/S1598F mice, a large cohort of triple 
ABC mutant animals may be necessary to attain statistical significance.  Finally, it is 
possible that tumor formation will not occur in the triple ABC mutant animals.  In this 
case, we will conclude that the tumor suppression function of Brca1 is mediated primarily 
by its interaction(s) with unknown BRCT phospho-ligands.  In any event, analysis of the 
tumor susceptibility of ABC mice should provide invaluable insights into the 
















C.  DISCUSSION 
      Since the germline BRCA1 lesions implicated in familial breast cancer are usually 
frameshift or nonsense mutations, most tumor-associated BRCA1 alleles encode truncated 
polypeptides that have lost one or both BRCT motifs (Williams et al., 2003; Wooster and 
Weber, 2003).  Moreover, in some breast cancer families, tumor susceptibility can be 
ascribed to missense mutations that cause a single amino acid substitution in either the 
first (e.g., the S1655F mutation) or the second (e.g., the M1775R mutation) BRCT 
domain (Williams et al., 2001), underscoring the importance of the BRCT domain in 
modulating tumor susceptibility.  Although the exact mechanism of tumor suppression by 
BRCA1 remains elusive, it is likely that BRCA1 suppresses tumor formation in part by 
promoting genome stability.   
      The BRCT sequences of BRCA1 engage in interactions with different phospho-
ligands to mediate unique aspects of BRCA1 function in the DNA damage response 
(Greenberg et al., 2006).  For example, the interaction of BRCA1 with the 
phosphorylated isoform of BACH1 is required for activation of the G2 accumulation 
checkpoint (Yu et al., 2003), while its interaction with phosphorylated CtIP mediates the 
transient G2/M checkpoint (Yu and Chen, 2004).  More recently, the BRCT sequences of 
BRCA1 were also found to bind the Abraxas protein in a phospho-dependent manner to 
facilitate BRCA1 localization to sites of DNA damage (Kim et al., 2007; Kim et al., 
2007a; Liu, Z. et al., 2007; Sobhian et al., 2007; Wang et al., 2007; Yan et al., 2007).  Not 
surprisingly, cells with a mutation that prevents BRCT phosphopeptide binding by 
BRCA1 (e.g., Brca1S1598F/S1598F) have a highly unstable genome (Shakya et al., 2011).  
Brca1S1598F/S1598F MEFs display proliferation defects, chromosomal instability, 
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centrosome amplification, as well as impaired recruitment of Brca1 and Rad51 to sites of 
DNA damage (Shakya et al., 2011).  Furthermore, mice homozygous for the Brca1-
S1598F mutation are tumor-prone (Shakya et al., 2011), indicating that the BRCT 
phosphopeptide binding property of BRCA1 is necessary for tumor suppression.  Thus, 
the genome maintenance functions of BRCA1 appear to be a major determinant of its 
tumor suppression activity.  
      To determine which phosphoprotein interaction mediates the tumor suppression 
function of Brca1, a single amino acid substitution was made to eliminate the cognate 
phosphorylation site of Abraxas (S404A), Bach1 (S994A), or Ctip (S326A).  
Unexpectedly, the genome maintenance and tumor suppression activities of BRCA1 
appeared to be normal in cells expressing any of the three BRCT phospho-ligand mutants 
(data not shown (Abraxas and Bach1); Chapter III (Ctip)).  Therefore, we examined 
whether these aspects of BRCA1 function are affected by simultaneous disruption of its 
interaction with two or more of these phosphoproteins.   
      To test this hypothesis, we generated each of the three combinations of homozygous 
double mutant animals: AB (AbxS404A/S404A/Bach1FH-S994A/FH-S994A), AC 
(AbxS404A/S404A/CtipS326A/S326A), and BC (Bach1FH-S994A/FH-S994A/CtipS326A/S326A).  These 
double mutant mice were born at the expected Mendelian ratio and were 
indistinguishable from littermate controls.  MEFs derived from each of the double mutant 
mice proliferate normally.  Moreover, the AB, AC, and BC double mutant mice showed 
normal resistance to ionizing radiation and the BC mice displayed no signs of tumor 
susceptibility (AB and AC mice are still being monitored).  Thus, although cells 
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expressing a Brca1 polypeptide that lacks BRCT phospho-recognition entirely (i.e., 
Brca1S1598F/S1598F) are markedly compromised with respect to genome maintenance and 
tumor suppression (Shakya et al., 2011), the interaction of Brca1 with any one of its three 
known BRCT phospho-ligands appears to be sufficient to overcome these defects. 
      Remarkably, many of the phenotypic abnormalities associated with the 
Brca1S1598F/S1598F genotype are recapitulated when, as in ABC triple mutant cells, the 
interaction of Brca1 with its three known BRCT phospho-ligands are ablated 
simultaneously.  In particular, ABC MEFs display proliferation defects, centrosome 
amplification, chromosomal instability, and impaired recruitment of Brca1 and Rad51 to 
sites of DNA damage.  Yet some phenotypic differences were observed.  For example, 
HU-induced Brca1 hyperphosphorylation occurs in ABC MEFs, but not Brca1S1598F/S1598F 
MEFs.  This result suggests that HU-induced phosphorylation of Brca1 may be 
dependent on its interaction with a distinct, as yet undiscovered, BRCT phospho-ligand.  
Nonetheless, at the cellular level, the phenotype of ABC MEFs closely resembles that of 
Brca1S1598F/S1598F MEFs.  Thus, although the three major BRCA1 supercomplexes 
(complexes A, B, and C) are thought to have distinct functions in BRCA1-mediated 
genome stability (Yu et al., 2003; Yu and Chen, 2004; Greenberg et al., 2006; Sobhian et 
al., 2007; Wang et al., 2007; Huen et al., 2010), our results suggest that these complexes 
also have the potential to act in a compensatory fashion with respect to one another, at 
least within the biological settings examined here.         
      Previous studies have shown that the BRCA1-Abraxas interaction facilitates the 
recruitment of BRCA1 polypeptides to the remodeled chromatin that forms adjacent to 
192 
	  
chromosomal DSBs (Kim et al., 2007; Kim et al., 2007a; Liu, Z. et al., 2007; Sobhian et 
al., 2007; Wang et al., 2007; Yan et al., 2007).  In accord with this notion, we observed 
impaired recruitment of Brca1 to the S-phase foci of AbraxasS404A/S404A single mutant 
MEFs (Figure 48).  Surprisingly, however, the localization of Brca1 to these structures 
was further impaired in ABC triple mutant MEFs (Figure 48), suggesting that the Brca1-
Bach1 and/or Brca1-Ctip interactions promote Brca1 localization in the absence of the 
Brca1-Abraxas interaction.  To assess which of these interaction(s) are compensatory, 
one could compare Brca1 focus formation in AbxS404A/S404A single mutant, AB double 
mutant, and AC double mutant MEFs.  Given that AB and AC double mutant MEFs 
display relatively normal genome stability phenotypes, it is likely that both the Brca1-
Bach1 and the Brca1-Ctip interactions can act in a compensatory manner when the 
Brca1-Abraxas interaction is ablated.  Interestingly, CtIP was recently detected in 
immunoprecipitates of RAP80 (Wang et al., 2007), a protein that harbors the ubiquitin-
interacting motif (UIM) and targets BRCA1 to sites of DNA damage through its 
association with Abraxas (Kim et al., 2007a; Liu, Z. et al., 2007; Sobhian et al., 2007; 
Wang et al., 2007).  Thus, in the absence of Abraxas, CtIP may bridge the association 
between RAP80 and BRCA1, thereby mediating BRCA1 localization to sites of DNA 
damage.   
      A scenario can be envisioned in which the proportion of the BRCA1 polypeptide pool 
that binds a yet to be discovered BRCT phospho-ligand, if it exists, increases following 
simultaneous ablation of BRCA1’s interaction with its three known BRCT phospho-
ligands.  This fourth BRCA1 supercomplex may inhibit BRCA1 function in response to 
DNA damage eliciting the phenotypic abnormalities observed with the ABC mutations.  
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Therefore, future studies should be aimed at identifying any unknown BRCA1 BRCT-
interacting phospho-ligands and determining their in vivo functions.   
      To determine whether BRCA1’s interaction with all three known BRCT 
phosphoproteins is involved in animal development and tumor suppression, we generated 
ABC triple mutant mice.  In contrast to Brca1S1598F/S1598F mice, which are born at the 
expected Mendelian ratio (Shakya et al., 2011), ABC mice were observed at a much 
lower frequency than expected.  Since mothers of either genotype (AbxS404A/+/Bach1FH-
S994A/FH-S994A/CtipS326A/S326A or AbxS404A/S404A/Bach1FH-S994A/FH-S994A/CtipS326A/+) produced a 
comparable number of viable ABC pups, a sub-optimal uterine environment is unlikely to 
account for the reduced viability of ABC progeny (data not shown).  Instead, ABC mice 
may have a developmental defect that renders them less fit than their littermates, and 
consequently more susceptible to late gestation/postnatal arrest.   
       Consistent with this reduced viability, we observed phenotypic variation among the 
ABC embryos examined at E13.5.  While some exhibited the embryonic lethal condition 
exencephaly, others appeared normal despite being smaller in size.  Additionally, we 
noticed that a number of ABC animals died just after birth on P0.  The appearance of 
ABC embryos at the expected Mendelian frequency on E13.5 defines the time of death 
for some ABC mutants between E13.5 and P10, when the viable pups were genotyped.  
The phenotypic variation observed among ABC embryos and mice may be due to 
differences in their mixed genetic background (C57BL6 x 129Sv).   
      Despite variability in the severity of the ABC phenotype, we successfully generated 
viable ABC mice that survive to adulthood.  Similar to the BRCT phospho-recognition 
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mutant Brca1S1598F/S1598F mice (data not shown), the viable ABC mice showed a number 
of developmental defects to varying degrees, including growth retardation, white hind 
feet/belly spot, and kinked tails.  Thus, not only do ABC triple mutants share a 
phenotypic resemblance to the Brca1S1598F/S1598F mutants at the cellular level, but also at 
the organismal level.  However, unlike the male sterility of Brca1S1598F/S1598F mice 
(Shakya et al., 2011), ABC males are sub-fertile, suggesting that other unknown BRCT 
phospho-ligands may also contribute to BRCA1 function in spermatogenesis.      
      Our results show that BRCA1 functions in animal development, cell proliferation, 
centrosome regulation, assembly of DNA repair foci, and chromosomal stability, are 
grossly perturbed when the interaction of BRCA1 with its three known BRCT phospho-
ligands are simultaneously ablated.  Notably, these effects are only observed in the 
absence of all three phosphoprotein interactions, suggesting that the major BRCA1 
supercomplexes assembled from these interactions (complexes A, B, and C) have the 
potential to act in a compensatory manner with respect to one another.  Ultimately it will 
be important to determine whether tumor suppression requires the interaction of BRCA1 
with these three BRCT phosphoproteins.  Thus, future analysis of tumor susceptibility in 
ABC mice may provide novel insights into the molecular mechanisms underlying 






























      Germline mutations in the BRCA1 gene confer an increased risk of breast and ovarian 
cancer, but the mechanisms by which its protein product suppresses tumor formation 
remain elusive.  The BRCA1 protein is involved in a broad spectrum of biological 
processes and interacts with many diverse proteins.  One of these, CtIP, associates with 
the BRCT sequences of BRCA1 in a phosphorylation-dependent manner to mediate 
BRCA1 function in response to DNA damage (Wong et al., 1998; Yu et al., 1998; Yu and 
Chen, 2004; Greenberg et al., 2006).  A missense mutation in the BRCT repeats of Brca1 
(Brca1-S1598F) that ablates the Brca1-Ctip interaction has been shown to promote 
genomic instability in cells and tumorigenesis in mice (Shakya et al., 2011).  Importantly, 
this single amino acid substitution not only prevents CtIP binding to BRCA1, but the 
binding of all known BRCA1 BRCT phospho-ligands, including Abraxas/CCDC98 and 
BACH1/ BRIP1/FancJ (reviewed in Huen et al., 2010; Moynahan and Jasin, 2010; 
Shakya et al., 2011).   
      As a candidate tumor suppressor itself, CtIP may modulate the tumor suppressor 
function of its interacting partner BRCA1 by promoting genome stability.  CtIP has been 
implicated in at least two critical aspects of the DNA damage response: cell cycle 
checkpoint control (Yu and Chen, 2004) and DNA resection and homology-directed 
repair (HDR) of double-strand breaks (DSBs) (Sartori et al., 2007).  In this study, we 
examined the role of CtIP in BRCA1-mediated genome stability and tumor suppression 
using murine cells expressing Ctip polypeptides (Ctip-S326A) that fail to interact with 
Brca1.  Moreover, to assess whether CtIP is itself required for tumor suppression, we 
evaluated tumor development in mice following mammary-specific inactivation of a 
conditional Ctip gene.  Finally, given our recent finding that BRCA1 tumor suppression 
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does not depend on its individual interaction with the BRCT phospho-ligands Abraxas, 
BACH1, or CtIP (a collaboration with Dr. Thomas Ludwig; Columbia University), we 
are currently analyzing how the phospho-dependent interaction of BRCA1 with two or 
more of its BRCT-binding partners affects its tumor suppressor activity. 
 
The role of the BRCA1-CtIP interaction in genome stability 
 
      To analyze the role of the BRCA1-CtIP interaction in genome stability, we used a 
knock-in approach to introduce the S326A mutation into the mouse Ctip gene by 
homologous recombination.  By doing this, we produced isogenic panels of ES cells and 
MEFs that express either wildtype Ctip or the Ctip-S326A mutant.  We also demonstrated 
that this single amino acid substitution in Ctip was sufficient to ablate the Brca1-Ctip 
interaction (Figure 10).         
Assembly of repair proteins at sites of DNA damage in mutant Ctip-S326A cells 
      In cells subjected to ionizing radiation (IR), several repair proteins, including 
BRCA1, CtIP, RPA, and Rad51, accumulate at sites of DNA damage to form IR-induced 
foci (IRIFs) which can be visualized by immunofluorescent microscopy.  We examined 
how loss of the BRCA1-CtIP interaction affected recruitment of these proteins to IRIFs 
in Ctip-S326A mutant murine cells.  To our surprise, we found that the BRCA1-CtIP 
interaction is dispensable for proper recruitment of BRCA1, CtIP, RPA, and Rad51 to 
sites of DNA damage (Figures 15-18).       
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      In response to DNA damage, BRCA1 ubiquitinates CtIP in manner that depends on 
CtIP’s association with the BRCT repeats of BRCA1 (Yu et al., 2006).  It has been 
reported that BRCA1-dependent ubiquitination of CtIP is required for CtIP focus 
formation and activation of the transient G2/M checkpoint in human cells (Yu et al., 
2006).  Thus, the BRCA1 RING and BRCT domains appear to act together to regulate 
the genomic stability functions of BRCA1, and in doing so, may modulate its tumor 
suppressor function.   
      In contrast to human cells (Yu et al., 2006), we observed normal Ctip focus formation 
in Ctip-S326A mutant MEFs.  Although this result indicates that the Brca1-Ctip 
interaction is dispensable for Ctip accumulation at sites of DNA damage, it does not 
specifically address whether the E3 ligase activity of Brca1 is required for Ctip 
recruitment.  Given that resection-dependent events, such as Rad51 foci formation and 
HDR of DSBs, occur normally in E3 ligase-deficient Brca1-I26A mutant murine cells 
(Reid et al., 2008), it seems likely that Ctip can accumulate at sites of DNA damage in 
the absence of Brca1’s E3 ligase activity.  In any case, it should be feasible to address 
this issue by testing whether Ctip can localize to IRIFs in Brca1-I26A mutant MEFs 
(Reid et al., 2008). 
      CtIP functions together with the MRN complex to promote DNA resection, a process 
in which DSB ends are converted into 3’ single-stranded DNA (ssDNA) tails (Sartori et 
al., 2007; Gravel et al., 2008; Raynard et al., 2008).  Since BRCA1 can form an in vivo 
protein complex (BRCA1 complex C) involving CtIP and MRN (Greenberg et al., 2006; 
Chen et al., 2008), both of which have been implicated in DNA resection, BRCA1 may 
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collaborate with these proteins to resect DSB ends.  In the absence of the BRCA1-CtIP 
interaction, however, we observed normal assembly of RPA at sites of DNA damage.  
Although the BRCA1-CtIP interaction is essential for in vivo assembly of BRCA1 
complex C (Chen et al., 2008), our result suggests that BRCA1 is not required for CtIP-
mediated DNA resection.  
    Recently, BRCA1 and CtIP have each been individually implicated in ssDNA 
formation at ultraviolet (UV)-stalled forks (Pathania et al., 2011).  Moreover, CtIP 
recruitment to UV-damaged DNA was impaired in BRCA1-depleted U2OS cells 
(Pathania et al., 2011).  Therefore, in contrast to our work, which focused on IR-induced 
DNA damage, future studies should also explore the role of the BRCA1-CtIP interaction 
in response to UV-induced DNA damage.   
DNA resection and DSB repair in mutant Ctip-S326A cells 
      BRCA1 and CtIP are individually required for several DSB repair pathways, 
including homology-directed repair (HDR), single-strand annealing (SSA), and 
alternative non-homologous end joining (alt-NHEJ) (Moynahan et al., 1999; Moynahan 
et al., 2001; Zhong et al., 2002; Stark et al., 2004; Sartori et al., 2007; Bennardo et al., 
2008).  Importantly, each of these repair pathways requires CtIP-mediated DNA resection 
(Bennardo et al., 2008).  To elucidate the role of the BRCA1-CtIP interaction in DSB 
repair and to further assess whether BRCA1 mediates the DNA resection function of 
CtIP, we generated wildtype and Ctip-S326A mutant ES cells that contain a 
recombination substrate specific for each of the above repair pathways integrated into a 
defined chromosomal locus.  In this study, we report that the BRCA1-CtIP interaction is 
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dispensable for proficient repair by each of these resection-dependent repair pathways 
(Figures 12-14).  Thus, in contrast to previous reports (Chen et al., 2008; Yun and Hiom, 
2010), but consistent with recent studies of resection in Xenopus cell-free extracts 
(Peterson et al., 2011), our data collectively demonstrates that BRCA1 is not required for 
CtIP-mediated DNA resection.   
      Future studies should examine which properties of CtIP are required for its DNA 
resection function.  The conserved C-terminal sequence of mammalian CtIP, referred to 
here as the “Sae2 motif”, was implicated in DNA resection because an siRNA-resistant 
CtIP C-terminal truncation mutant failed to promote RPA focus formation upon 
camptothecin treatment (Sartori et al., 2007).  In yeast, two specific elements of the Sae2 
motif, a CxxC sequence and a potential CDK phosphorylation site (T847 in humans), 
have been implicated in DNA resection (Limbo et al., 2007; Huertas et al., 2008).  Thus, 
it should be possible to use a similar gene knock-in approach in murine cells to determine 
whether the resection function of these residues is conserved in mammals.   
Chromosomal stability and cellular resistance to genotoxic stress in mutant Ctip-S326A 
cells 
 
      The inability to properly repair DSBs gives rise to chromosomal instability and 
cellular sensitivity to DNA damaging agents.  Consistent with this, cells bearing the 
Brca1-S1598F phospho-recognition mutation display impaired HDR, marked 
chromosomal instability, and hypersensitivity to the DNA cross-linking agent mitomycin 
C (MMC) (Shakya et al., 2011).  Since resection-dependent DSB repair pathways are 
proficient in the absence of the BRCA1-CtIP interaction (Figures 12-14), it was not 
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surprising to find normal suppression of spontaneous and MMC-induced chromosomal 
rearrangements (Figures 21-22; Table 3), as well as normal cellular resistance to MMC-
induced genotoxic stress (Figure 19), in Ctip-S326A mutant cells.  Thus, although 
BRCA1-mediated suppression of both chromosomal instability and MMC sensitivity 
requires the BRCT phospho-recognition property of BRCA1 (Shakya et al., 2011), the 
BRCA1-CTIP interaction itself does not appear to be essential for these aspects of 
BRCA1 function.     
      Of note, ablation of the BRCA1-CtIP interaction caused a weak hypersensitivity to 
the topoisomerase inhibitors camptothecin (CPT) and etoposide (ETO) (Figure 20).  
Importantly, the survival of Ctip-S326A mutant cells was not impaired to the same extent 
as that of ES cells homozygous for the hypomorphic Brca1Δ223-763 mutation (Figure 20).  
Thus, the BRCA1-CtIP interaction is required for some, but not all, of the cellular 
resistance mediated by BRCA1 in response to the topoisomerase inhibitors CPT and 
ETO.  Given that Ctip-S326A mutant cells are modestly sensitive to CPT and ETO, 
despite being proficient in HDR (Figure 12) and NHEJ (as assessed by a total-NHEJ 
reporter assay; data not shown), we conclude that the BRCA1-CtIP interaction promotes 
cellular tolerance to CPT and ETO independently of HDR or NHEJ, possibly by 
eliminating covalently-bound polypeptides from DSB ends.   
      A role for the BRCA1-CtIP complex in eliminating covalently-bound topoisomerases 
from DSBs was recently shown in avian cells; in contrast to the modest effects observed 
in mammalian Ctip-S326A cells (Figure 20), chicken DT40 cells bearing the 
corresponding mutation (S332A) displayed marked hypersensitivity to CPT and ETO 
(Nakamura et al., 2010).  Moreover, Nakamura et al. (2010) observed that CtIP-S332A 
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chicken DT40 cells are also hypersensitive to the DNA alkylating agent methyl 
methanesulfonate (MMS).  Therefore, it would be interesting to see if the BRCA1-CtIP 
interaction is required for cellular resistance to MMS in mammalian cells, especially 
since HCC1937 human breast cancer cells, which encode a C-terminally-truncated 
BRCA1 polypeptide that lacks one of the tandem BRCT motifs, displayed 
hypersensitivity to this genotoxic agent (Zhong et al., 1999).  Additionally, given that 
BRCA1 suppresses hypersensitivity to UV (Pathania et al., 2011) and CtIP appears to be 
involved in BRCA1-dependent ssDNA gap formation at UV-stalled forks (Pathania et al., 
2011), the sensitivity of Ctip-S326A mutant cells to UV-induced DNA damage should 
also be examined.   
Cell cycle checkpoint control and damage-induced phosphorylation of CtIP in mutant 
Ctip-S326A cells 
      Since cell cycle checkpoints induced by genotoxic stress are common targets for 
oncogenic lesions in human cancer (Zhou and Elledge, 2000; Abraham, R. T. 2001; 
Shiloh and Kastan, 2001), the checkpoint functions of BRCA1 may represent an 
important aspect of its tumor suppression activity.  Both BRCA1 and CtIP have been 
implicated in the IR-induced transient G2/M checkpoint (Xu, B. et al., 2001; Xu, B. et al., 
2002; Yu and Chen, 2004).  Moreover, activation of this checkpoint in human cells 
appears to require the BRCA1-CtIP interaction, as well as the E3 ligase activity of the 
BRCA1/BARD1 heterodimer (Yu and Chen, 2004; Yu et al., 2006).  In light of our 
results, which demonstrate proficient DSB repair and normal suppression of 
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chromosomal rearrangements in Ctip-S326A murine cells, it would be interesting to 
ascertain whether checkpoint functions are also intact in these cells.   
      In response to IR, CtIP is phosphorylated in an ATM-dependent manner on residues 
S664 and S745 (Li et al., 2000).  It has been suggested that the BRCA1-CtIP interaction 
may facilitate the subsequent hyperphosphorylation of CtIP by ATM since BRCA1 is 
required for damage-induced phosphorylation of CtIP (Foray et al., 2003).  Therefore, to 
address this issue, hyperphosphorylation of CtIP in response to DNA damage should also 
be examined in the Ctip-S326A mutant cells.   
Conclusions 
      Overall, the results presented in this study indicate that significant aspects of BRCA1 
and CtIP function in genome maintenance are independent of the BRCA1-CtIP 
interaction.  In mammalian cells, the BRCA1-CtIP interaction is dispensable for the 
assembly of repair proteins at sites of DNA damage, resection-dependent DSB repair, 
suppression of spontaneous and MMC-induced chromosomal rearrangements, and 
cellular resistance to MMC-induced genotoxic stress.  However, the BRCA1-CtIP 
interaction does appear to modestly affect clonogenic survival to the topoisomerase 






The role of the BRCA1-CtIP interaction in development and tumor suppression 
      To determine whether the BRCA1-CtIP interaction is required for normal animal 
development and tumor suppression, we injected CtipS326A-neo/+ 129Sv ES clones (Figure 
9) into C57Bl6 blastocysts to obtain germline-transformed mice bearing the Ctip-S326A 
mutant allele.  A breeding regimen was then employed to generate mice that solely 
express Ctip-S326A mutant polypeptides which fail to interact with the BRCT domains 
of Brca1 (i.e., CtipS326A/– and CtipS326A/S326A mice). 
Animal development in mutant Ctip-S326A mice 
      BRCA1 and CtIP are individually thought to be essential for the viability of 
mammalian cells (Elledge and Amon, 2002; Chen, P.-L. et al., 2005).  This is consistent 
with the early embryonic lethality of mice bearing homozygous-null mutations of either 
Brca1 (Hakem et al., 1996; Ludwig et al., 1997) or Ctip (Chen, P.-L. et al., 2005).  
Importantly, Ctip-null mice die at an earlier stage of embryogenesis than Brca1-null 
mice, suggesting that Ctip likely executes at least some functions independent of Brca1 
(Chen, P.-L. et al., 2005).   
      We report that the BRCA1-CtIP interaction is dispensable for mammalian cell 
viability.  Consistent with our ability to generate Ctip-S326A mutant ES cells and MEFs 
with relative ease, viable CtipS326A/– and CtipS326A/S326A mice were born at the expected 
Mendelian ratios, survived to adulthood, were fertile, and otherwise appeared 
indistinguishable from their littermate controls (data not shown).  Thus, the BRCA1-CtIP 
interaction is not required for all functions of either BRCA1 or CtIP.  Additionally, we 
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examined the sensitivity of Ctip-S326A mutant mice to whole-body ionizing radiation 
(IR).  In accord with the proficient DSB repair observed in Ctip-S326A cells (see above), 
Ctip-S326A mutant mice were resistant to a sublethal dose of IR (data not shown).   
Tumor suppression in mutant Ctip-S326A mice 
      Given that CtIP is a BRCT phospho-ligand and enzymatic substrate of BRCA1 with 
prominent functions in genome stability, we investigated the role of the BRCA1-CtIP 
interaction in tumor suppression.  In contrast to the marked tumor susceptibility of mice 
expressing a Brca1 polypeptide that lacks BRCT phospho-recognition activity 
(Brca1S1598F/S1598F) (Shakya et al., 2011), Ctip-S326A animals developed tumors with 
kinetics indistinguishable from control mice (Figure 23).  Thus, suppression of 
spontaneous tumor development occurs normally in the absence of the Brca1-Ctip 
interaction.  This result indicates that the tumor suppression function of BRCA1 is not 
mediated specifically by its interaction with the BRCT phospho-ligand CtIP.     
      The BRCT repeats of BRCA1 form distinct protein complexes with at least two other 
DNA damage response proteins, Abraxas and BACH1 (reviewed in Huen et al., 2010; 
Moynahan and Jasin, 2010).  Surprisingly, mice bearing mutations that specifically ablate 
either the Brca1-Abraxas or the Brca1-Bach1 interaction, like Ctip-S326A animals, do 
not display a heightened susceptibility to tumor formation (unpublished data).  This result 
suggests that the tumor suppression function of BRCA1 is not dependent on its individual 




Conclusions   
      We have demonstrated that most functions of BRCA1 and CtIP in normal animal 
development are independent of the BRCA1-CtIP interaction.  Thus, unlike Brca1- and 
Ctip-null animals, which undergo early embryonic lethality (Hakem et al., 1996; Liu et 
al., 1996; Ludwig et al., 1997; Chen, P.-L. et al., 2005), Ctip-S326A mice are viable, 
healthy, fertile, and resistant to IR.  Moreover, these mice do not display a heightened 
susceptibility to tumor formation.  Thus, the BRCA1-CtIP interaction appears to be 
dispensable for BRCA1-mediated tumor suppression.   
 
The role of CtIP in tumor suppression  
      Previous studies have raised the possibility that CtIP functions as a tumor suppressor 
(Wong et al., 1998; Vilkki et al., 2002; Chen, P.-L. et al., 2005).  For example, 
monoallelic genetic alterations of the CtIP gene have been identified in several human 
tumor cell lines derived from breast, ovarian, pancreas, and colon carcinomas (Wong et 
al., 1998).  Furthermore, since heterozygous Ctip+/– mice developed tumors at an 
increased rate (T50 = 625 days) relative to wildtype Ctip+/+ mice (T50 = 780 days), Chen, 
P.-L. et al. (2005) proposed that haploid insufficiency of Ctip leads to tumorigenesis.  
Thus, although a potential role for CtIP in tumor suppression has been suggested, these 
studies do not address whether CtIP serves as a tumor suppressor in mammary epithelial 
cells.  As an interacting partner with the breast cancer-associated protein BRCA1, we 
proposed that CtIP may be involved in mammary tumorigenesis.   
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The effects of Ctip inactivation on tumor suppression 
      To determine whether CtIP is required for tumor suppression, we used a Cre-loxP 
gene targeting system to generate mice that inactivate the Ctip gene in a mammary-
specific fashion.  Since Ctip-null (Ctip–/–) mice are embryonic lethal (Chen, P.-L. et al., 
2005), we bred mice to carry a Ctip conditional-null allele (CtipCo) (Figure 24).   We then 
showed that the Cre-recombined product of the CtipCo allele is functionally null (Figure 
27) and that CtipCo recombination is specifically induced in mammary cells during late 
pregnancy and lactation in mice bearing the WapCre transgene (Figure 28).  Given these 
findings, CtipCo/+/WapCre/+ control and CtipCo/–,Co/ Co/WapCre/+ experimental females were 
mated to induce pregnancy, lactation, Cre recombinase expression, and mammary-
specific CtipCo inactivation.  Surprisingly, these mice remained tumor-free over the entire 
24-month observation period (Figure 29) suggesting that Ctip is dispensable for 
suppression of mammary tumorigenesis.  
 
The effects of Ctip inactivation on tumor suppression in a p53-deficient background 
      Given the well-established observation that p53 deficiency accelerates tumor 
formation in animals bearing Brca1 mutations (Brodie and Deng, 2001; Ludwig et al., 
2001; Moynahan, M. E., 2002; Evers and Jonkers, 2006; Shakya et al., 2011), we 
examined the effects of mammary-specific Ctip inactivation in tumor-prone settings 
incurred by either a p53 conditional-null mutation (p53Co) (Chen, Z. et al., 2005) or a p53 
dominant-negative point mutation (p53LSL-R270H) (Olive et al., 2004).  Quite unexpectedly, 
tumor formation in CtipCo/–,Co/Co/p53Co/+,Co/Co/WapCre/+ experimental mice was 
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significantly reduced (longer latency and lower frequency) relative to control mice 
(Ctip+/+,Co/+/p53Co/+, Co/Co/WapCre/+) (Figure 30).  This result indicates not only that Ctip 
inactivation does not potentiate mammary tumorigenesis, but also that Ctip loss instead 
provides a protective effect against mammary tumorigenesis in a p53-deficient 
background.  Similarly, Ctip also inhibited mammary tumor formation induced by 
expression of the dominant-negative p53R270H allele (Figure 31).  Thus, in two 
independent tumor-prone settings, we observed prolonged tumor latency as a result of 
Ctip loss.  This study raises new questions regarding whether Ctip is a bona fide tumor 
suppressor and whether the monoallelic mutations observed in human CtIP are truly 
oncogenic.         
      The Ctip/p53 double-deficient mammary tumors that arise with delayed kinetics 
relative to Brca1/p53 double-deficient and p53 single-deficient tumors display an 
interesting phenotype.  Like the Brca1/p53 tumors, but unlike the p53-only tumors, the 
Ctip/p53 tumors are basal-like, in that they stain positive for the basal cytoskeletal 
markers, CK5 and CK14, and negative for the estrogen and progesterone receptors 
(Figure 32).  However, like the p53 tumors and unlike the Brca1/p53 tumors, the 
Ctip/p53 tumors exhibit amplification of the proto-oncogene c-Met (Figure 33).  Thus, 
the mammary carcinomas arising on conditional co-inactivation of the Ctip/p53 genes 
display a unique phenotype that appears to be intermediate to that of the Brca1/p53 and 




Conclusions   
      In this study, we have established that CtIP is not required for tumor suppression in 
mammary epithelial cells.  Moreover, loss of CtIP appears to provide a protective effect 
against mammary tumorigenesis in tumor-prone settings resulting from p53-deficiency.  
The mechanisms by which CtIP loss inhibits tumorigenesis are unclear, but their 
elucidation may alter our current understanding of the role of CtIP in cancer 
development.     
The role of CtIP in genome stability  
      Although Ctip-null ES cells and MEFs are not viable (Chen, P.-L. et al., 2005), Ctip-
null mammary cell lines from the breast tumors of conditional Ctip/p53-mutant female 
mice were readily cultured in vitro.  In addition to the programmed p53 lesions, these 
cells presumably harbor additional genetic defects that arose during oncogenic 
development and may allow for viability in the absence of Ctip (Figures 34-35, 37).  In 
any case, through analysis of these cells, we were able to evaluate several parameters of 
genomic stability in the absence of Ctip expression.    
The DNA damage response in Ctip-null tumor cells  
      There is substantial evidence that CtIP is required for maintenance of genome 
stability, particularly through its role in DNA resection and DSB repair (Sartori et al., 
2007; Chen et al., 2008).  For example, previous studies have shown that siRNA-
mediated depletion of CtIP dramatically impairs ssDNA generation and RPA focus 
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formation (Sartori et al 2007; Chen et al., 2008).  In contrast, however, we observe proper 
recruitment of RPA to IRIFs in Ctip-null (CtipCo-rec/–) mammary tumor cells (Figure 39), 
suggesting that Ctip is not essential for DNA resection.  To explore this provocative 
finding more rigorously, independent methods to monitor ssDNA formation in CtipCo-rec/– 
tumor cells should be applied, such as anti-BrdU staining to detect replication-dependent 
incorporation of BrdU (Sartori et al., 2007).  In any case, this observation, as well as the 
normal recruitment of Brca1 and Rad51 to sites of DNA damage in CtipCo-rec/– cells 
(Figures 38 and 40, respectively), suggests that at least some aspects of the DNA damage 
response can be elicited in the absence of Ctip.  It would be intriguing to determine via 
recombination reporter assays whether the resection-dependent DSB repair pathways 
(HDR, SSA, and alt-NHEJ) are also functional in CtipCo-rec/– tumor cells.  Furthermore, 
cytogenetic analyses of the cell lines derived from Ctip/p53 and p53-alone mammary 
tumors suggest that Ctip loss does not enhance either spontaneous or damage-induced 
chromosomal instability (Figure 41; Table 5).  Although we do not understand how these 
Ctip-null tumor cells mediate aspects of the DNA damage response that are thought to be 
Ctip-dependent, perhaps genetic lesions acquired during the oncogenic process facilitate 
not only the viability of these cells in the absence of Ctip, but also their capacity to mount 
a DNA damage response.   
Chromosomal stability in Ctip-null tumor cells 
      Recent evidence suggests that chromosomal translocations arise when DSBs on 
different chromosomes are misjoined by alternative non-homologous end joining (alt-
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NHEJ), a resection-dependent repair process (Zhang and Jasin, 2011).  Consistent with 
this notion, the rate of chromosomal rearrangements was dramatically reduced in ES cells 
by shRNA-mediated Ctip depletion (Zhang and Jasin, 2011).  In light of these results, it 
would be interesting to compare the translocation frequency in Ctip/p53 and p53-alone 
mammary tumors by spectral karyotyping (SKY).  Based on the findings published by 
Zhang and Jasin (2011), we would expect to see fewer chromosomal translocations in the 
Ctip/p53-deficient mammary tumor cells relative to p53-deficient cells.  However, since 
chromosomal translocations are relatively infrequent in p53-alone mammary tumors 
(Shakya et al., 2008), it may be difficult to accurately measure a reduction in 
translocation frequency due to Ctip loss.  Therefore, it may be beneficial to integrate the 
pCr15 translocation reporter (Zhang and Jasin, 2011) into Ctip/p53-deficient and p53-
deficient mammary tumor cells.  Repair of two I-SceI-induced DSBs on independent 
chromosomes by alt-NHEJ results in a chromosomal translocation and neo+ gene 
expression; thus, the translocation frequency can be quantified by counting the surviving 
neomycin-resistant colonies (Zhang and Jasin, 2011).  The results from this experiment 
may provide an explanation as to how Ctip loss inhibits mammary tumor induction in 
p53-deficient mice.   
A second source of Ctip-null cells (MEFs) 
      To assess the genomic stability functions of CtIP in non-malignant cells, we recently 
generated control (CtipCo/+/RosaCreERT2/+) and experimental (CtipCo/–/RosaCreERT2/+) 
immortalized MEFs (data not shown).  In these cells, Cre recombinase is expressed as a 
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fusion protein with the estrogen receptor T2 (ERT2) moiety.  Although the Cre-ERT2 
fusion is normally retained in the cytosol, upon 4-OH-Tamoxifen treatment, it is 
transported to the nucleus, where it catalyzes recombination and inactivation of the CtipCo 
allele.  In preliminary studies, we observed cellular senescence of the experimental 
CtipCo/– RosaCreERT2/+ cells within 72 hours after 4-OH-Tamoxifen treatment (data not 
shown).  These results are consistent with the fact that Ctip is essential for the viability of 
ES cells, MEFs, and murine embryos (Chen, P.-L. et al., 2005).  In any case, this 
inducible system of Ctip inactivation may allow Ctip functions to be evaluated in the 
period prior to cell senescence.  Indeed, a similar approach has been used successfully to 
study the genome maintenance functions of loss-of-viability mutants of the Mre11 repair 
protein (Buis et al., 2008).  It would be particularly interesting to compare results 
obtained in this MEF-based system, in which Ctip loss occurs in the absence of 
secondary oncogenic lesions, to the findings reported in this study using Ctip-null 
mammary tumor cells.   
Conclusions 
      These results show that viable Ctip-null cells can be derived from mouse mammary 
tumors.  Although these cells lack Ctip, they appear to be proficient for several aspects of 
the DNA damage response, including recruitment of repair proteins (Brca1, RPA, and 
Rad51) to sites of DNA damage and suppression of both spontaneous and MMC-induced 
chromosomal aberrations.  Perhaps genetic lesions acquired during the oncogenic process 
can facilitate cell viability and genomic maintenance in the absence of Ctip.  
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The role of the BRCT phospho-ligands of BRCA1 in genome stability and tumor 
suppression  
 
Analysis of AB, AC, and BC double mutant mice 
      Although BRCT phospho-recognition is critical for the genome stability and tumor 
suppression functions of BRCA1 (Shakya et al., 2011), these processes are not abrogated 
when the interactions of BRCA1 with its known phospho-ligands (Abraxas, BACH1, or 
CtIP) are individually disrupted.  To assess whether these functions are dependent on the 
interaction of BRCA1 with two of its known BRCT phospho-ligands, we generated each 
of the three possible combinations of double homozygous mutant mice 
(AbxS404A/S404A/Bach1FH-S994A/FH-S994A, AbxS404A/S404A/CtipS326A/S326A, and Bach1FH-S994A/FH-
S994A/CtipS326A/S326A), denoted herein as AB, AC, and BC mice, respectively.  Of note, 
these mice were fully viable and appeared to be indistinguishable from their littermate 
controls.  The AB, AC, and BC mice also displayed normal resistance to a sub-lethal dose 
of whole-body ionizing radiation (data not shown).  Moreover, double homozygous 
mutant MEFs derived from these mice proliferate normally in vitro (Figure 42).  Thus, 
disrupting the interaction of BRCA1 with any combination of two of its three known 
BRCT phospho-ligands does not appear to affect its functions in cell viability and 
genome maintenance.  Importantly, BC mice do not display a heightened susceptibility to 
tumor development (Figure 43).  Although further monitoring of the AB and AC double 




Analysis of ABC triple mutant mice     
      In parallel, we have begun to examine whether the genome maintenance and tumor 
suppression functions of BRCA1 are affected when the interaction of BRCA1 with its 
three known BRCT phospho-ligands are ablated simultaneously.  To this end, we 
generated ABC (AbxS404A/S404A/Bach1FH-S994A/FH-S994A/CtipS326A/S326A) triple mutant mice.  It 
is important to note, that in these cells, unlike the BRCT phospho-recognition mutant 
cells (Brca1S1598F/S1598F), the BRCT domains of Brca1 should retain the ability to interact 
with other undiscovered phospho-ligands, if they exist.  As described in Chapter V, 
viable ABC triple mutant mice were obtained, but at a significantly lower frequency then 
expected based on the Mendelian ratios (data not shown).  The ABC animals that survive 
to adulthood display a plethora of developmental defects, including growth retardation, 
white hind feet/belly spot, and kinked tails (Figure 52).  In addition, male ABC mice are 
sub-fertile (data not shown).  Nonetheless, we were able to generate both primary and 
SV40-immortalized MEFs from ABC mice.   
      Although ABC MEFs undergo damage-induced Brca1 hyperphosphorylation (Figure 
51), they display proliferation defects (Figure 46), centrosome amplification (Figure 47), 
chromosomal instability (Figure 50; Table 7), and diminished recruitment of Brca1 and 
Rad51 to sites of DNA damage (Figure 49).  Thus, ABC cells exhibit defects in genome 
maintenance similar to those observed in Brca1S1598F/S1598F MEFs (Shakya et al., 2011).  
Since the genomic stability functions of BRCA1 are only impaired upon simultaneous 
disruption of all three known BRCT phospho-ligand interactions, and not after ablation of 
any individual interaction or combination of two interactions, it appears that the major 
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BRCA1 supercomplexes assembled from these interactions (complexes A, B, and C) 
have the potential to act in a compensatory manner with respect to one another. 
      To confirm that the defects we observe are due to ablation of these BRCT phospho-
ligand interactions and not a result of reduced protein expression, the steady-state levels 
of mutant Abraxas, Bach1, and Ctip polypeptides should be examined in ABC triple 
mutant MEFs.  As yet, there are no reliable antibodies to recognize mouse Abraxas.  We 
have already established that mutant Bach1 and Ctip polypeptides are expressed at 
wildtype levels in the corresponding single mutant (Bach1FH-S994A/FH-S994A and 
CtipS326A/S326A) MEFs, but it will also be necessary to ascertain whether these levels of 
expression are maintained in double mutant (AB, AC, and BC) and triple mutant (ABC) 
MEFs.  Given the normal phenotype of AB, AC, and BC cells, we anticipate that the 
steady-state levels of these mutant polypeptides will be normal in each of the double 
mutant settings.  Nonetheless, it is conceivable that the combined loss of all three BRCT 
phospho-ligand interactions may inadvertently affect the stability of one or more of these 
proteins in a manner that elicits the phenotypic abnormalities observed in ABC cells.  
Therefore, it is essential to confirm normal steady-state expression of mutant Abraxas, 
Bach1, and Ctip polypeptides in ABC triple mutant MEFs.  
      Since the impaired recruitment of HDR factors Brca1 and Rad51 to sites of DNA 
damage in ABC cells suggests a potential HDR defect (Figure 49), it would be intriguing 
to examine HDR directly in these cells by using an integrated DR-GFP recombination 
reporter.  In addition, clonogenicity assays could be used to evaluate the cellular 
resistance of ABC MEFs to genotoxic stresses, such as the DNA cross-linking agent 
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MMC.  In this regard, Brca1S1598F/S1598F cells are hypersensitive to MMC, indicating that 
BRCT phospho-recognition is necessary for BRCA1-mediated MMC resistance (Shakya 
et al., 2011).  Additionally, cellular tolerance to the topoisomerase inhibitors CPT and 
ETO should be examined, especially since the Brca1-Ctip interaction is required for 
some, but not all, of the cellular resistance mediated by Brca1 in response to the 
topoisomerase inhibitors CPT and ETO (Figure 20).  Furthermore, since one of the 
hallmarks of a defective DNA damage response is increased sensitivity to ionizing 
radiation, it would be interesting to assess the IR sensitivity of ABC mice.  
The tumor suppression activity of ABC triple mutant mice 
      Overall, this study indicates that the animal development and genome maintenance 
functions of BRCA1 are disrupted only when its interactions with the three known BRCT 
phospho-ligands are ablated simultaneously.  However, the most relevant function of 
BRCA1 from a medical standpoint is its ability to suppress breast and ovarian cancer.  To 
assess the effects of these lesions on BRCA1-mediated tumor suppression it will be 
critical to monitor whole-body tumor formation in ABC triple mutant mice.  If these 
interactions are required, then triple ABC mutant mice will likely develop tumors in 
various tissues, including the mammary glands.  The timing and manner of tumor 
development should be compared to the BRCT phospho-recognition mutant mice 
(Brca1S1598F/S1598F), which develop tumors with an average latency (T50) of 575 days 
(Shakya et al., 2011).  
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      It would also be intriguing to determine the effect of the triple mutant (ABC) 
genotype on suppression of basal-like breast cancer.  To this end, a cohort of conditional 
ABC (AbxS404A/S404A/Bach1FH-S994A/FH-S994A/CtipS326A/Co/WapCre/+) females could be 
prepared.   Females of this genotype should appear at the expected Mendelian ratios, and 
therefore, it may be easier to generate a sizable cohort.  Following pregnancy, lactation, 
Cre recombinase expression, and mammary-specific recombination of the conditional-
null CtipCo allele, these females will express the triple ABC mutations specifically in their 
mammary epithelial cells.  If breast tumors do not develop in these females or occur at a 
low penetrance and/or long latency, tumorigenicity could also be examined in a p53-
deficient background. 
Conclusions 
      Given the importance of genomic instability in tumor development, the genome 
maintenance functions of BRCA1 may be a key aspect of its tumor suppression activity.  
In this study, we have provided substantial evidence that the interaction of all three 
BRCT phospho-ligands with BRCA1 serves to maintain the genomic stability functions 
of BRCA1.  The relevance of these findings to BRCA1-mediated tumor suppression is an 
important avenue of future research, as these interactions may provide valuable targets 
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